<SEC-DOCUMENT>0001104659-20-067982.txt : 20200601
<SEC-HEADER>0001104659-20-067982.hdr.sgml : 20200601
<ACCEPTANCE-DATETIME>20200601070814
ACCESSION NUMBER:		0001104659-20-067982
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		37
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200601
DATE AS OF CHANGE:		20200601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		20930894

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tm2014552-1_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>(Mark One) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30.6pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&#120;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>QUARTERLY
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><FONT STYLE="font-size: 10pt"><B>For the quarterly
period ended March&nbsp;31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>OR </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30.6pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&#168;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>TRANSITION
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><FONT STYLE="font-size: 10pt"><B>For the transition
period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PROTALIX
BIOTHERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><B><U>Delaware</U></B></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%">&nbsp;<B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporati<FONT STYLE="font-size: 10pt">on
        or organization)</FONT></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S.
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification
        No.)</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>2
        Snunit Street</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Science
        Park</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>POB
        455</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Carmiel,
        Israel</U></B></FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>2161401</U></B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>+972-4-988-9488</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Registrant&#8217;s
telephone number, including area code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>N/A</U><BR>
(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Securities
registered pursuant to Section 12(b) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title
                                         of each class</B></FONT></P></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading
                                         Symbol(s)</B></FONT></P></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
                                         of each exchange on which registered</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Common
    stock, $0.001 par value</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">PLX</FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">NYSE
    American</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Indicate by
check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Indicate by
check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). Yes <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
 &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="text-align: right; width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">On May&nbsp;24,
2020, approximately 32,442,636 shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Page</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><A HREF="#a_001">PART I &ndash; FINANCIAL INFORMATION</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_002">Item&nbsp;1.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_002">Financial Statements&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003">Condensed Consolidated Balance
    Sheets (Unaudited) &ndash; As of March&nbsp;31, 2020 and December&nbsp;31, 2019</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: center"><A HREF="#a_003">2</A></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_004">Condensed Consolidated Statements of Operations (Unaudited) &ndash; For the Three Months Ended March&nbsp;31, 2020 and 2019</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_004">3</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left"><A HREF="#a_005">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited)
    &ndash; For the Three Months Ended March&nbsp;31, 2020 and 2019</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_005">4</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_006">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash; For the Three Months Ended March&nbsp;31, 2020 and 2019</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_006">5</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left"><A HREF="#a_007">Notes to Condensed Consolidated Financial Statements</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_007">7</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_008">Item&nbsp;2.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_008">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&#9;&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_008">12</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_019">Item 3.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_019">Quantitative and Qualitative Disclosures About Market Risk&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_019">25</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_009">Item&nbsp;4.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_009">Controls and Procedures&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_009">26</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><A HREF="#a_010">PART II &ndash; OTHER INFORMATION</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_011">Item&nbsp;1.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_011">Legal Proceedings &#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_011">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_012">Item&nbsp;1A.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_012">Risk Factors&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_012">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_013">Item&nbsp;2.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_013">Unregistered Sales of Equity Securities and Use of Proceeds&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_013">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_014">Item&nbsp;3.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_014">Defaults Upon Senior Securities&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_014">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_015">Item&nbsp;4.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_015">Mine Safety Disclosures&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_015">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_016">Item&nbsp;5.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_016">Other Information&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_016">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_017">Item&nbsp;6.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="#a_017">Exhibits&#9;</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_017">27</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_018">Signatures</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_018">30</A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I &#8211; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_002"></A>Item&nbsp;1. Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left; padding-left: 0.125in">Cash and cash equivalents&#9;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">14,166</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">17,792</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Short-term bank deposits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts receivable &ndash; Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,876</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,728</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,832</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.125in">Inventories&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,488</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,155</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">57,767</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,479</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">NON-CURRENT ASSETS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Long-term bank deposits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,505</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Funds in respect of employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,879</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,963</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Property and equipment, net&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,012</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,273</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Operating lease right of use assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,713</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,677</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total non-current assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,109</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,913</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">82,876</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts payable and accruals:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in">Trade&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,430</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6,495</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in">Other&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,757</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,905</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,139</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Contracts liability&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,014</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,335</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Promissory Note&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,301</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,301</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,628</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,175</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Convertible notes&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">51,777</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">50,957</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Contracts liability&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,130</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,980</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Liability for employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,531</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,565</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Operating lease liabilities&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,481</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,528</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">210</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">509</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total long term liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">66,129</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">75,539</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">113,757</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">115,714</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">COMMITMENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">CAPITAL DEFICIENCY&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30,881</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(70,322</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities net of capital deficiency&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">82,876</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="a_004"></A>PROTALIX
BIOTHERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
</B>(U.S. dollars in thousands, except per share data)<BR>
</FONT>(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">March&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">REVENUES FROM SELLING GOODS</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,031</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,530</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">REVENUES FROM LICENSE AND R&amp;D SERVICES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,615</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,909</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">TOTAL REVENUE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,646</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,439</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">COST OF GOODS SOLD</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,426</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,045</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">RESEARCH AND DEVELOPMENT EXPENSES, NET (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10,340</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(11,698</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,187</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">OPERATING INCOME (LOSS)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,693</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,534</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL EXPENSES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,229</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,920</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL INCOME</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">203</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">190</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FINANCIAL EXPENSES, NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,026</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,730</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">NET INCOME (LOSS) FOR THE PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,667</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">EARNINGS (LOSS) PER SHARE OF
    COMMON STOCK &ndash; BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.10</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">WEIGHTED AVERAGE NUMBER OF SHARES OF
    COMMON STOCK - BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,381,074</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,838,213</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left">(1) Includes share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">78</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">178</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left">(2) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">353</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">112</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CHANGES IN<BR>
CAPITAL DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except per share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center">Common</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center">Common</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center">Additional<BR> Paid&ndash;In</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font: bold 9pt Times New Roman, Times, Serif">Balance at January&nbsp;1, 2019</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: bold 9pt Times New Roman, Times, Serif; text-align: right">14,838,213</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 9pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 9pt Times New Roman, Times, Serif; text-align: right">269,657</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(322,553</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(52,881</TD><TD STYLE="width: 1%; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif">Changes during the three-month period ended March&nbsp;31, 2019:</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">290</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">290</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">(7,264</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at March&nbsp;31, 2019&#9;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">14,838,213</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">269,947</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(329,817</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(59,855</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif">Balance at January&nbsp;1, 2020</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: right">14,838,213</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: right">270,492</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: right">(340,829</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: right">(70,322</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif">Changes during the three-month period ended March&nbsp;31, 2020:</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock and warrants, net of&nbsp;issuance cost</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">17,604,423</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">41,325</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">41,343</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Note receivable from issuance of common stock and&nbsp;warrants</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">(4,000</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">(4,000</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">431</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">431</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Net income for the period</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">1,667</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">1,667</TD><TD STYLE="padding-bottom: 1pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at March&nbsp;31, 2020&#9;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">32,442,636</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">308,248</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(339,162</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 9pt Times New Roman, Times, Serif; text-align: right">(30,881</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold">March&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center"><B>March&nbsp;31, 2019</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net income (loss)&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,667</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(7,264</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Adjustments required to reconcile
    net income (loss) to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">Share based compensation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">431</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">290</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">Depreciation&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">376</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Financial expenses (income), net (mainly exchange differences) &#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(241</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in accrued liability for employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">44</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(24</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Loss on amounts funded in respect of employee rights upon retirement&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">59</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amortization of debt issuance costs and debt discount&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">820</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">704</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease in contracts liability (including non-current portion)&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,171</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(487</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase in accounts receivable and other assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,091</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,608</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Changes in right of use assets&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(36</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease (increase) in inventories&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,333</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,862</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase in accounts payable and accruals&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,611</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">864</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -16.2pt; padding-left: 0.35in">Decrease in other long term liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(299</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -11.45pt; padding-left: 16.2pt">Net cash used in operating activities&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,117</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,276</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Increase in bank deposits (including long-term deposits)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(35,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(66</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(170</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Decrease (increase) in restricted deposit&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(214</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amounts funded in respect of employee rights upon retirement, net&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(35</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net cash used in investing activities&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(35,079</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(371</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; padding-left: 0.35in">Proceeds from issuance of common stock and warrants, net of issuance cost&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38,607</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; padding-left: 0.35in">Net cash provided by financing activities&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38,607</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 16.2pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 9pt">EFFECT
    OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(37</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">202</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">NET DECREASE IN CASH AND CASH EQUIVALENTS&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,626</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,445</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">BALANCE
    OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD&#9;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,792</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,808</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD&#9;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,166</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">30,363</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.9pt 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) &#8211; 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">March&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">March&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.125in">SUPPLEMENTARY
    INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; width: 74%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1pt; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">147</TD><TD STYLE="padding-bottom: 1pt; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right">128</TD><TD STYLE="padding-bottom: 1pt; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Right of use assets obtained in exchange for new operating lease liabilities</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">233</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Note receivable
    from issuance of common stock and warrants, net of issuance cost</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,736</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_007"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Protalix BioTherapeutics, Inc. (collectively
with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;),
are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the
Company&#8217;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company
has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other
Latin American countries and Elelyso<SUP>&reg;</SUP> in the rest of the territories) for the treatment of Gaucher disease that
has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates
in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins
that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company&#8217;s product pipeline
currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(1) pegunigalsidase alfa, or PRX-102,
a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(2) alidornase alfa, or PRX-110,
a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(3) OPRX-106, the Company&#8217;s
oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as
a natural capsule for the expressed protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Obtaining marketing approval with
respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory
steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">On May&nbsp;28, 2020,
the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&rsquo;s development
and commercialization partner (&ldquo;Chiesi&rdquo;), announced the submission on May 27, 2020 of a Biologics License
Application (BLA) to the U.S.&nbsp;Food and Drug Administration (the &ldquo;FDA&rdquo;) for pegunigalsidase alfa for the
treatment of adult patients with Fabry disease via the FDA&rsquo;s Accelerated Approval pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On March&nbsp;18, 2020, the Company completed a
private placement of common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered
shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), at a purchase price
per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36
per share. The warrants are exercisable commencing six months following their issuance for a period of five years from the
date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&rsquo; terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The net proceeds committed from the private placement
were approximately $41.3&nbsp;million, after deducting advisory fees and other estimated offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In April and May, 2020, the Company collected total
proceeds of approximately $9.0&nbsp;million from accounts receivable outstanding at March&nbsp;31, 2020. Total proceeds of approximately
$4.7&nbsp;million in connection with its collaboration with Chiesi, total proceeds of approximately $3.0&nbsp;million from sales
of alfataliglicerase to Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;), an arm of the Brazilian Ministry of Health
(the &ldquo;Brazilian MoH&rdquo;), and total proceeds of approximately $1.3&nbsp;million from sales of drug substance to Pfizer
Inc. (&ldquo;Pfizer&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On October&nbsp;19, 2017, Protalix
Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which
Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase
alfa. On July&nbsp;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi
US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Unaudited)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under each of the Chiesi Ex-US Agreement
and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd.
of $25.0&nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix
Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million
per year, and to receive additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone
payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover
development costs for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per year, and to receive additional payments
of up to a maximum of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under the terms of both of the
Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain
exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi
Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual
sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to
make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration
for product supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Since its approval by the FDA, taliglucerase alfa
has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into
between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer
entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant
to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization
of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights
to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of
expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On June&nbsp;18, 2013, the Company
entered into a Supply and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Fiocruz for taliglucerase alfa.
Fiocruz&rsquo;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase
milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right,
the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients
continue to be treated with BioManguinhos alfataliglicerase in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Basis of presentation</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">These unaudited condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year
ended December&nbsp;31, 2019, filed by the Company with the U.S Securities and Exchange Commission (the &#8220;Commission&#8221;).
The comparative balance sheet at December&nbsp;31, 2019 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="padding-right: 81.35pt"><B> Earnings (loss) per share</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Basic and diluted earnings per share (&ldquo;EPS&rdquo;)
are computed by dividing net income (loss) by the weighted average number of shares of the Company&rsquo;s Common Stock attributable
to common stockholders outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The calculation of diluted EPS does
not include 7,826,946 and 10,694,517 shares of Common Stock underlying outstanding options and restricted shares of Common Stock
and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March&nbsp;31,
2019 and 2020, respectively, because their effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The computation of basic and diluted
net income (loss) per common stock was adjusted retrospectively for all periods presented to reflect the Company&rsquo;s reverse
stock split at a ratio of one-for-ten, effective as of December&nbsp;19, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Unaudited)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Revenue recognition</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">Effective January&nbsp;1,
2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&ldquo;ASC 606&rdquo;).
Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform
their respective obligations, the Company can identify each party&rsquo;s rights regarding the distinct goods or services to be
transferred (&ldquo;performance obligations&rdquo;), the Company can determine the transaction price for the goods or services
to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to
which it will be entitled in exchange for the goods or services that will be transferred to the customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><FONT STYLE="background-color: white">Revenues
are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations
upon transfer of control to the customer</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Revenues from selling products</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company recognizes revenues from selling goods&nbsp;<FONT STYLE="background-color: white">at
a point in time when control over the product is transferred to customers (upon delivery).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Revenue from Chiesi Agreements</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company has identified two performance obligation
in Chiesi agreements as follows: (1) the license and research and development services and (2)&nbsp;contingent performance obligation
regarding future manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company determined that the license together
with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from
the license without the&nbsp;research and development services. The research and development services are highly specialized and
are dependent on the supply of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The future manufacturing is contingent on regulatory
approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in
the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research
and development services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The transaction price was comprised of fixed consideration
and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company
would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are
a form of variable consideration. The Company estimates variable consideration using the most likely method. <FONT STYLE="background-color: white">Amounts
included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will
not occur.</FONT> Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine
the probability of significant reversal of such revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Unaudited)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Since the customer benefits from the research and
development services as the entity performs the service, revenue from granting the license and the research and development services
is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected
to be incurred upon satisfying the identified performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Revenue from additional research and
development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Revenue from R&amp;D services</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Revenue from the research and development services
is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as
the entity performs the service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Other assets</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Other assets include $1.0&nbsp;million in connection
with the March 2020 private placement of Common Stock and warrants,  which was received after the quarter-end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>f.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Recently issued accounting pronouncements</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="color: #212529; background-color: white">In
June 2016, the </FONT>Financial Accounting Standards Board <FONT STYLE="color: #212529; background-color: white">issued an </FONT><FONT STYLE="background-color: white">Accounting
Standards Update <FONT STYLE="color: #212529">that supersedes the existing impairment model for most financial assets to a current
expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate
of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020,
with no material impact on its consolidated financial statements.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">Inventories at March<FONT STYLE="font-size: 10pt">&nbsp;</FONT>31,
2020 and December&nbsp;31, 2019 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March&nbsp;30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Raw materials&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,424</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,607</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Work in progress&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">759</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">552</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Finished goods&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,305</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,996</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total inventory&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,488</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,155</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &#8211; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The accounting standard establishes a fair value hierarchy
that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>1:
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>2:
Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Unaudited)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &#8211; FAIR VALUE MEASUREMENT</B> <FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)<B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>3:
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In determining fair value, the Company utilizes valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible
notes derivative is based on Level<FONT STYLE="font-size: 10pt">&nbsp;</FONT>3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of March 31, 2020, the carrying amounts of short-term
and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The fair value of the $57.9&nbsp;million aggregate
principal amount of the <FONT STYLE="font-family: Times New Roman, Times, Serif">Company&rsquo;s outstanding </FONT>7.50% convertible
promissory notes due November 2021 (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">2021 Notes&rdquo;)</FONT>
as of March&nbsp;31, 2020 is approximately $56.2&nbsp;million based on a Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes (a Level 3 valuation) as of </FONT>March&nbsp;31,
2020<FONT STYLE="font-family: Times New Roman, Times, Serif">. The value of these notes was estimated by implementing the binomial
model. The liability component was valued based on the Income Approach. The following parameters were used:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021 Notes</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-indent: -1.25pt; padding-left: 1.25pt">Stock price (USD)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2.35</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -1.25pt; padding-left: 1.25pt">Expected term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -1.25pt; padding-left: 1.25pt">Risk free rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.23</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -1.25pt; padding-left: 1.25pt">Volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100.57</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -1.25pt; padding-left: 1.25pt">Yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15.41</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &#8211; REVENUES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table summarizes the Company&#8217;s
disaggregation of revenues:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three months ended March&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt">Pfizer&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,016</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,356</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Brazil&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,174</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total revenues from selling goods&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,031</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,530</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Revenues from license and R&amp;D services&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,615</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,909</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">During the three months ended March&nbsp;31,
2020, the Company recorded revenue in the amount of $6.7&nbsp;million following a change in estimate of the total costs expected
to be incurred in connection with the Chiesi Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On March&nbsp;16, 2020, the Company agreed to conduct
a feasibility study with Kirin Holdings Company, Limited (&ldquo;Kirin&rdquo;) to evaluate the production of a novel complex protein
utilizing ProCellEx<SUP>&reg;</SUP>, the Company&rsquo;s proprietary plant cell-based protein expression system. Kirin will bear
the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides
Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0&nbsp;million.
The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_008"></A>Item&nbsp;2.
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form</I>&nbsp;<I>10-Q and in our Annual Report on Form</I>&nbsp;<I>10-K
for the year ended December</I>&nbsp;<I>31, 2019. Some of the information contained in this discussion and analysis, particularly
with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or
the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this
report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;can,&rdquo;
 &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to
future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating
or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or
to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are
subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed
or implied by the forward-looking statements as a result of several factors including those set forth under &ldquo;Risk Factors&rdquo;
in our Annual Report on Form</I>&nbsp;<I>10-K for the year ended December</I>&nbsp;<I>31, 2019, and in this Quarterly Report on
Form</I>&nbsp;<I>10-Q for the quarter ended March</I>&nbsp;<I>31, 2020.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Examples
of the risks and uncertainties include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
risk that the FDA will not accept an application for Accelerated Approval of PRX-102 with the data generated to date or will request
additional data or other conditions of the submission, or that the FDA, the European Medicines Agency, or the EMA, or other foreign
regulatory authorities may not accept or approve a marketing application we file for any of our other product candidates;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks associated with the novel corona virus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical
studies and clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks relating to our evaluation and pursuit of strategic alternatives;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks related to our ability to identify and obtain financing on attractive terms or at all within the time period required
to regain compliance with the continued listing standards of the NYSE American LLC, or the NYSE American, or to otherwise maintain
compliance with its continued listing standards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several
factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues;
lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards
to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient
funding to finance our clinical trials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product
candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks relating to our ability to manage our relationship with our collaborators, distributors or partners;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health,
or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material
adverse effect on us and may also result in the termination of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
our dependence on performance by third-party providers of services and supplies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the impact of development of competing therapies and/or technologies by other companies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks related to our supply of drug product to Pfizer Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks related to our expectations with respect to the potential commercial value of our product and product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
potential product liability risks, and risks of securing adequate levels of related insurance coverage;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining
patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recent
Company Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On February&nbsp;6, 2020, we announced, together with Chiesi, our development and commercialization partner, an agreement
with the FDA for the Initial Pediatric Study Plan (iPSP) for pegunigalsidase alpha, or PRX-102. The announcement was made we and
Chiesi completed discussions with the FDA and receiving confirmation in an official &#8220;Agreement Letter&#8221; which outlines
an agreed approach to address the needs of pediatric patients with Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On March&nbsp;12, 2020, we entered into securities purchase agreements, or the Purchase Agreements, with certain existing
and new institutional and other accredited investors, or the Purchasers. Pursuant to the Purchase Agreements, we, in a private
placement in reliance on the exemption from the registration requirements of the Securities Act, agreed to issue and sell to the
Purchasers an aggregate of approximately 17.6&nbsp;million unregistered shares of our common stock at a price per share of $2.485,
or aggregate net committed proceeds equal to approximately $41.3&nbsp;million. Each share of our common stock issuable in the transaction
was to be accompanied by a warrant to purchase an additional share of common stock, or the Warrant Shares, at an exercise price
equal to $2.36.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On March&nbsp;16, 2020, we announced that we have agreed to conduct a feasibility study with Kirin Holdings Company, Limited,
or Kirin, to evaluate the production of a novel complex protein utilizing ProCellEx<SUP>&reg;</SUP>, our proprietary plant cell-based
protein expression system. Kirin will provide research funding for Protalix scientists to conduct cell line engineering and protein
expression studies on the target protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On May 11, 2020, we announced positive topline results from our phase III <I>BRIDGE</I> clinical trial of pegunigalsidase
alfa, or PRX-102, or the <I>BRIDGE </I>Study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>On
May 28, 2020, we, together with Chiesi, announced the submission on May 27, 2020 of a Biologics License Application (BLA) to
the FDA for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA&#8217;s Accelerated
Approval pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we continue to actively advance all our clinical programs, we are in close contact with our principal investigators and clinical
sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical
trials have not been adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus
of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for
conducting clinical trials issued on March 18, 2020, we and our contract research organizations have made certain adjustments
to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial
integrity during the pandemic and generally, and we may need to make further adjustments in the future. We intend to continuously
assess the impact of COVID-19 on our trials, expected timelines and costs. In response to the spread of COVID-19, and with local
directives issued in response thereof, we have restructured the work day within our facilities to consist of two shifts thereby
reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing.
Employees that are able to work from home have been instructed to do so. Such efforts have resulted in minor delays in the performance
of administrative activities outside of the clinical programs. We will continue to evaluate the impact of the COVID-19 pandemic
on our business and our clinical trials as we learn more and the impact of COVID-19 on our industry becomes more clear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ProCellEx:
Our Proprietary Protein Expression System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell cultures
in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced
genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent
proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing,
genetically-stable cell lines capable of expressing recombinant proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex
protein expressions; the potential for oral delivery of proteins; flexible manufacturing with improvements through efficiencies,
enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations
from mammalian components; and intellectual property advantages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx
platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel
bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow
for the major advantage of rapid horizontal scale-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plant
Cell Production Advantages Versus Mammalian Cell Production</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="tm2014552-1_10qimg01.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="tm2014552-1_10qimg02.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Pegunigalsidase
Alfa (PRX&#45;102) for the Treatment of Fabry Disease</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">PRX-102 is our proprietary, investigational,
plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &alpha;-Galactosidase-A protein
under development for the treatment of Fabry disease. Fabry disease is a serious life-threatening rare genetic disorder. Fabry
patients lack the lysosomal enzyme, &alpha;-galactosidase-A leading to the progressive accumulation of abnormal deposits of a fatty
substance called globotriaosylceramide (Gb<SUB>3</SUB>) in blood vessel walls throughout their body. The abnormal storage of Gb<SUB>3</SUB>
increases with time and, as a result, Gb<SUB>3</SUB> accumulates, primarily in the blood and in the blood vessel walls. The accumulation
leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences
of Gb<SUB>3</SUB> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of
the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.
The global market for Fabry disease was approximately $1.7&nbsp;billion in 2019 (Global Data) and continues to grow at a CAGR of
approximately 10% (Data Bridge Market Research).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 28, 2020, we, together with Chiesi, announced the submission on May 27, 2020 of a BLA to the FDA for pegunigalsidase alfa
for the treatment of adult patients with Fabry disease via the FDA&#8217;s Accelerated Approval pathway. The BLA submission
includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical
trial of PRX-102, including the related extension study succeeding the phase I/II clinical trial, interim clinical data from
our <I>BRIDGE</I> Study and safety data from our on-going clinical studies of PRX-102, including extension studies. Upon the
BLA approval, if approved, we will be eligible to receive a milestone payment from Chiesi.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2017, the European Commission granted Orphan Drug Designation for PRX&#45;102 for the treatment of Fabry disease. Orphan
Drug Designation for PRX&#45;102 qualifies Chiesi for access to a centralized marketing authorization procedure, including applications
for inspections and for protocol assistance. If the orphan drug designation is maintained at the time PRX&#45;102 is approved
for marketing in the European Union, if at all, we expect that PRX&#45;102 will benefit from 10 years of market exclusivity within
the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2018, the FDA granted Fast Track designation to PRX&#45;102. Fast Track designation is a process designed to facilitate
the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Key
Trials and Design</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
phase&nbsp;III clinical program of PRX&#45;102 for the treatment of Fabry disease includes three individual studies; the <I>BALANCE</I>,
<I>BRIDGE</I> and <I>BRIGHT</I> Studies. In 2015, we completed a phase&nbsp;I/II clinical trial of PRX&#45;102. Patients that
completed the phase&nbsp;I/II clinical trial were offered the opportunity to continue PRX-102 treatment as part of a long-term
extension study. In the phase III clinical program, we are studying two alternative dosing regimens for PRX&#45;102, 1&nbsp;mg/kg
every two weeks and 2&nbsp;mg/kg every four weeks, with the potential for improved efficacy and safety. The 2&nbsp;mg/kg every
four weeks regimen has the potential to lower treatment burden versus existing treatments for a subset of Fabry patients. The
1&nbsp;mg/kg every two weeks regimen offers the potential for superior enzyme replacement therapy while the 2&nbsp;mg/kg every
four weeks regimen offers the potential for better quality of life. Enrolment has been completed in each of the <I>BALANCE</I>,
<I>BRIDGE</I> and <I>BRIGHT</I> Studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Phase
III BALANCE Study </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The </FONT>phase&nbsp;III
<I>BALANCE</I> clinical trial of PRX-102 for the treatment of Fabry disease, or the <FONT STYLE="background-color: white"><I>BALANCE</I>
Study, is a 24</FONT>-<FONT STYLE="background-color: white">month, randomized, double blind, active control study of PRX-102 in
Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is </FONT>designed
to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme<SUP>&reg;</SUP>) on renal function in Fabry
patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. <FONT STYLE="background-color: white">Patients
previously treated with </FONT>Fabrazyme <FONT STYLE="background-color: white">for approximately one year and on a stable dose
for at least six months were screened and then randomized on a 2:1 ratio to 1</FONT>&nbsp;<FONT STYLE="background-color: white">mg/kg
of PRX-102 or 1</FONT>&nbsp;<FONT STYLE="background-color: white">mg/kg of </FONT>Fabrazyme<FONT STYLE="background-color: white">.
Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt; or &ge; 1 g/g by spot urine sample. The
study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled
patients are female.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary endpoint for the <I>BALANCE </I>Study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme
and PRX<FONT STYLE="color: #333333; background-color: white">-</FONT>102. eGFR is considered a reliable and accepted test to measure
the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: <FONT STYLE="background-color: white">cardiac
assessment, Lyso-Gb<SUB>3</SUB></FONT> (a biomarker for monitoring Fabry patients during therapy)<FONT STYLE="background-color: white">,
pain, quality of life, immunogenicity, Fabry clinical events and pharmacokinetic and other parameters. The study also evaluates
the safety and tolerability of PRX-102.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to conduct an interim analysis when the last patient reaches 12 months of treatment to test for non-inferiority to support
anticipated regulatory filings with the EMA. Patients enrolled in the <I>BALANCE</I> Study will continue to be treated for a total
of 24 months, at which point the data will be analyzed to test for superiority. If the anticipated BLA filing results in an approval
from the FDA under the Accelerated Approval pathway, this analysis will also be used to support converting the accelerated approval
into a full approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Phase&nbsp;III
BRIDGE Study</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
<I>BRIDGE</I> Study is an open label, switch-over study designed to evaluate the safety and efficacy of 1&nbsp;mg/kg of <FONT STYLE="background-color: white">PRX-102
</FONT>infused every two weeks, in up to 22 Fabry patients. The trial, which is fully enrolled, enrolled patients currently treated
with agalsidase alfa (Replagal<SUP>&reg;</SUP>) for at least two years and on a stable dose for at least six months. Patients
were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient
was enrolled and switched from Replagal treatment to receive intravenous (IV) infusions of <FONT STYLE="background-color: white">PRX-102
</FONT>1&nbsp;mg/kg every two weeks for 12 months. Topline results from the study were released in May 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Topline
results of the data generated in the <I>BRIDGE</I> Study showed significant improvement in renal function as measured by mean
annualized estimated Glomerular Filtration Rate (eGFR slope) and an amelioration of the course of disease in both male and female
patients who were switched from Replagal<SUP>&reg;</SUP> to PRX-102. Consistent with previously announced interim data, PRX-102
was found to be well tolerated, with all adverse events being transient in nature without sequelae. Twenty-two patients were enrolled
in the study; two of those patients withdrew early from the study due to hypersensitivity reaction, and 20 of the patients successfully
completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term
extension study and continue to be treated with PRX-102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the study, the mean annualized eGFR slope of the study participants improved from &#45;5.90&nbsp;mL/min/1.73m<SUP>2</SUP>/year
while on Replagal<SUP>&reg;</SUP> to &#45;1.16 mL/min/1.73m<SUP>2</SUP>/year on PRX-102 in all patients. Male patients improved
from &#45;6.36&nbsp;mL/min/1.73m<SUP>2</SUP>/year to &#45;1.67&nbsp;mL/min/1.73m<SUP>2</SUP>/year and female patients improved
from 5.03&nbsp;mL/min/1.73m<SUP>2</SUP>/year to 0.21&nbsp;mL/min/1.73m<SUP>2</SUP>/year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Baseline
characteristics of the patients, ranging from ages 24 to 60 years, were as follows: mean eGFR 75.87 in males and 86.14 mL/min/1.73m<SUP>2
</SUP>in females; mean residual leucocytes enzymatic activity was 4.8% of lab normal mean in males and 27.9% in females; and plasma
lyso-Gb3 mean levels were 49.7 nM and 13.8 nM in males and females, respectively. While lyso-Gb3 levels remain slightly high,
particularly within the male cohort, continuous reduction in lyso-Gb3 levels was observed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Data from the interim analysis of
the <I>BRIDGE</I> Study was included in the PRX-102 BLA submission to the FDA under the Accelerated Approval pathway, and we
anticipate that the final analysis will be used to support a Marketing Authorization Application (MAA) with the EMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Phase&nbsp;III
BRIGHT Study </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">phase&nbsp;III <I>BRIGHT</I> clinical trial of PRX-102 for the
treatment of Fabry disease, or the <FONT STYLE="background-color: white"><I>BRIGHT</I> Study, </FONT>is a 12<FONT STYLE="background-color: white">-</FONT>month,
open-label switch-over study designed to assess the safety, efficacy and pharmacokinetics (PK) of <FONT STYLE="background-color: white">PRX-102
</FONT>via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks in up to 30 patients with Fabry disease, previously
treated with an ERT (Fabrazyme or Replagal). To determine eligibility for participation in the study<I>,</I> candidates were screened
to identify and select Fabry patients with stable kidney disease. Patients who matched the criteria were enrolled in the study
and switched from their current treatment of intravenous (IV) infusions every 2 weeks to 2 mg/kg of PRX-102 every 4 weeks for
12 months. We completed enrollment of the <I>BRIGHT</I> study in June 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Patients participating in the study
are evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated
with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<SUB>3</SUB>, as well as other parameters. In addition, participating
patients are evaluated to assess the safety and tolerability of PRX-102. In February 2019, we announced preliminary pharmacokinetic
(PK) data from the <I>BRIGHT</I> study. The results demonstrate that <FONT STYLE="background-color: white">PRX-102</FONT> was present
and remained active in the plasma over the 4-week infusion intervals. The mean concentration of PRX-102 at day 28 was 138 ng/mL.
In comparison, published data on Fabrazyme (1&nbsp;mg/kg every 2 weeks) shows a mean concentration of 20 ng/mL at 10 hours post
infusion. In addition, the area under the curve (AUC) for <FONT STYLE="background-color: white">PRX-102 </FONT>was measured to
be approximately 2,000,000 ng&middot;hr/mL over 28 days. Based on published data, the AUC of Fabrazyme is approximately 10,000
ng&middot;hr/mL. Pre-existing anti-drug antibodies (ADA) generated in patients prior to switching to <FONT STYLE="background-color: white">PRX-102
</FONT>had substantially little effect on the circulation of PRX-102 for the 4-week period evaluated, and <FONT STYLE="background-color: white">PRX-102
</FONT>concentration in circulation was higher than agalsidase beta, even in the presence of ADAs. A preliminary safety analysis
of 19 patients enrolled in the <I>BRIGHT</I> study was also conducted, and indicated that <FONT STYLE="background-color: white">PRX-102</FONT>
is well tolerated. To date, substantially all of the patients who completed the study opted, with the advice of the treating physician,
to continue treatment under the 4-week dosing regimen in a long-term extension study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Phase
I/II Study</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our phase&nbsp;I/II clinical trial of PRX-102, which we completed
in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics,
immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&iuml;ve Fabry patients (9 male and
7 female) completed the trial, each in one of three dosing groups, 0.2 mg/kg, 1&nbsp;mg/kg and 2&nbsp;mg/kg. Each patient received
intravenous (IV) infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods.
The majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study
under which all patients were switched to receive 1&nbsp;mg/kg of the drug, the selected dose for our <I>BALANCE</I> Study and
<I>BRIDGE</I> Study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
adult symptomatic, ERT-na&iuml;ve Fabry disease patients enrolled in the phase&nbsp;I/II study were evaluated for Gb<SUB>3</SUB>
levels in kidney biopsies and for plasma Lyso-Gb<SUB>3</SUB> concentration by the quantitative BLISS methodology. Biopsies were
available from 14 patients. The outcome of &#8805; 50% reduction in the average number of Gb<SUB>3</SUB> inclusions per kidney
PTC from baseline to month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate
that PRX-102 reaches the affected tissue and reduces kidney Gb<SUB>3</SUB> inclusions burden and Lyso-Gb<SUB>3</SUB> in the circulation.
A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<SUB>3</SUB> inclusions and the reduction
of plasma Lyso-Gb<SUB>3</SUB> over six months of treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Data
was recorded at 24 months from 11 patients who completed 12 months of the long-term open-label extension trial that succeeded
the phase&nbsp;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned
to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to
a location where treatment was not available under the clinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Results
have shown that Lyso-Gb<SUB>3</SUB> levels decreased approximately 90% from baseline. Renal function remained stable with mean
eGRF levels of 108.02 and 107.20 at baseline and 24 months, respectively, with a modest annual eGFR slope of -2.1. An improvement
across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea,
was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion,
an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index (MSSI), a score compiling
the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement
was noted in each of the individual parameters of the MSSI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment,
only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had
neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&nbsp;months
of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Commercialization
Agreements with Chiesi Farmaceutici</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into two exclusive global licensing and supply agreements for PRX&#45;102 for the treatment of Fabry disease with
Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&nbsp;million
in upfront payments and was entitled to development cost reimbursements of up to $45.0&nbsp;million, up to more than $1.0&nbsp;billion
in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October&nbsp;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an
exclusive license for all markets outside of the United States to commercialize PRX&#45;102. Under the Chiesi Ex-US Agreement,
Chiesi made an upfront payment to Protalix Ltd. of $25.0&nbsp;million in connection with the execution of the agreement, and Protalix
Ltd. was entitled to additional payments of up to $25.0&nbsp;million in development costs in the aggregate, capped at $10.0&nbsp;million
per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&nbsp;million in regulatory
and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX&#45;102 needed for all purposes under the
agreement, subject to certain exceptions, and Chiesi will purchase PRX&#45;102 from Protalix Ltd., subject to certain terms and
conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales,
as consideration for the supply of PRX&#45;102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July&nbsp;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of
PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&nbsp;million
from Chiesi and was entitled to additional payments of up to a maximum of $20.0&nbsp;million to cover development costs for PRX&#45;102,
subject to a maximum of $7.5&nbsp;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum
of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments
of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject
to certain terms and conditions, as consideration for product supply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Elelyso<SUP>&reg;
</SUP>for the Treatment of Gaucher Disease </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Elelyso
(taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy
(ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&nbsp;1 Gaucher disease. In August 2014,
the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to
be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gaucher
disease is a $1.5&nbsp;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<SUP>&reg;</SUP>, Shire&#8217;s
(acquired by Takeda Pharmaceutical Company Limited) Vpriv<SUP>&reg;</SUP> and Sanofi&#8217;s Cerdelga<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Commercialization
Agreements for Elelyso</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses
100% of direct costs. We manufacture drug substance for Pfizer, subject to certain terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer
for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods
subject to certain terms and conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
maintain distribution rights to Elelyso in Brazil (marketed as alfataliglicerase) through a supply and technology transfer agreement
with Fiocruz, an arm of the Brazilian MoH. In 2019, we generated $9.1&nbsp;million from sales of BioManguinhos alfataliglicerase
to the Brazilian MoH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Tulinercept
(OPRX-106)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tulinercept
is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting
TNF alpha. It is in development for oral administration. When administered orally and while passing through the digestive tract,
the plant cells function as a natural delivery vehicle, having the unique attribute of a cellulose cell wall, which makes them
resistant to degradation compared to proteins produced via mammalian cell expression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: a5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through oral administration, tulinercept is designed to work
locally in the gut, avoiding the systemic exposure that occurs when TNF alpha inhibitors are administered by injection or intravenous
infusion. Oral administration may potentially lead to a safer to use anti-TNF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX&#45;106 may also be less immunogenic which can potentially
result in longer-term efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our oral delivery mechanism can potentially
prove to be a safer and more convenient method of protein administration and could be applied to additional proteins in certain
indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Alidornase Alfa (PRX&#45;110) </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alidornase alfa is our proprietary chemically-modified plant
cell&#45;expressed recombinant of human deoxyribonuclease I (DNase I), administered through inhalation. In cystic fibrosis (CF)
patients, the accumulation of sputum in the lungs exposes them to recurrent infections and compromises lung function. DNase I therapy,
or dornase alfa, is generally recommended for CF&nbsp;patients to improve lung function and reduce exacerbations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, DNase I activity is compromised by actin, a globular
multi-functional protein, found in high concentration in the sputum of CF patients, that is a potent inhibitor of DNase I. As such,
we believe that actin may decrease the enzyme&#8217;s DNA degradation activity and potentially interfere with the effectiveness
of inhaled DNase I in the lungs of CF&nbsp;patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to reduce the actin-DNase I interaction and the subsequent
inhibition of DNase I activity by actin, we developed alidornase alfa by chemically modifying the enzyme forming an actin inhibition
resistant DNase I. This novel treatment candidate may result in improved lung function and decreased incidence of recurrent infections
in patients. Thus, we believe there is the potential that our recombinant form of the enzyme will demonstrate significantly enhanced
efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PRX-115</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase
(Urate Oxidase) &#8211; a chemically modified enzyme to treat Gout. The Uricase enzyme converts uric acid to allantoin, which is
easily eliminated through urine. We use our proprietary plant-based system to express an optimized recombinant enzyme under development
for the potential treatment of Gout which is designed to have an improved half-life, reduced immunogenicity and better efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A key element of our overall strategy is to establish a
broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their
methods of use. As of March&nbsp;31, 2020, we hold a broad portfolio of over 85 patents in Europe, the United States,
Israel and additional countries worldwide, as well as over 40 pending patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the fiscal quarter ended March 31, 2020, a patent
was granted in  China for the patent family named &ldquo;TNF&alpha; inhibitor polypeptides, polynucleotides
encoding same, cells expressing same and methods of producing same&rdquo; adding to the four previously granted patents
in this family.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Scientific Presentations </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February&nbsp;13, 2020, Dr. Raphael Schiffmann of Baylor
Scott &amp; White Health , delivered an oral presentation entitled &#8220;Pegunigalsidase alfa, a novel PEGylated ERT, evaluated
in Fabry patients with progressing kidney disease, RCT study design,&#8221; describing the design and methods of the <I>BALANCE</I>
Study protocol, and the baseline characteristics for approximately 75 patients enrolled at 29 U.S. and European study sites. The
presentation was delivered at the 16th Annual WORLD<I>Symposium</I>&#8482; 2020, which took place February 10-13, 2020 at the Hyatt
Regency Orlando in Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the oral presentation, the following poster presentations
were delivered at the conference with respect to PRX&#45;102:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8220;Pegunigalsidase
alfa, a novel PEGylated ERT, evaluated in Fabry patients with progressing kidney disease, RCT study design.&#8221;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD>
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8220;Pegunigalsidase alfa, PEGylated &#945;-Galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal Gb3 inclusion clearance and reduction of plasma Lyso-Gb3,&#8221; by Dr. Derralynn Hughes of University College London in London, UK, a principal investigator in our phase&nbsp;III clinical trial of pegunigalsidase alfa for the treatment of Fabry disease.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8220;Switching
from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open
label study,&#8221; to be presented by Dr. Ales Linhart, of Charles University in Praha, Czech Republic, a principal investigator
in our phase&nbsp;III clinical trial of PRX-102 for the treatment of Fabry disease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research &amp; Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We continuously work on the further development of our ProCellEx
plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in
different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety.
Our development strategy focuses on the utilization of different modification approaches and development improvements, customized
for each protein product, in all stages of expression and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March&nbsp;16, 2020, we announced that we have agreed to
conduct a feasibility study with Kirin to evaluate the production of a novel complex protein utilizing ProCellEx. Kirin will provide
research funding for Protalix scientists to conduct cell line engineering and protein expression studies on the target protein.
Upon successful completion of the study, we anticipate holding discussions with Kirin regarding the licensing of the ProCellEx
technology and expression cells to Kirin for the continued development of the product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes
to our critical accounting policies since we filed our Annual Report on Form 10-K for the year ended December&nbsp;31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended March</I></B>&nbsp;<B><I>31, 2020 compared
to the three months ended March</I></B>&nbsp;<B><I>31, 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from selling goods of $5.0&nbsp;million
during the three months ended March&nbsp;31, 2020, an increase of $1.5&nbsp;million, or 43%, compared to revenues of $3.5&nbsp;million
for the three months ended March&nbsp;31, 2019. The increase resulted primarily from an increase of $0.8&nbsp;million in sales
of drug product to Brazil as well as an increase of $0.7&nbsp;million in sales of drug substance to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from license and R&amp;D services of $16.6&nbsp;million
for the three months ended March&nbsp;31, 2020, an increase of $9.7&nbsp;million, or 140%, compared to revenues of $6.9&nbsp;million
for the three months ended March&nbsp;31, 2019. Revenues from the license agreements represent the revenues we recognized in connection
with the Chiesi Agreements. The increase is primarily due to revenues recognized in connection with the progress of our clinical
trial that have been performed, and with revenues recognized in connection with an updated costs estimation throughout the trials
until completion in the amount of $6.7&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $3.4&nbsp;million for the three months
ended March&nbsp;31, 2020, an increase of $1.4&nbsp;million, or 68%, from cost of goods sold of $2.0&nbsp;million for the three
months ended March&nbsp;31, 2019. The increase is primarily due to an increase in sales of goods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $10.3&nbsp;million for
the three months ended March&nbsp;31, 2020, a decrease of $1.4&nbsp;million, or 12%, compared to $11.7&nbsp;million of research
and development expenses for the three months ended March&nbsp;31, 2019. The decrease was primarily due to a decrease in costs
related to manufacturing of our drug in development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: yellow"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses to continue to be
our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were $3.2&nbsp;million
for the three months ended March&nbsp;31, 2020, an increase of $1.0&nbsp;million, or 43%, compared to $2.2&nbsp;million for the
three months ended March&nbsp;31, 2019. The increase resulted primarily from a $0.6&nbsp;million increase in compensation related
costs and a $0.2&nbsp;million increase in professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses, Net </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expenses net were $3.0&nbsp;million for the three
months ended March&nbsp;31, 2020, an increase of $1.3&nbsp;million, or 75%, compared to financial expenses net of $1.7&nbsp;million
for the three months ended March&nbsp;31, 2019. Financial expenses are comprised primarily from expenses on outstanding convertible
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our sources of liquidity include our cash balances. At March&nbsp;31,
2020, we had $14.1&nbsp;million in cash and cash equivalents and $35.0&nbsp;million in bank deposits (both short and long term).
We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding. In the
fourth quarter of 2017, Chiesi made a payment to Protalix Ltd. of $25.0&nbsp;million in connection with the execution of the Chiesi
Ex-US Agreement and in the third quarter of 2018, Chiesi made a payment to Protalix Ltd. of $25.0&nbsp;million in connection with
the execution of the Chiesi US Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended March&nbsp;31, 2020, we completed
a private placement of common stock and warrants with committed net proceeds of approximately $41.3&nbsp;million. In connection
with the offering, we issued 17,604,423 unregistered shares of our common stock at a purchase price per share of $2.485 and warrants
to purchase an additional 17,604,423 shares of common stock at an exercise price of $2.36 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash used in operations was $7.1&nbsp;million for the three
months ended March&nbsp;31, 2020. The net income for the three months ended March&nbsp;31, 2020 of $1.7&nbsp;million decreased
by a $7.2&nbsp;million decrease in contracts liability, a $4.1&nbsp;million increase in account receivable and other assets and
a $1.3&nbsp;million increase in inventories, and was increased by an increase of $2.6&nbsp;million in accounts payable and accruals,
and by $0.8&nbsp;million amortization of debt issuance costs and debt discount. Net cash used in investing activities for the three
months ended March&nbsp;31, 2020 was $35.0&nbsp;million and consisted primarily of an increase in bank deposits. Net cash provided
by financing activities was $38.6&nbsp;million resulting from our issuance of common stock and warrants on March 18, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $7.3&nbsp;million
for the three months ended March&nbsp;31, 2019. The net loss for the three months ended March&nbsp;31, 2019 of $7.3&nbsp;million
was further increased by a $3.6&nbsp;million increase in accounts receivable, but was partially offset by an increase of $0.9&nbsp;million
in accounts payable and accruals and by a decrease in inventories of $1.9&nbsp;million. Net cash used in investing activities for
the three months ended March&nbsp;31, 2019 was $0.4&nbsp;million and consisted primarily of purchases of property and equipment,
and an increase in restricted deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of our significant research and development expenditures
and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations
since our inception. We currently have outstanding $57.9&nbsp;million aggregate principal amount of our <FONT STYLE="font-family: Times New Roman, Times, Serif">2021
Notes that are </FONT>secured with a perfected lien on all of our assets<FONT STYLE="font-family: Times New Roman, Times, Serif">.
Under the terms of the indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million.
</FONT><FONT STYLE="color: #333333">As previously disclosed, we have received a deficiency letter from the NYSE American stating
that we are not in compliance with the continued listing standards as set forth in Section 1003(a)(i) &#8211; (iii) of the NYSE
American Company Guide as we have reported a stockholders&#8217; equity deficiency as of June</FONT>&nbsp;<FONT STYLE="color: #333333">30,
2019 and net losses in our five most recent fiscal years ended December</FONT>&nbsp;<FONT STYLE="color: #333333">31, 2018. The
letter has no immediate effect on the listing of our common stock on the NYSE American. Our common stock will trade on the NYSE
American while we regain compliance with the continued listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future, including significant research and development expenses related primarily to the clinical trials of PRX-102. Our material
cash needs for the next 24 months will include, among other expenses, (i) costs of preclinical and clinical trials, (ii) employee
salaries, (iii) payments for rent and operation of our manufacturing facilities, (iv) fees to our consultants and legal advisors,
patents and fees for service providers in connection with our research and development efforts and (v) payment of principal and
interest on our outstanding convertible promissory notes and other debt. We believe that the funds currently available to us are
sufficient to satisfy our capital needs for at least 12 months from the date that the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be required to raise additional capital in the future
in order to develop and commercialize our product candidates and continue research and development activities. Our ability to raise
capital, and the amounts of necessary capital, will depend on many other factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain the listing of our common stock with the NYSE American;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our efforts, combined with those of Chiesi, to commercialize PRX-102;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs of commercialization activities, including product marketing, sales and distribution;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the progress and results of our clinical trials, particularly our clinical trials of PRX-102;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>conversions of our 2021 Notes from time to time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing and outcome of regulatory review of our product candidates; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual
property rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to finance our future cash needs through corporate
collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not
have any commitments for future external funding, except with respect to the development-related payments and milestone payments
that may become payable under the Chiesi Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our management is in the process of evaluating
refinancing and restructuring alternatives, including a restructuring of our outstanding convertible notes, and related transactions.
However, there is no certainty about our ability to obtain such funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the three months ended March&nbsp;31, 2020 and March&nbsp;31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of March&nbsp;31, 2020 and March&nbsp;31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_019"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The currency of the primary economic environment in which our
operations are conducted is the dollar. Most of our revenues and approximately 50% of our expenses and capital expenditures are
incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional
currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at
the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured
at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are
recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 40% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three
                                         Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March</B>&nbsp;<B>31,</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year
    Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt">Average rate for period</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center">3.504</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center">3.644</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center">3.565</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Rate at period end</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3.565</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3.632</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">3.456</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_009"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&nbsp;10&#45;Q.
The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure
that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&nbsp;10&#45;Q,
is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure
controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management,
including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&nbsp;10&#45;Q,
our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed
in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission,
and that material information relating to our company and our consolidated subsidiary is made known to management, including the
Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in Internal Control over Financial Reporting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">There were no changes in our internal
control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter
ended March&nbsp;31, 2020 that have materially affected, or that are reasonably likely to materially affect, our internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><A NAME="a_010"></A>PART II &#8211; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_012"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Except as set forth below, there have been
no material changes to the risk factors previously disclosed in our Annual Report on Form&nbsp;10&#45;K for the year ended December&nbsp;31,
2019.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The COVID-19 pandemic, or any other pandemic, epidemic
or outbreak of an infectious disease, may adversely affect our business, results of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a pandemic, epidemic or outbreak of an infectious
disease occurs in the United States, Europe, Israel or elsewhere, our business and operations may be adversely affected. In
December 2019, a novel strain of coronavirus, COVID&#45;19, was identified in Wuhan, China. The virus has spread globally. To
date, our clinical trials have not been adversely affected by COVID&#45;19. In response to the spread of COVID&#45;19 in
Israel, and with local directives issued in response thereof, we have restructured the work day within our facilities to
consist of two shifts thereby reducing the number of employees present in the facilities at any time, and facilitating their
ability to practice social distancing. Employees that are able to work from home have been instructed to do so. Such efforts
have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The spread of
an infectious disease, including COVID&#45;19, may also result in the inability of our suppliers to deliver components or raw
materials on a timely basis. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response
to the spread of an infectious disease, including the diversion of hospitals serving as our clinical trial sites and hospital
staff supporting the conduct of clinical trials. Such events may result in a period of business and manufacturing disruption,
and in reduced operations, any of which could materially affect our business, financial condition and results of operations.
While the extent of the impact of the current COVID&#45;19 pandemic on our business and financial results depends on future
developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the
severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others, a continued and
prolonged public health crisis such as the COVID&#45;19 pandemic may adversely affect <FONT STYLE="background-color: white">our
business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_013"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">Except
as set forth in our Current Report on Form</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">8&#45;K
filed on March 18, 2020, there were no unregistered sales of equity securities during the three months ended March</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">31,
2020.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_014"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
<TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Incorporated by Reference</B></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 8%"><B>Exhibit<BR> Number</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 40%"><B><BR>Exhibit Description</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 9%"><B><BR>Form</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 9%"><B>File<BR> Number</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 9%"><B>Exhibit</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 9%"><B>Date</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 9%"><B>Filed or<BR> Furnished Herewith</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company &nbsp;</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">333-48677</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">April&nbsp;1, 2016</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Def 14A</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Appen. A</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">July&nbsp;1, 2016</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">3.3</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Second Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Def 14A</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Appen. A</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">October&nbsp;17, 2018</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.4</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">Third Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm" STYLE="-sec-extract: exhibit">December 19, 2019</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.5</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">Bylaws of the Company</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">April&nbsp;1, 2016 &nbsp;</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Agreement/Notice &nbsp;</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">July&nbsp;18, 2012 &nbsp;</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">Indenture, dated as of December&nbsp;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent &nbsp;</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016</A></TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="width: 40%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing) &nbsp;</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="text-align: center; width: 9%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="text-align: center; width: 9%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="text-align: center; width: 9%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="width: 9%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016 &nbsp;</A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="text-align: center; width: 9%">&nbsp;</TD>
<TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.4</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange) &nbsp;</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016 &nbsp;</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.5</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">First Supplemental Indenture, dated as of July&nbsp;24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">July&nbsp;25, 2017</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.6</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">Second Supplemental Indenture, dated as of November&nbsp;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent &nbsp;</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K </A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">December&nbsp;1, 2017</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">4.7</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Warrant</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K </A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm" STYLE="-sec-extract: exhibit">March&nbsp;12, 2020</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">Form of Securities Purchase Agreement</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm" STYLE="-sec-extract: exhibit">March&nbsp;12, 2020</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="tm2014552d1_ex31-1.htm" STYLE="-sec-extract: exhibit">31.1</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="tm2014552d1_ex31-1.htm" STYLE="-sec-extract: exhibit">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="tm2014552d1_ex31-1.htm" STYLE="-sec-extract: exhibit">X</A></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="tm2014552d1_ex31-2.htm" STYLE="-sec-extract: exhibit">31.2</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="tm2014552d1_ex31-2.htm" STYLE="-sec-extract: exhibit">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="tm2014552d1_ex31-2.htm" STYLE="-sec-extract: exhibit">X</A></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><A HREF="tm2014552d1_ex32-1.htm" STYLE="-sec-extract: exhibit">32.1</A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="tm2014552d1_ex32-1.htm" STYLE="-sec-extract: exhibit">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="tm2014552d1_ex32-1.htm" STYLE="-sec-extract: exhibit">X</A></TD>
<TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><A HREF="tm2014552d1_ex32-2.htm" STYLE="-sec-extract: exhibit">32.2</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%"><A HREF="tm2014552d1_ex32-2.htm" STYLE="-sec-extract: exhibit">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer </A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><A HREF="tm2014552d1_ex32-2.htm" STYLE="-sec-extract: exhibit">X</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 54%">&nbsp;</TD>
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 41%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>(Registrant) &nbsp; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Date: June 1, 2020</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Dror Bashan</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Dror Bashan<BR>
 President and Chief Executive Officer<BR>
 (Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Date: June 1, 2020</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Eyal Rubin</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Eyal Rubin<BR>
 Senior Vice President and Chief Financial<BR>
 Officer, Treasurer and Secretary<BR>
 (Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tm2014552d1_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Dror Bashan, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">4.</TD><TD>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during
the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">5.</TD><TD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June 1, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Dror Bashan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dror Bashan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Chief Executive
    Officer &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tm2014552d1_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Eyal Rubin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">4.</TD><TD>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during
the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">5.</TD><TD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June 1, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Eyal Rubin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Eyal Rubin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sr. Vice President &amp; Chief
    Financial Officer, Treasurer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tm2014552d1_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&nbsp;31, 2020 as filed with the Securities and Exchange
Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June 1, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Dror Bashan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dror Bashan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Chief Executive
    Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tm2014552d1_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&nbsp;31, 2020 as filed with the Securities and Exchange
Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby
certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that
to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June 1, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Eyal Rubin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Eyal Rubin </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Senior Vice President
    and Chief Financial Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20200331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:31 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://www.protalix.com/20200331" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20200331.xsd" />
  <!--Context Section-->
  <context id="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-12-19</startDate>
      <endDate>2019-12-19</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_srt_StatementGeographicalAxis_plx_PfizerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_srt_StatementGeographicalAxis_country_BR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_srt_StatementGeographicalAxis_plx_PfizerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_srt_StatementGeographicalAxis_country_BR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_3_18_2020_To_3_18_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2020-03-18</startDate>
      <endDate>2020-03-18</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-18</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2020_To_5_31_2020_srt_ProductOrServiceAxis_plx_DrugSubstanceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:DrugSubstanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2020_To_5_31_2020_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2020_To_5_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-05-31</endDate>
    </period>
  </context>
  <context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-18</startDate>
      <endDate>2020-03-18</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-23</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-23</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-10-19</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-10-19</endDate>
    </period>
  </context>
  <context id="Duration_3_16_2020_To_3_16_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2020-03-16</startDate>
      <endDate>2020-03-16</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_3_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-07-23</instant>
    </period>
  </context>
  <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-10-19</instant>
    </period>
  </context>
  <context id="As_Of_5_24_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2020-05-24</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_3_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2020_To_3_31_2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2020_To_3_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2020_To_3_31_2020">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2020_To_3_31_2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2020_To_3_31_2020">2020-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2020_To_3_31_2020">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2020_To_3_31_2020">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_5_24_2020" unitRef="Unit1" decimals="0">32442636</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2020_To_3_31_2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2020_To_3_31_2020">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2020_To_3_31_2020">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2020_To_3_31_2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2020_To_3_31_2020">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="Duration_1_1_2020_To_3_31_2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="Duration_1_1_2020_To_3_31_2020">true</dei:EntitySmallBusiness>
  <dei:TradingSymbol contextRef="Duration_1_1_2020_To_3_31_2020">PLX</dei:TradingSymbol>
  <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">320000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
  <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">760000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
  <plx:AdditionalAmountsPayableToCoverDevelopmentCosts contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
  <plx:AdditionalAmountsPayableToCoverDevelopmentCosts contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">20000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
  <plx:ChangeInEstimateOfTotalCostsExpectedToBeIncurred contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">6700000</plx:ChangeInEstimateOfTotalCostsExpectedToBeIncurred>
  <plx:ChangeInOperatingLeaseRightOfUseAssets contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">36000</plx:ChangeInOperatingLeaseRightOfUseAssets>
  <plx:ChangeInOperatingLeaseRightOfUseAssets contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-10000</plx:ChangeInOperatingLeaseRightOfUseAssets>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember" unitRef="Unit13" decimals="2">1.00</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:FairValueAssumptionsExpectedDividendRates contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">0.1541</plx:FairValueAssumptionsExpectedDividendRates>
  <plx:FairValueAssumptionsExpectedVolatilityRates contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">1.0057</plx:FairValueAssumptionsExpectedVolatilityRates>
  <plx:FairValueAssumptionsRiskFreeInterestRates contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">0.0023</plx:FairValueAssumptionsRiskFreeInterestRates>
  <plx:FairValueAssumptionsTerm contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">P1Y7M17D</plx:FairValueAssumptionsTerm>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-59000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:IncreaseDecreaseInBankDeposits contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">35000000</plx:IncreaseDecreaseInBankDeposits>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">128000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">147000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
  <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
  <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
  <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
  <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
  <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
  <plx:NatureOfOperationsPolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;a.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;General&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Protalix BioTherapeutics,&amp;nbsp;Inc. (collectively with its subsidiaries, the &amp;#x201C;Company&amp;#x201D;) and its wholly-owned subsidiaries, Protalix&amp;nbsp;Ltd. and Protalix B.V. (the &amp;#x201C;Subsidiaries&amp;#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#x2019;s proprietary ProCellEx&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; protein expression system (&amp;#x201C;ProCellEx&amp;#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s product pipeline currently includes, among other candidates:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;pegunigalsidase alfa, or PRX&amp;#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;alidornase alfa, or PRX&amp;#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;OPRX&amp;#8209;106, the Company&amp;#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&amp;#x2019;s development and commercialization partner (&amp;#x201C;Chiesi&amp;#x201D;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &amp;#x201C;FDA&amp;#x201D;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA&amp;#x2019;s Accelerated Approval pathway.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 18, 2020, the Company completed a private placement of common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&amp;#x2019;s common stock, par value $0.001 per share (the &amp;#x201C;Common Stock&amp;#x201D;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing six months following their issuance for a period of five years from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&amp;#x2019; terms.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The net proceeds committed from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April and May, 2020, the Company collected total proceeds of approximately $9.0 million from accounts receivable outstanding at March 31, 2020. Total proceeds of approximately $4.7 million in connection with its collaboration with Chiesi, total proceeds of approximately $3.0 million from sales of alfataliglicerase to Funda&amp;#xE7;&amp;#xE3;o Oswaldo Cruz (&amp;#x201C;Fiocruz&amp;#x201D;), an arm of the Brazilian Ministry of Health (the &amp;#x201C;Brazilian MoH&amp;#x201D;), and total proceeds of approximately $1.3 million from sales of drug substance to Pfizer Inc. (&amp;#x201C;Pfizer&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October&amp;nbsp;19, 2017, Protalix&amp;nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &amp;#x201C;Chiesi Ex-US Agreement&amp;#x201D;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;nbsp;23, 2018, Protalix&amp;nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#x201C;Chiesi US Agreement&amp;#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&amp;nbsp;the &amp;#x201C;Chiesi Agreements&amp;#x201D;), Chiesi made an upfront payment to Protalix&amp;nbsp;Ltd. of $25.0&amp;nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&amp;nbsp;Ltd. is entitled to additional payments of up to $25.0&amp;nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&amp;nbsp;million per&amp;nbsp;year, and to receive additional payments of up to $320.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&amp;nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&amp;nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;nbsp;million per&amp;nbsp;year, and to receive&amp;nbsp;&amp;nbsp;additional payments of up to a maximum of $760.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&amp;nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into&amp;nbsp;between Protalix&amp;nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&amp;nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#x201C;Brazil Agreement&amp;#x201D;) with Fiocruz for taliglucerase alfa. Fiocruz&amp;#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NonRefundablePayment contextRef="Duration_3_16_2020_To_3_16_2020" unitRef="Unit12" decimals="-5">1000000</plx:NonRefundablePayment>
  <plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">2736000</plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
  <plx:OtherAssetsPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;e.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:normal;"&gt;Other assets include $1.0 million in connection with the March 2020 private placement of Common Stock and warrants, which was received after the quarter-end.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:OtherAssetsPolicyPolicyTextBlock>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit13" decimals="2">0.35</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit13" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit13" decimals="2">0.40</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit13" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
  <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">38607000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
  <plx:ReceivableFromIssuanceOfCommonStockAndWarrants contextRef="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit12" decimals="-5">1000000</plx:ReceivableFromIssuanceOfCommonStockAndWarrants>
  <plx:ReceivablesFromSaleOfCommonStockAndWarrants contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
  <plx:ReceivablesFromSaleOfCommonStockAndWarrants contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
  <plx:RevenueDisclosureTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;4&amp;nbsp;&amp;#x2013; REVENUES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table summarizes the Company&amp;#x2019;s disaggregation of revenues:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Three months ended March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Pfizer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1,356&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Brazil&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,174&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total revenues from selling goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,031&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,530&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenues from license and R&amp;amp;D services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 16,615&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 6,909&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the three months ended March 31, 2020, the Company recorded revenue in the amount of $6.7 million following a change in the estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&amp;#x201C;Kirin&amp;#x201D;) to evaluate the production of a novel complex protein utilizing ProCellEx&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt;, the Company&amp;#x2019;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0 million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:RevenueDisclosureTextBlock>
  <plx:ShortTermBankDeposits contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">0</plx:ShortTermBankDeposits>
  <plx:ShortTermBankDeposits contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">22509000</plx:ShortTermBankDeposits>
  <plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit14" decimals="3">2.485</plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues>
  <plx:SupplementaryIncomeStatementInformationTableTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table summarizes the Company&amp;#x2019;s disaggregation of revenues:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Three months ended March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Pfizer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1,356&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Brazil&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,174&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total revenues from selling goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,031&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,530&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenues from license and R&amp;amp;D services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 16,615&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 6,909&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
  <plx:TotalProceedsFromAccountsReceivableOutstandingChiesi contextRef="Duration_4_1_2020_To_5_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">4700000</plx:TotalProceedsFromAccountsReceivableOutstandingChiesi>
  <plx:TotalProceedsFromAccountsReceivableOutstandingFiocruz contextRef="Duration_4_1_2020_To_5_31_2020_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">3000000</plx:TotalProceedsFromAccountsReceivableOutstandingFiocruz>
  <plx:TotalProceedsFromAccountsReceivableOutstandingPfizer contextRef="Duration_4_1_2020_To_5_31_2020_srt_ProductOrServiceAxis_plx_DrugSubstanceMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">1300000</plx:TotalProceedsFromAccountsReceivableOutstandingPfizer>
  <plx:UpfrontNonrefundableNonCreditablePaymentReceivable contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
  <plx:UpfrontNonrefundableNonCreditablePaymentReceivable contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
  <plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">P6M</plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants>
  <us-gaap:AccountsPayableOtherCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">11905000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">13757000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">6495000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">9430000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">4700000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">8876000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">178000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">112000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">78000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">353000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">704000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">820000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit1" decimals="0">7826946</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit1" decimals="0">10694517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">45392000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">82876000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">32479000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">57767000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">12913000</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">25109000</us-gaap:AssetsNoncurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;b.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Basis of presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&amp;nbsp;year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S Securities and Exchange Commission (the &amp;#x201C;Commission&amp;#x201D;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;1&amp;nbsp;- SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;a.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;General&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Protalix BioTherapeutics,&amp;nbsp;Inc. (collectively with its subsidiaries, the &amp;#x201C;Company&amp;#x201D;) and its wholly-owned subsidiaries, Protalix&amp;nbsp;Ltd. and Protalix B.V. (the &amp;#x201C;Subsidiaries&amp;#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#x2019;s proprietary ProCellEx&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; protein expression system (&amp;#x201C;ProCellEx&amp;#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s product pipeline currently includes, among other candidates:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;pegunigalsidase alfa, or PRX&amp;#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;alidornase alfa, or PRX&amp;#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;OPRX&amp;#8209;106, the Company&amp;#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&amp;#x2019;s development and commercialization partner (&amp;#x201C;Chiesi&amp;#x201D;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &amp;#x201C;FDA&amp;#x201D;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA&amp;#x2019;s Accelerated Approval pathway.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 18, 2020, the Company completed a private placement of common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&amp;#x2019;s common stock, par value $0.001 per share (the &amp;#x201C;Common Stock&amp;#x201D;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing six months following their issuance for a period of five years from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&amp;#x2019; terms.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The net proceeds committed from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April and May, 2020, the Company collected total proceeds of approximately $9.0 million from accounts receivable outstanding at March 31, 2020. Total proceeds of approximately $4.7 million in connection with its collaboration with Chiesi, total proceeds of approximately $3.0 million from sales of alfataliglicerase to Funda&amp;#xE7;&amp;#xE3;o Oswaldo Cruz (&amp;#x201C;Fiocruz&amp;#x201D;), an arm of the Brazilian Ministry of Health (the &amp;#x201C;Brazilian MoH&amp;#x201D;), and total proceeds of approximately $1.3 million from sales of drug substance to Pfizer Inc. (&amp;#x201C;Pfizer&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October&amp;nbsp;19, 2017, Protalix&amp;nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &amp;#x201C;Chiesi Ex-US Agreement&amp;#x201D;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;nbsp;23, 2018, Protalix&amp;nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#x201C;Chiesi US Agreement&amp;#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&amp;nbsp;the &amp;#x201C;Chiesi Agreements&amp;#x201D;), Chiesi made an upfront payment to Protalix&amp;nbsp;Ltd. of $25.0&amp;nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&amp;nbsp;Ltd. is entitled to additional payments of up to $25.0&amp;nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&amp;nbsp;million per&amp;nbsp;year, and to receive additional payments of up to $320.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&amp;nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&amp;nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;nbsp;million per&amp;nbsp;year, and to receive&amp;nbsp;&amp;nbsp;additional payments of up to a maximum of $760.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&amp;nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into&amp;nbsp;between Protalix&amp;nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&amp;nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#x201C;Brazil Agreement&amp;#x201D;) with Fiocruz for taliglucerase alfa. Fiocruz&amp;#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;b.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Basis of presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&amp;nbsp;year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S Securities and Exchange Commission (the &amp;#x201C;Commission&amp;#x201D;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;c.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Earnings (loss) per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic and diluted earnings per share (&amp;#x201C;EPS&amp;#x201D;) are computed by dividing net income (loss) by the weighted average number of shares of the Company&amp;#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The calculation of diluted EPS does not include 7,826,946 and 10, 694,517 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March 31, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The computation of basic and diluted net income (loss) per common stock was adjusted retrospectively for all periods presented to reflect the Company&amp;#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December 19, 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;d.&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&amp;#x201C;ASC 606&amp;#x201D;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&amp;#x2019;s rights regarding the distinct goods or services to be transferred (&amp;#x201C;performance obligations&amp;#x201D;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;1.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenues from selling products&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;2.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue from Chiesi Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has identified two performance obligation in Chiesi agreements as follows: (1) the license and research and development services and (2) contingent performance obligation regarding future manufacturing.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;3.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue from R&amp;amp;D services&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;e.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:normal;"&gt;Other assets include $1.0 million in connection with the March 2020 private placement of Common Stock and warrants, which was received after the quarter-end.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;f.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Recently issued accounting pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2019" unitRef="Unit12" decimals="-3">30363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">14166000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">14166000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-7445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-3626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit14" decimals="2">2.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="0">17604423</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_3_31_2020" unitRef="Unit12" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">16335000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">19014000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">16980000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">7130000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-5">56200000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">50957000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">51777000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CostOfRevenue contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">2045000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">3426000</us-gaap:CostOfRevenue>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-5">57900000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember" unitRef="Unit13" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">1963000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">1879000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">405000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">376000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit14" decimals="2">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit14" decimals="2">0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;c.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Earnings (loss) per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic and diluted earnings per share (&amp;#x201C;EPS&amp;#x201D;) are computed by dividing net income (loss) by the weighted average number of shares of the Company&amp;#x2019;s Common Stock attributable to common stockholders outstanding for each period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The calculation of diluted EPS does not include 7,826,946 and 10, 694,517 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March 31, 2019 and 2020, respectively, because their effect would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The computation of basic and diluted net income (loss) per common stock was adjusted retrospectively for all periods presented to reflect the Company&amp;#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December 19, 2019.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">202000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-37000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_plx_Notes2021Member">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#x2019;s outstanding 2021 Notes&amp;nbsp;(a Level 3 valuation) as of March 31, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2021&amp;nbsp;Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Stock price (USD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2.35&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Expected term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1.63&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Risk free rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 0.23&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 100.57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 15.41&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;3&amp;nbsp;&amp;#x2013; FAIR VALUE MEASUREMENT&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of March 31, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the $57.9&amp;nbsp;million aggregate principal amount of the Company&amp;#x2019;s outstanding 7.50% convertible promissory notes due November 2021 (the &amp;#x201C;2021 Notes&amp;#x201D;) as of March 31, 2020 is approximately $56.2&amp;nbsp;million based on a Level 3 measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#x2019;s outstanding 2021 Notes&amp;nbsp;(a Level 3 valuation) as of March 31, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2021&amp;nbsp;Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Stock price (USD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2.35&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Expected term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1.63&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Risk free rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 0.23&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 100.57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 15.41&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-20000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">241000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">864000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">2611000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">3608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">4091000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-487000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-7171000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-1862000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">1333000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-2000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-299000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">214000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-22000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InventoryDisclosureTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;2&amp;nbsp;- INVENTORIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;Inventories at March 31, 2020 and December&amp;nbsp;31, 2019 consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;March 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,424&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,607&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 759&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 552&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,305&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,996&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 9,488&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 8,155&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">3996000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">5305000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">8155000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">8155000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">9488000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">9488000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">3607000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">3424000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">552000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">759000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentsAndOtherNoncurrentAssets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">0</us-gaap:InvestmentsAndOtherNoncurrentAssets>
  <us-gaap:InvestmentsAndOtherNoncurrentAssets contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">12505000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">115714000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">113757000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">45392000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">82876000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">40175000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">47628000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">75539000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">66129000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">38607000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-35079000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-7276000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-7117000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-7264000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">1667000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">1667000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">1667000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">1667000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;f.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Recently issued accounting pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-1730000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">-3026000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">4301000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">4301000</us-gaap:NotesPayableCurrent>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-5534000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">4693000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">1139000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">1126000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">4528000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">4481000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">5677000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">5713000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">1832000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">2728000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">509000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">210000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">1920000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">3229000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">190000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">203000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-13000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">35000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">170000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">66000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">2565000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">2531000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">-24000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">44000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Duration_3_18_2020_To_3_18_2020" unitRef="Unit12" decimals="-5">41300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromSaleAndCollectionOfReceivables contextRef="Duration_4_1_2020_To_5_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">9000000</us-gaap:ProceedsFromSaleAndCollectionOfReceivables>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">5273000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">5012000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">11698000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">10340000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;d.&lt;font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&amp;#x201C;ASC 606&amp;#x201D;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&amp;#x2019;s rights regarding the distinct goods or services to be transferred (&amp;#x201C;performance obligations&amp;#x201D;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;1.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenues from selling products&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;2.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue from Chiesi Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has identified two performance obligation in Chiesi agreements as follows: (1) the license and research and development services and (2) contingent performance obligation regarding future manufacturing.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;3.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Revenue from R&amp;amp;D services&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">10439000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_StatementGeographicalAxis_country_BR" unitRef="Unit12" decimals="-3">2174000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_StatementGeographicalAxis_plx_PfizerMember" unitRef="Unit12" decimals="-3">1356000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">6909000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">6909000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">3530000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">3530000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">21646000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_StatementGeographicalAxis_country_BR" unitRef="Unit12" decimals="-3">3015000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_StatementGeographicalAxis_plx_PfizerMember" unitRef="Unit12" decimals="-3">2016000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">16615000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">16615000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">5031000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">5031000</us-gaap:Revenues>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">233000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Duration_1_1_2020_To_3_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;Inventories at March 31, 2020 and December&amp;nbsp;31, 2019 consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;March 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,424&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,607&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 759&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 552&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,305&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,996&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 9,488&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 8,155&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">2230000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">3187000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit12" decimals="-3">290000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit12" decimals="-3">431000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharePrice contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit14" decimals="2">2.35</us-gaap:SharePrice>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">14838213</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">14838213</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">14838213</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">32442636</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">-52881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269657000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">15000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-322553000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2019" unitRef="Unit12" decimals="-3">-59855000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269947000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">15000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-329817000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">-70322000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">-70322000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">270492000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">15000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-340829000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">-30881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2020" unitRef="Unit12" decimals="-3">-30881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">308248000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">33000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-339162000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="Duration_12_19_2019_To_12_19_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="0">17604423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2019_To_3_31_2019" unitRef="Unit1" decimals="0">14838213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2020_To_3_31_2020" unitRef="Unit1" decimals="0">17381074</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:45 PM-->
<!--Modified on: 5/31/2020 7:30:45 PM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20200331" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20200331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element id="plx_SupplementaryIncomeStatementInformationTableTextBlock" name="SupplementaryIncomeStatementInformationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsRiskFreeInterestRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsRiskFreeInterestRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedVolatilityRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedVolatilityRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedDividendRates" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerMember" substitutionGroup="xbrli:item" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ReceivablesFromSaleOfCommonStockAndWarrants" name="ReceivablesFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_OtherAssetsPolicyPolicyTextBlock" name="OtherAssetsPolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_DrugSubstanceMember" name="DrugSubstanceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" name="StockIssuedDuringPeriodIssuePricePerShareNewIssues" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" name="WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ReceivableFromIssuanceOfCommonStockAndWarrants" name="ReceivableFromIssuanceOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" name="TotalProceedsFromAccountsReceivableOutstandingFiocruz" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" name="TotalProceedsFromAccountsReceivableOutstandingPfizer" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" name="TotalProceedsFromAccountsReceivableOutstandingChiesi" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" name="ChangeInEstimateOfTotalCostsExpectedToBeIncurred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_NonRefundablePayment" name="NonRefundablePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:45 PM-->
<!--Modified on: 5/31/2020 7:30:45 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637265502442684314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637265502442684314" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502442684314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637265502442684314" xlink:to="plx_ShortTermBankDeposits_637265502442684314" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637265502442684314" xlink:to="us-gaap_AccountsReceivableNetCurrent_637265502442684314" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637265502442684314" xlink:to="us-gaap_OtherAssetsCurrent_637265502442684314" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637265502442684314" xlink:to="us-gaap_InventoryNet_637265502442684314" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637265502442684314" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637265502442684314" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_637265502442684314" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637265502442684314" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637265502442684314" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637265502442684314" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637265502442684314" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637265502442684314" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637265502442684314" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637265502442684314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637265502442684314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637265502442684314" xlink:to="us-gaap_LiabilitiesNoncurrent_637265502442684314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637265502442684314" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637265502442694314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637265502442684314" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637265502442694314" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637265502442684314" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637265502442694314" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637265502442684314" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637265502442694314" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637265502442684314" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637265502442694314" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637265502442684314" xlink:to="us-gaap_LiabilitiesCurrent_637265502442694314" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637265502442694314" xlink:to="us-gaap_AccountsPayableTradeCurrent_637265502442694314" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637265502442694314" xlink:to="us-gaap_AccountsPayableOtherCurrent_637265502442694314" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637265502442694314" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637265502442694314" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637265502442694314" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637265502442694314" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637265502442694314" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637265502442694314" xlink:to="us-gaap_NotesPayableCurrent_637265502442694314" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637265502442704316" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637265502442704316" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637265502442704316" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637265502442704316" xlink:to="us-gaap_OtherNonoperatingExpense_637265502442704316" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637265502442704316" xlink:to="us-gaap_OtherNonoperatingIncome_637265502442704316" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_NetIncomeLoss_637265502442704316" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_ShareBasedCompensation_637265502442704316" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637265502442704316" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_Depreciation_637265502442704316" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637265502442714409" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637265502442714409" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637265502442714409" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_AmortizationOfFinancingCosts_637265502442714409" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637265502442714409" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637265502442714409" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637265502442714409" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_IncreaseDecreaseInInventories_637265502442714409" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637265502442714409" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502442704316" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637265502442714409" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" xlink:to="plx_IncreaseDecreaseInBankDeposits_637265502442714409" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637265502442714409" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637265502442714409" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637265502442724325" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502442714409" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637265502442724325" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637265502442724325" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637265502442724325" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502442724325" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637265502442724325" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637265502442724325" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637265502442724325" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637265502442724325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637265502442724325" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:45 PM-->
<!--Modified on: 5/31/2020 7:30:45 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637265502442734320" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637265502442734320" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637265502442744321" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637265502442744321" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637265502442754309" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637265502442754309" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637265502442764309" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637265502442764309" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502442774325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502442774325" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637265502442774325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637265502442774325" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637265502442774325" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637265502442774325" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637265502442784317" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637265502442784317" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637265502442804319" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637265502442804319" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637265502442814316" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637265502442814316" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_DrugSubstanceMember" xlink:label="plx_DrugSubstanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_DrugSubstanceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivableFromIssuanceOfCommonStockAndWarrants" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ReceivableFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502442874314" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502442874314" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedDividendRates" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NonRefundablePayment" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:45 PM-->
<!--Modified on: 5/31/2020 7:30:45 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Long-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Long-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory Note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total capital deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET (1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK-BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of receivables from sale of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivables From Sale of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase in bank deposits (including long-term deposits)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Decrease (increase) in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_OtherAssetsPolicyPolicyTextBlock" xlink:label="plx_OtherAssetsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsPolicyPolicyTextBlock" xlink:to="plx_OtherAssetsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Other Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_OtherAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Per share price at which the new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Issue Price Per Share, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Warrants And Rights, Commencement Period For Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, commencement period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Proceeds from Sale and Collection of Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Chiesi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total Proceeds from Accounts Receivable Outstanding - Chiesi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Chiesi</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Fiocruz</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total Proceeds from Accounts Receivable Outstanding - Fiocruz</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Fiocruz</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Pfizer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_lbl" xml:lang="en-US">Total Proceeds from Accounts Receivable Outstanding - Pfizer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_lbl" xml:lang="en-US">Total proceeds from accounts receivable outstanding - Pfizer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivableFromIssuanceOfCommonStockAndWarrants" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReceivableFromIssuanceOfCommonStockAndWarrants" xlink:to="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of receivable from issuance of common stock and warrants in connection with a stock offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivable From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (USD)</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsTerm" xlink:to="plx_FairValueAssumptionsTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Fair Value Assumptions Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsRiskFreeInterestRates" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedVolatilityRates" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedDividendRates" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">Change In Estimate Of Total Costs Expected To Be Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_lbl" xml:lang="en-US">Revenue recognized due to change in estimate of total costs expected to be incurred</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NonRefundablePayment" xlink:to="plx_NonRefundablePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Amount of non refundable payment not yet recognized to revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non Refundable Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NonRefundablePayment_lbl" xml:lang="en-US">Non refundable payments not yet recognized to revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_DrugSubstanceMember" xlink:label="plx_DrugSubstanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DrugSubstanceMember" xlink:to="plx_DrugSubstanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DrugSubstanceMember_lbl" xml:lang="en-US">This member stands for the product, drug substance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DrugSubstanceMember_lbl" xml:lang="en-US">Drug Substance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DrugSubstanceMember_lbl" xml:lang="en-US">Drug Substance [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/31/2020 7:30:45 PM-->
<!--Modified on: 5/31/2020 7:30:45 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20200331.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract_637159310362986621" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_DocumentType_637265502442914324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_DocumentPeriodEndDate_637265502442914324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityRegistrantName_637265502442914324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_TradingSymbol_637265502442914324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityCurrentReportingStatus_637265502442914324" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityInteractiveDataCurrent_637265502442914324" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityFilerCategory_637265502442914324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637265502442914324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntitySmallBusiness_637265502442914324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityEmergingGrowthCompany_637265502442924325" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityShellCompany_637265502442924325" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityCommonStockSharesOutstanding_637265502442924325" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_EntityCentralIndexKey_637265502442924325" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_CurrentFiscalYearEndDate_637265502442924325" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_DocumentFiscalYearFocus_637265502442924325" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_DocumentFiscalPeriodFocus_637265502442924325" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_637159310362986621" xlink:to="dei_AmendmentFlag_637265502442924325" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637265502442924325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637265502442924325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637265502442924325" xlink:to="us-gaap_AssetsCurrentAbstract_637265502442924325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502443084323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502443084323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="plx_ShortTermBankDeposits_637265502443094334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="us-gaap_AccountsReceivableNetCurrent_637265502443094334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="us-gaap_OtherAssetsCurrent_637265502443094334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="us-gaap_InventoryNet_637265502443094334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637265502442924325" xlink:to="us-gaap_AssetsCurrent_637265502443094334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637265502442924325" xlink:to="us-gaap_AssetsNoncurrentAbstract_637265502443094334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637265502443094334" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_637265502443094334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637265502443094334" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637265502443094334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637265502443094334" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637265502443094334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637265502443094334" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637265502443094334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637265502443094334" xlink:to="us-gaap_AssetsNoncurrent_637265502443094334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637265502442924325" xlink:to="us-gaap_Assets_637265502443094334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637265502443094334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_AccountsPayableTradeCurrent_637265502443094334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637265502443094334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_AccountsPayableOtherCurrent_637265502443094334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637265502443104317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637265502443104317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_NotesPayableCurrent_637265502443104317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637265502443094334" xlink:to="us-gaap_LiabilitiesCurrent_637265502443104317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637265502443104317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637265502443104317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637265502443104317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637265502443104317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637265502443104317" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637265502443104317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_LiabilitiesNoncurrent_637265502443104317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_Liabilities_637265502443104317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637265502443104317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_CommitmentsAndContingencies_637265502443104317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_StockholdersEquity_637265502443114317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637265502443094334" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637265502443114317" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637265502443114317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443114317" xlink:to="srt_ProductOrServiceAxis_637265502443114317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637265502443114317" xlink:to="srt_ProductsAndServicesDomain_637265502443114317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443114317" xlink:to="us-gaap_ProductMember_637265502443114317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443114317" xlink:to="us-gaap_LicenseAndServiceMember_637265502443114317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443114317" xlink:to="us-gaap_StatementLineItems_637265502443114317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_Revenues_637265502443114317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_CostOfRevenue_637265502443114317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637265502443114317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637265502443114317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_OperatingIncomeLoss_637265502443114317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637265502443114317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_OtherNonoperatingExpense_637265502443114317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_OtherNonoperatingIncome_637265502443124317" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_NonoperatingIncomeExpense_637265502443124317" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_NetIncomeLoss_637265502443124317" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637265502443124317" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443114317" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637265502443124317" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443124317" xlink:to="us-gaap_IncomeStatementLocationAxis_637265502443124317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637265502443124317" xlink:to="us-gaap_IncomeStatementLocationDomain_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637265502443124317" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637265502443124317" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637265502443124317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443124317" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637265502443124317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637265502443124317" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443124317" xlink:to="us-gaap_StatementEquityComponentsAxis_637265502443124317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637265502443124317" xlink:to="us-gaap_EquityComponentDomain_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637265502443124317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637265502443124317" xlink:to="us-gaap_CommonStockMember_637265502443124317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637265502443124317" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637265502443134317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637265502443124317" xlink:to="us-gaap_RetainedEarningsMember_637265502443134317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443124317" xlink:to="us-gaap_StatementLineItems_637265502443134317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_StockholdersEquity_637265502443134317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_SharesOutstanding_637265502443134317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637265502443134317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637265502443134317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637265502443134317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637265502443134317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637265502443134317" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_NetIncomeLoss_637265502443134317" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6372655024431343171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_StockholdersEquity_6372655024431343171" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6372655024431343171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443134317" xlink:to="us-gaap_SharesOutstanding_6372655024431343171" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_NetIncomeLoss_637265502443134317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_ShareBasedCompensation_637265502443144317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_Depreciation_637265502443144317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637265502443144317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637265502443144317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637265502443144317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_AmortizationOfFinancingCosts_637265502443144317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637265502443144317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637265502443144317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637265502443144317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInInventories_637265502443144317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637265502443144317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637265502443144317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637265502443134317" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637265502443144317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" xlink:to="plx_IncreaseDecreaseInBankDeposits_637265502443144317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637265502443144317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637265502443144317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637265502443144317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637265502443154317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637265502443144317" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637265502443154317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637265502443154317" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637265502443154317" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502443154317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637265502443154317" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637265502443154317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637265502443154317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637265502443154317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637265502443154317" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6372655024431543171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6372655024431543171" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637265502443154317" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637265502443154317" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637265502443154317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637265502443154317" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637265502443154317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502443154317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637265502443154317" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637265502443154317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637265502443164317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637265502443164317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637265502443164317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637265502443164317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637265502443164317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637265502443164317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637265502443164317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637265502443164317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637265502443174318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_OtherAssetsPolicyPolicyTextBlock" xlink:label="plx_OtherAssetsPolicyPolicyTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_OtherAssetsPolicyPolicyTextBlock_637265502443174318" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637265502443174318" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443174318" xlink:to="us-gaap_DebtInstrumentAxis_637265502443174318" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637265502443174318" xlink:to="us-gaap_DebtInstrumentNameDomain_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637265502443174318" xlink:to="plx_Notes2021Member_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443174318" xlink:to="us-gaap_StatementLineItems_637265502443174318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443174318" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637265502443174318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637265502443174318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="us-gaap_TypeOfArrangementAxis_637265502443174318" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637265502443174318" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443184315" xlink:to="plx_AmendedPfizerAgreementMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443184315" xlink:to="plx_ChiesiUSAgreementMember_637265502443184315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443184315" xlink:to="plx_ChiesiExUSAgreementMember_637265502443184315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="dei_LegalEntityAxis_637265502443184315" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637265502443184315" xlink:to="dei_EntityDomain_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637265502443184315" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="srt_StatementGeographicalAxis_637265502443184315" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637265502443184315" xlink:to="srt_SegmentGeographicalDomain_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637265502443184315" xlink:to="country_BR_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="srt_RangeAxis_637265502443184315" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637265502443184315" xlink:to="srt_RangeMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637265502443184315" xlink:to="srt_MinimumMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637265502443184315" xlink:to="srt_MaximumMember_637265502443184315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637265502443184315" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637265502443184315" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637265502443184315" xlink:to="us-gaap_PrivatePlacementMember_637265502443184315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637265502443184315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="us-gaap_SubsequentEventTypeAxis_637265502443184315" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637265502443184315" xlink:to="us-gaap_SubsequentEventTypeDomain_637265502443194312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637265502443194312" xlink:to="us-gaap_SubsequentEventMember_637265502443194312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="srt_ProductOrServiceAxis_637265502443194312" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637265502443194312" xlink:to="srt_ProductsAndServicesDomain_637265502443194312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443194312" xlink:to="plx_AlfataligliceraseMember_637265502443194312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_DrugSubstanceMember" xlink:label="plx_DrugSubstanceMember_637265502443194312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443194312" xlink:to="plx_DrugSubstanceMember_637265502443194312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637265502443174318" xlink:to="plx_SignificantAccountingPoliciesLineItems_637265502443214323" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637265502443214323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637265502443214323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637265502443214323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637265502443214323" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637265502443214323" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637265502443214323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637265502443214323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637265502443224316" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637265502443224316" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637265502443224316" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_PaymentOnNetSalesPercentage_637265502443224316" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637265502443224316" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637265502443224316" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637265502443224316" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637265502443224316" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637265502443224316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637265502443224316" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637265502443234324" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637265502443234324" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637265502443234324" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndCollectionOfReceivables" xlink:label="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_ProceedsFromSaleAndCollectionOfReceivables_637265502443234324" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingChiesi" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingChiesi_637265502443234324" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz_637265502443234324" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_TotalProceedsFromAccountsReceivableOutstandingPfizer" xlink:label="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_TotalProceedsFromAccountsReceivableOutstandingPfizer_637265502443234324" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_637265502443234324" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ReceivableFromIssuanceOfCommonStockAndWarrants" xlink:label="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_637265502443234324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637265502443214323" xlink:to="plx_ReceivableFromIssuanceOfCommonStockAndWarrants_637265502443234324" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637265502443244318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637265502443244318" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637265502443244318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_StatementTable_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443244318" xlink:to="us-gaap_DebtInstrumentAxis_637265502443244318" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637265502443244318" xlink:to="us-gaap_DebtInstrumentNameDomain_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637265502443244318" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443244318" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443244318" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443244318" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443244318" xlink:to="us-gaap_FairValueInputsLevel3Member_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443244318" xlink:to="us-gaap_StatementLineItems_637265502443244318" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637265502443244318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443244318" xlink:to="us-gaap_SharePrice_637265502443244318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443244318" xlink:to="plx_FairValueAssumptionsTerm_637265502443254331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443244318" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_637265502443254331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443244318" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_637265502443254331" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443244318" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_637265502443254331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_StatementTable_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443254331" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443254331" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637265502443254331" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637265502443254331" xlink:to="us-gaap_FairValueInputsLevel3Member_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443254331" xlink:to="us-gaap_DebtInstrumentAxis_637265502443254331" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637265502443254331" xlink:to="us-gaap_DebtInstrumentNameDomain_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637265502443254331" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443254331" xlink:to="us-gaap_StatementLineItems_637265502443254331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443254331" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637265502443254331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443254331" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637265502443254331" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637265502443254331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443254331" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637265502443254331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443264318" xlink:to="srt_ProductOrServiceAxis_637265502443264318" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637265502443264318" xlink:to="srt_ProductsAndServicesDomain_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443264318" xlink:to="us-gaap_ProductMember_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637265502443264318" xlink:to="us-gaap_LicenseAndServiceMember_637265502443264318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443264318" xlink:to="us-gaap_TypeOfArrangementAxis_637265502443264318" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637265502443264318" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637265502443264318" xlink:to="plx_ChiesiUSAgreementMember_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443264318" xlink:to="srt_StatementGeographicalAxis_637265502443264318" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637265502443264318" xlink:to="srt_SegmentGeographicalDomain_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637265502443264318" xlink:to="plx_PfizerMember_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637265502443264318" xlink:to="country_BR_637265502443264318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637265502443264318" xlink:to="us-gaap_StatementLineItems_637265502443264318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443264318" xlink:to="us-gaap_Revenues_637265502443264318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred" xlink:label="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443264318" xlink:to="plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred_637265502443264318" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20200331.xsd#plx_NonRefundablePayment" xlink:label="plx_NonRefundablePayment_637265502443264318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637265502443264318" xlink:to="plx_NonRefundablePayment_637265502443264318" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2014552-1_10qimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2014552-1_10qimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $W FL# 2(  A$! Q$!_\0
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MO-SG/X4>S=[7#VJM>S-FBLFQOKX*_P!N6 MGY?*)Z>^:@N;W5S<-]E6T$/\
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M>RNYX)I'CN#*MK#Y>"0=_P#%CWJ2YM9K?[7%';S/;M-$1]Y@!M^8X!R>>HH
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M-+2YU&^6V9@T4>_[V[.,=OQKG%NA::[/)'G**&&#[\UUF@:ZL^HZ@96=/,*
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MTYH ]UM0!(1[5;K/TQ%ABCA7)"1A06.2<>M:% !1110 4444 %%%% !1110
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M[*&O[Q<GF-V^OS8J]J@)@=1U9@!^)I;+2S9:G.ZHJQ- 43!YZY(I;I?-VC(
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MUU>K:+9W'AR2[;4DB,L#2)$Y)/';ZU7_ .$/M;/3UN[O4E-LRJ)7C()&1P*
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M[DFI],F23>T;C:PZ^U;NL>%TU%69(P&/\)X_*N?'A>6TG86\LD1/!5QQGZT
M=1IDK0VK+&1A0<8%;YOV%I:E4C#$Y/R]?K7$6\.LV<(!C60L"OR'-;(N[R.&
MT2:TE$@!RH7I0!U-QXCGVGS+>WD'T(_E7.W>J133;VLH!S]T$XK.O-:>-&#Q
M.&Z %<9-9<UY?+C=I]QD_P"P: -K6);:ZM$@2PM[<$'YHR<^_6KD&O3OX2GM
M?LZ/*&\M&\@%=H'<_P![TKD[W4;DPJS6DZ,,CE#3='\8:YI\+06$+A&;<0T6
M>?QH VS;ZRT >.&["R+M;RXR/Y5MZKHU[J][;R06SQ0+"JO<W6%C3;UW9.:Y
M&Z\2>-+T!5NYH5/]PA:I+9:UJ9V:EJ4TJ-_ '+9_"@#IM<U'1O$MW#I5G$+N
M]B'S7V"(QCJJ#N*K#PE#N4O#'Y@_B49/ZU;\.Z NE1!HT*'KE_O-_A6\/]I?
MQH YC_A$;,966!';^\PYJS8^$K>.9!"&)!R%7L:Z>UTV2Z;.-D8/+'O]*W;6
MTAM5Q$G/<GJ: )?"NF&SN6D<_.8]N!V&174UD:3_ ,?+>FW^M:] !1110 44
M44 %%%% !1110 5BI=Q7KRO"2560H<C'(ZUM5SFG6LMHEPDR[6:=W SG@GBM
M()6;,JC=TNA;HHHIB"BBB@ K'\5C=H4B_P!YL?H:V*R/%(']@S,3@)\WZ&@#
MP..(LPW2!L9SMZ#\:ZO2YXO^$?NGC9HHQM^8CD'UQ7.6)F@"PPPJV?O2*,G'
MUKJ]/A%SI]RGFB16*Y;'!QV_2LHJQJW<SO#SPB]<%I;DRABT>TX"^GU->JVD
M&R%!LV<#Y?3VK/T*S%O '9%5GYX&,#M6Y&G>J;N(5(_:IT6D45*HH ;MYHVU
M)CFC% #0M&VGXI<4@(]M-*5-BD(H J20@U0O;>)(WF:($J,DA<MBM=A5>5:
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M10 M%)N'J*-P]10 M%)N'J*-P]10 M%)N'J*-P]10 M%)N'J*-P]10 M%%%
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MVW=GC'N* -S;'D#"9(R!Q0%C(R A'J,8K#70+@0/%O@RZ;1,<[X_E(POM_\
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M\EL?A0!7M;N6:29&09A&UL#JW;'X8/XU275[DP&3RXV;@A!UYSD?AC/YUI1
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M;Q8I2FQVVJ&=EZ*#Z_D:0Z?;$L?+Z_[1XYSQZ<@5)+:0S2!Y$RP&.IP?J.]
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M[QN1C&#STQQBGQ6-C(9GBC5M^Z.09./1ACMTHU#01]51;AH(X)I95)RJ =
M2>?]X5#!K2O%*TT#H8]QP"#E0^P5,-'LMI7RFZ[B?,;)R #DYSC ''M43V.E
MM&96 V>85)#L!NW<C_OKMZT ,?Q%;QB,O#,-X+ 8&=H.-WY]NM3:AJ9M"4AA
M:610C,?X4#-@$_K4K:7:.L:F+ C!48<C@G.#SR,]C4<\-A>F&:4AM[;$8,0&
M(.0..N"#UH K_P#"26A$C+',RJ>" ,,,XSGM^-..N1@R;8992J^9M0#(4*&)
M)S@]:G&F61,BJC Y&0'8;3UXYXZ]JKW>@P30B.V*P#!5L DX(QZ^@^E&H:$]
MMJT=S<+$L4JABRJ[8P2 "1^1J"YUV.*=X(XSYJL "Q&#\P4]#D=>]7H;&W@,
M>Q,-&2P.><D8)_2J_P#9>G?:?N#S3F0+O/J"2!GU H @AUY&M5ED@D/ #L@&
MT.1D+USTI6\16F'V)*^QL':.W'S?3G&?K5J/2[.*1'2( KC:-QQP, XZ$X[U
M&NF:="XA2)4=H]H"L0=JG/7V)HU#02ZU%QID-S:1AFFD1 &((7<<9Z\TW^W(
ML)BWG)EQY0P/W@)QD<\<^M6OLMK!:)%L"PQ,&49/!SD'\Z8FE6<;[UB&58,/
MF)VX.>/09[4 1RZJL&K"RD7EHA(N.HZ[B?8 56'B:S:,,$ERQ&Q<#Y@03G/3
MM5^YM[1IDEN%7S'955B>I&2!^II@TBR";1&P&05(D;*X]#G@<GI1J&A ==A,
M;.L,PC  $C+QN*[@,9S2+KT)3<T,P!R%; P[ @$#GU(I\>DV0NIV;YBVW"%C
MA1MV_0G&>>M23:5;26IBC54(#;2>=I;&3C\!1J&@C:M%'937,T4D?DR>4R-C
M=NR!CT[U$NO0/'O2"=@N/,P!^[RVT9]>?2GVNGV\-L]E-()6E8S,,G/7J.<\
M''.:;<:593XMT)295#@AB3C=G)YYY'>@!9-9C"PF.-R90& QR021CZ\4R;Q!
M:Q1&4)(\8 )8$#L">IY(!'%68]*LHI?-2+#!@02Y(&#D8YXY)XJ*?2M-CMSY
ML2I$F[.&(^^><X[$T:AH0#Q# DICE5BWF,/D'1=V 3_]:G'70RQ^5:RDR,@7
M>0-REMI(Y]:M?V59[PPBPRG/#D9YSSSSSZTITRT**IBP$ "X8C #;A^M %ND
MI:2F(HZI(\;V.QV7-T@.#C(]*Z:LE$A>>+SPA ;*[_[W;'O6M2F[I(=.-FV%
M%(P)4@'!]:C\M_\ GLWY"LS4EHJ+RW_Y[-^0H\M_^>S?D* ):*B\M_\ GLWY
M"CRW_P">S?D* ):*B\M_^>S?D*/+?_GLWY"@"6BHO+?_ )[-^0H\M_\ GLWY
M"@"6BHO+?_GLWY"CRW_Y[-^0H EHJ+RW_P">S?D*/+?_ )[-^0H EHJ+RW_Y
M[-^0H\M_^>S?D* ):*B\M_\ GLWY"CRW_P">S?D* ):*B\M_^>S?D*/+?_GL
MWY"@"6BHO+?_ )[-^0H\M_\ GLWY"@"6BHO+?_GLWY"CRW_Y[-^0H EHJ+RW
M_P">S?D*/+?_ )[-^0H EHJ+RW_Y[-^0H\M_^>S?D* ):*B\M_\ GLWY"CRW
M_P">S?D* ):*B\M_^>S?D*/+?_GLWY"@"6BHO+?_ )[-^0H\M_\ GLWY"@"6
MBHO+?_GLWY"CRW_Y[-^0H EHI ,  G/O2T %%%% !7/V5D]B)XY&5BTS.-OH
M3705S]E>O?">2154K,R +Z UI"]GV,JEN97W+%! 8%6&01@CVI""3PQ'X4FU
MO[Y_(4Q&'_8EUM!D,5P5W1JCN0-F,(?J.3^-!T>^C254DCD:5&0LSD==OS?7
M@UN;6_OG\A1M;^^?R%*P[F*V@N=SCR_-(<AMQ^\9 RG\!D5/I>ESV6H2332;
MPV[+;\[\MD$C'8>YK3VM_?/Y"C:W]\_D*+ 8UKHLT,RRR%#*LR,&#'(09W#\
M<TMYI%U-JDES'(,-@H6?&WY<;< 9P3[UL;6_OG\A1M;^^?R%%@N8$.B7<8/F
M)!*A;(@9R%SLQG@=B,_CZU=L-*>TNTF.P,6E,A4GY@Q!7\L5I;6_OG\A1M;^
M^?R% &"=%OFNI96,.UL[D#$"3YPP!XST&.<TBZ%<@#,=O@R!U'F']P!(6.WC
MG(/Z5O[6_OG\A1M;^^?R%%@N8,&A7462[)+AE+(TGRSX)//''7WJQ_94PTFR
MMVA@D:WEWO$SD*1\W ./<5K;6_OG\A1M;_GH?R%%@N8(T.[5"':*<;2H5W("
MDJ &_#%$^@7#Q##J[F1V?+XW@@!23@],'\ZWMK?\]#^0HV-_?/Y"BP7,&71+
MY[EG$L:_*R[PQRP*8&>,]1ZTZ319WD$D<%M%\I4QJYQC<IQGT."#BMS:W]\_
MD*-K?\]#^0HL%S-TW2WMKU[B98\%2(T5B1%EB<#VP:JOHMUY[2*(=XW'S2YW
M2DN& /IP,5N;6_OG\A1M;^^?R% 7,8:/<R//+-Y0ED.4PY.S]YN/Z<5#+I4E
MG#'(55E&WSD!8B4[R><=L'K6_M;^^?R%&UO^>A_(46"YD6FG-<Z18Q3Q*JI/
MYKQN3]W+8'ZBH?[#O/+";HR^%"S%SNC !&T>QK=VM_ST/Y"C:W]\_D*+!<PY
M]$F\M88X8'A98U<%\$;0=V#CJ2>M))H=S)E<1("Q+,)#F12P(4^P Q6[M;^^
M?R%&UO[Y_(46"YB3:).)':!(""'50Q^ZI<, /PS5C2=,N+)W,[(08V10K9QE
MR1V'8UI[6_OG\A1M;^^?R%%@N8,.B7<2;72"6,-GR7D.&^7&2P'./SI'T2^>
MY=RT(#!@=K'YAE2.V>,=S6_M;^^?R%&UO[Y_(46"YEZ5I<]E=RRS2;@P(+;\
M[R6SDC'^-4Y=-O4%LLD44RHT<>P2'#@,Q);C@<BN@VM_?/Y"C:W_ #T/Y"BP
M7(=/MWM;&*&5@77.<'('.<#Z=*L4W:W]\_D*-K?WS^0IB*.K E[# )_TM*ZB
MLA;F&UGA,SA0[[%R.K'H*UZ4WHD.FDFV5-52ZDTNY33W"7;1D1,3T;'%5/#4
M.JV^CHFN2K+>AVW,I!&,\=*UJ*S-3/NH[AKUS"0J_9\9*D@G)Z<]:HFXN;:V
M;)>(+'N!"9)8*O!]NM;U1R013%3)&KE>F1G% %&R%PEP-Q<QR/(2"O"\\<_G
M40-XDDWE^8JAV<#;G=\_^%:]% &)FZCD+[92>"%"9 P7Z>_3\ZELWN9;N,S"
M0JI;#$8X*CV'?-:U% &2'O!)(5WJJMD*$X;,A!_2FRSZ@%Z,JHWELVSDX!.X
M<'@\5L44 8LTM\ZR1MYF6B_@3&T[?IZ^]/9[XAV227&)"H\L=L;>W>M>B@#'
M-QJ)>8<J<G "9P-PP1QZ9J:W^T?V@/.:4JJNH)'!Y&"?PK2HH RXQ=20JUN<
M2EWWEC\H^;H1U_*JIQ'>W9>&:4$9;:&#=>!Z$'^5;H4+G: ,G)QW-+0!AF)E
M6%@'=ADI&8VVY+= >V*6-;A94$7F)(3MG;;GJ_7GCIFMNB@#'+W0M93.SD^5
MN4E<8<-@?TK7'09ZT,H888 @'/-+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %84%DM@9HU<N&E9\D>M;M<K9:HC_:/MEU&)%G
M=0'(!V@\5K34FG8QJRBFKD&LV^M2ZI8OI<ZQVBD?:%+ ;N?IZ5LORK8]#BFQ
MR),@>)@Z'HRG(-0G4;,$@W4((Z_.*%%["<DM3+M[N4:391)]IC9 JW#B$ED&
M#TR.><>M0F]UM=@\IR2 2?+_ +_RK_WR1N/UKH?,7R_,W#9C=NSQCUJ :C:,
M0!=0DGH XHY6QN26Y1U,727L36QDW"'875<X)D7)QTSC-4YOM[7 \PSE8I0N
M]4Y=0S@9P.1TKH))4@0O*X1!U9C@5''?6TKA([B)W/15;)-'*WJ',EH<[/<Z
MF\ @6*<(8=C)Y>!_J\Y&!Z^_X5J:B;L7EN+;>H9%5G5,[<NN?TS6C-<16X!F
ME6,'H6.,TV&[@G8K#-'(P&2%;-'*]PYEL9/VC5EVQHK.S[\.R 8V$]?]X;?U
MJM]MU86>\M(2&'2$[B=O*_=]?;VS6_-=P6[!9IHXV(R S8IT-Q%< F&59 ."
M5.<4<KM<.97L8!?4U-SY4ERK R2@-&#S\NU1QTY/ IUS<ZM#*8XV<HKL%D,6
M2Y^7 .!TY/I]:VI+ZVB<I)<1(Z]59L$5+%*DR!XG#H>C*<BCE:#F3T,"[;4G
MMI-TD^',F51.4"N,8XSR,_6K]V9'U$JGF'%J6B",%8L6P3SQG&/SJR=1M%)!
MNH01U!<5,?+95F.TA02']!]:.5H%)/8YS5H[P)9M>#SIE<[4C5MK>@)'1_?I
M2R+YTUP\,5S$JD"165MTR[P7)/3 &0 .V:W!J-F2 +J$D]/G%3R2K"A>5PB#
MJS' %'*T',GU.?C-^BN+5IHK<'="OEYRIDQWY^[SBKEL\_V^V$K,S_OD<L,%
MD5OE8C_/6K\=];2N$CN8G=NBJV2:=-)!;D23.D98;0S'&?:CE:T#F3U)**BB
MN[>=BL,T<C 9PK9-$UU!;L%FFCC)&0&;&:=G>PN96O<EHID-Q%< F&5) .NT
MYQ3)+VVA<I+<1(XZJS8(HL]@YE:]R:BFQ2I.@>%U=3QE3D5"=0M%)#74((."
M"XXHLPYDNI8HI ZM&) P*$9W=L>M0#4;,]+J'G_;%"38.26[+%%))(D2%Y&"
M(.K-P!4*7UK(X2.XB9FX"A@2:+-@VEN3T4R:>*W4--(L:DX!8XIL5W;SOLAG
MCD;&<*V319[A=7L2T5'-<P6Y FF2,GD!FQFB&XAN,^1*DFWKM.<46=KA=7L2
M45#)>6T+E);B)''56;!J2*6.=-\+K(N<94Y%%GN%TW8JZC;RW#V0A0N4N49L
M=@.IKI*P!J]K;74*^8LCO((]J$$@GCFM^E4O9)H=/ENVF%%%%9&P4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %5)=*L9I&DEM('=NK,@)-%%--K8
M32>Y/#!%;Q".&-8T'15& *K'1M.8DFRMR3R3Y8HHH4FMF)QB]T6O)C,/E;%\
MO;MVXXQZ5571].5@RV5N"#D$1CBBBA2:V8.*>Z+,]O%<Q&.>-)$/56&14$6E
MV,$JR0VD*.O1E0 BBBA2:5KC<4W=HEN+.WNU5;B&.4*<@.H.*9;Z?:6CE[>V
MBB8C!** <444<SM:X<JO>P7&GVEVX>XMHI6 P"Z@D"G6]G;V@86T$<08Y(10
M,T44<SM:X<JO>Q'+I=C/*TDUI"[MU9D!)J>"WBMHA'!&D:#HJC HHH<FU:X*
M*3ND5FT?3F8LUE;DDY),8YJT(8Q#Y01?+V[=N.,>E%%#DWNQ**6R*HT;3E((
MLK<$=/W8JS-!%<1&.:-9$/56&0:**')O=@HQ6R((M*L8)5DBM($=>0RH 14M
MQ:6]VH6XACE53D!USBBBCF=[W#EC:UAEOI]I:N7M[:*)R,$H@!Q2W%A:W;!K
MBWBE91@%U!P***.9WO<.6-K6%M[.WM PMH(X@W78H&:9-IEE<2F2:TAD<]69
M 2:**.9WO<.6-K6)8+>&VC$<$21H#G:HP*KMH^GNQ9K*W+,<DF,<FBBA2:Z@
MXQ>C1:6&-81$J*(PNT*!QCTJJ-&TX$$6-N"/^F8HHH4FMF#C%[HLS017$1CF
MC5XVZJPR#4$6E6,,BR16D".IR&5 "***%)K1,;BF[M$MQ:07:!;B&.50<@.N
M<&F0:=9VLGF6]M%&^,;D0 XHHHYG:UPY5>]A;BPM;ME:XMXI648!=0<4MO96
MUIN^S01Q;NNQ0,T44<SM:X<JO>PR;3+*XE,DUK#(YZLR DU+!;0VL?EP1)&F
J<[5&!111S-JUP44G>Q#_ &78^=YOV2#S-V[=L&<^M6Z**&V]P22V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2014552-1_10qimg02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2014552-1_10qimg02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" &D G # 2(  A$! Q$!_\0
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M6871Q?B;2[^X\7^==Z5<ZMIC1!8(8I=J(_?<,_6J5IX=U6'P+KVGMISI<RW
M:*)""&&1]TYZ#%>@_P!J6'_/[;_]_5_QH_M2P_Y_;?\ [^K_ (TN5VL',KW.
M3\2:-J%WX=\/06]K))+;RPM*@QE %YS3[BVU#3_B4VH1Z=/<6MU D/FQXQ&>
M,EOIBNI_M2P_Y_;?_OZO^-']J6'_ #^V_P#W]7_&G9WN%U:QYC/X=U:Y75(;
M[1+B]U.1V:*^DF_=JO;:,]?0>]:5UI]_IZ^&-0@A1K^S@\E[&214D<=/ER>>
MI_2N\_M2P_Y_;?\ [^K_ (UE:[I^@>(8XA?7,.^$YCDCG"NGT-%F@NF<S9F\
MU3XDS#4;<6DDVG,OE*^\QJ1@9([UF6_AO4+*R?2I?#T]U<^80MQ]I86[(3U(
M!%=KHFE:!H,\L]M>))<2C:\T]R'<CTS6S_:EA_S^V_\ W]7_ !HL',CCO$NC
MRAK*"?P\FI6$-N(P]JY$\3 =,D\K5[P!I>HZ;:7GVU)X+:27-M;SR;WC7W_3
M\JZ/^U+#_G]M_P#OZO\ C1_:EA_S^V__ ']7_&BS"Z.>\8:3?OJ>EZUID'VF
M:P<[[?."ZGT]ZK6-GJ?B'QC:ZS>Z?)IUI8Q%(TF(WR,<]AVYKJO[4L/^?VW_
M ._J_P"-']J6'_/[;_\ ?U?\:$F@;3.?\"Z9>::NK"]MWA\Z\:2/=CYE]:;\
M0=*N]6L=/CL[9[@I=*TBKCA>Y.:Z+^U+#_G]M_\ OZO^-']J6'_/[;_]_5_Q
MHLPYD1V>B:982^;:6%M#)_?2( _G6'I.F7D'Q#UB^EMW6UFA18Y3C#'C('Y5
MT']J6'_/[;_]_5_QH_M2P_Y_;?\ [^K_ (T6=PNCD5@U;PIXDU2YMM*EU*SU
M%Q*I@8;D;G@Y[<FL75=%O-,\!:M=ZDJQ76H7:3-$ISY8W<#Z\FO2/[4L/^?V
MW_[^K_C5'6$T?7=.>RO;N$PN02$G"G@Y'-+E=A\RN<G>PZWXHM](TN727M8K
M=XY9KIG!C8 <%?J.U;6E:9>0_$/6+Z6W=;6:!%CE.,,1MR!^5;T6H:?#"D27
MEOM10HS*.@_&G?VI8?\ /[;_ /?U?\:=G>Y-U8Y$>'+V\U_Q2)(6B@OH D,S
M8VL<#^M8=GX>OI+>UTR;PW.;A'"S7$]R_D%0?O !NOTKTK^U+#_G]M_^_J_X
MT?VI8?\ /[;_ /?U?\:$FA\R.5O;2_TWXB0:C!IT]U:2VRV^Z+'R'."3GTKG
M[GP_JMS<:M%?Z)<7]_*[FWO'F_=1KVP,]?05Z5_:EA_S^V__ ']7_&C^U+#_
M )_;?_OZO^-%F',CAUT/4G@\' V,H-DY^T X_=\CD\^U:_Q$M2= 34HF"7&G
M3+/&Q/O@C^7Y5T/]J6'_ #^V_P#W]7_&L;6])T'Q!<PRW]\&$0QY27(5&YSR
M.]#3!-#/ &GO:^'%NKC_ (^;^1KF0GK\W3]/YU!X^TF[U9=)2UM6N%CN@TH&
M,!.^<]JZ*/4=.BC5([NV5% "@2+@"E_M2P_Y_;?_ +^K_C0UY FNXRST73=/
MD\RSL+:"3INCC /YUR\>D:LGBCQ-<VT3P_:;8+:S$@!GQVKJ_P"U+#_G]M_^
M_J_XT?VI8?\ /[;_ /?U?\:5F',CRI_#>I7&D0JGAVZ&H0RJUQ=32[FEYZ*"
M>GK]*[.#3+S_ (64^HFV<6C6002G&-W'%=%_:EA_S^V__?U?\:/[4L/^?VW_
M ._J_P"-.S"Z..MM!U%O^$P1K5T^W,?LY8C$GWNE;/@=KM/#L%G>V$]G):*(
M_P![C]Y[CVK8_M2P_P"?VW_[^K_C1_:EA_S^V_\ W]7_ !H2871Q_B6TU6#Q
MS:ZK8Z1)J$,5ML*A@ 2<^OUJ&+3M9U_Q9IM_<:,NDP63;G?>"S^W'^>M=M_:
MEA_S^V__ ']7_&C^U+#_ )_;?_OZO^-"30-IGG5[H.J7.JZLFH:+/J-S,S?9
M+EIL0Q+SCC/;TJXVDZ@G@O2+6YT!+Y("PN('.)DY."A!KN?[4L/^?VW_ ._J
M_P"-']J6'_/[;_\ ?U?\:7*[6#F5S@_#OAF_E;5HH[:[T[2[FV,4<%U)N;>?
MXL=@/ZUGVOAV_-I;Z5-X<G>Y23;)<2W+_9RN?O !OY5Z9_:EA_S^V_\ W]7_
M !H_M2P_Y_;?_OZO^-.S"Z.3O;+4O#WC)]6L=.DU"UNK=872$C<A& .O;@5-
MX-T[4[;7M<O-3LS;F[=77# J>O /MD5TW]J6'_/[;_\ ?U?\:/[4L/\ G]M_
M^_J_XT6871SGC[2;O5DTI+2U:X6.Z#2@8P%[YSVKH+/1=-T^3S+.PMH).FZ.
M, _G3_[4L/\ G]M_^_J_XT?VI8?\_MO_ -_5_P :+,+HY(Z/JX\2^)KFTB>$
MW-L%M9B0 S8'2N8;PWJ,^FVOE>';E+V"96N;F:7<\O/\()Z5ZI_:EA_S^V__
M ']7_&C^U+#_ )_;?_OZO^-"30.29RMY;ZA8?$=-3BTV>YM;BW6$O'C]V<C)
M/TQ3M(T&[?5_%2W4+PP7[%8I#C# @C(_.NH_M2P_Y_;?_OZO^-']J6'_ #^V
M_P#W]7_&BS#F7<X*!/$5EX7D\,#1)))2&A2Z5QY6PGJ3^-79O#-Y9:CX3AAA
M:>&PR)Y5QA3US^==A_:EA_S^V_\ W]7_ !H_M2P_Y_;?_OZO^-%GN%UL<_J^
MF7D_Q T:]BMW>U@B=9)1C"DYQFH]'TJ]@\7>([J6V=(+E0(7.,/QVKI/[4L/
M^?VW_P"_J_XT?VI8?\_MO_W]7_&BS#F1A_#_ $Z[TOPT+>^@>";SW;8V,X)X
M/%5KE#9?%2UGDXCO;-HT/^TO./RKI?[4L/\ G]M_^_J_XU3U :/J;6S7%W!O
MMI1+$Z3 %6'OZ46=PNK&#%X<:\^(6I76HZ<LUA)"HB>50REL#I[]:Z*^TV&#
M0+VUTZUCCWPN%CB0+EBIJQ_:EA_S^V__ ']7_&C^U+#_ )_;?_OZO^-+E=K!
MS*]SF])\/7,_PT&CW,9MKEX64J_\+;B1G'X5CS)XBO\ PQ%X9;1)(I0%BDNV
M<>5L4]1^5=Y_:EA_S^V__?U?\:/[4L/^?VW_ ._J_P"--IL$TCEM:\,ZA8W6
ME:KH02>ZT^$0/"YQYJ 8Z_G2VA\4:[K]I<75N^D6%L<O&)03,?0^U=1_:EA_
MS^V__?U?\:/[4L/^?VW_ ._J_P"-%F%T>=W?AZ\TK5M4#:+=:E%=2&2VEMYV
M15)SPX!'K5[4?#5]'H?A^WM]/59(+P33Q0L66($Y/+&NV_M2P_Y_;?\ [^K_
M (T?VI8?\_MO_P!_5_QH2:!M,YJWTJ]7QQKEXULXMI[0)%)QAVP.!6)X;DU_
MP_I(LF\*27)#L_F-(H//;O7H']J6'_/[;_\ ?U?\:/[4L/\ G]M_^_J_XT)-
M!S(YG5;W7=2\,+:VNB/:W=VYA=2RE88^A8GWS3/">E:GX5U:?2GA>YTN4"2*
MZ4#"/CD$=>W\JZG^U+#_ )_;?_OZO^-']J6'_/[;_P#?U?\ &BS"Z[DRVL"S
MF988Q*>KA!N/XUREZAOOBE8+'R+&S9Y".V[( _6NE_M2P_Y_;?\ [^K_ (U3
MLQH]E>W=W%=P&>[8-*[3 G@8 'H!Z46=PNK&O153^U+#_G]M_P#OZO\ C1_:
MEA_S^V__ ']7_&BS"Z+=%5/[4L/^?VW_ ._J_P"-']J6'_/[;_\ ?U?\:+,+
MHMTUHT?&]%;'J,TZBD,C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\
M?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\
MBCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*
M/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\
MB+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(
MO^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_
MYY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_G
MDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2
M?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_
MWR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?
M(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\B
MI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*D
MHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B
M@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI**
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ME?R/^%']MZ?_ ,_*_D?\*+,.9=R_15#^V]/_ .?E?R/^%']MZ?\ \_*_D?\
M"BS#F7<OT50_MO3_ /GY7\C_ (4?VWI__/ROY'_"BS#F7<OT50_MO3_^?E?R
M/^%']MZ?_P _*_D?\*+,.9=R_15#^V]/_P"?E?R/^%']MZ?_ ,_*_D?\*+,.
M9=R_15#^V]/_ .?E?R/^%']MZ?\ \_*_D?\ "BS#F7<OT50_MO3_ /GY7\C_
M (4?VWI__/ROY'_"BS#F7<OT50_MO3_^?E?R/^%']MZ?_P _*_D?\*+,.9=R
M_15#^V]/_P"?E?R/^%']MZ?_ ,_*_D?\*+,.9=R_15#^V]/_ .?E?R/^%']M
MZ?\ \_*_D?\ "BS#F7<OT50_MO3_ /GY7\C_ (4?VWI__/ROY'_"BS#F7<OT
M50_MO3_^?E?R/^%']MZ?_P _*_D?\*+,.9=R_15#^V]/_P"?E?R/^%']MZ?_
M ,_*_D?\*+,.9=R_15#^V]/_ .?E?R/^%']MZ?\ \_*_D?\ "BS#F7<OT50_
MMO3_ /GY7\C_ (4?VWI__/ROY'_"BS#F7<OT50_MO3_^?E?R/^%']MZ?_P _
M*_D?\*+,.9=R_15#^V]/_P"?E?R/^%']MZ?_ ,_*_D?\*+,.9=R_15>VOK>\
MW?9Y5D*8W =JL4AWN%%%% !5*_\ ]?8_]=__ &5JNU2O_P#7V/\ UW_]E:A"
MEL6,T9KDM+\:3:CXQGT1K.-(XFD42AR2=OM6OXCN9K6RMS;R3(TES'&Q@4%R
MISD 'O0,ULT9K!.J-I&FR7MR-0EMTD E-TJJZ*>Z@#D9Q3I->NHO-9M/79;P
M)//B;E0V>!QR0!F@#<S1FL%?%"27[0QV[/")3#O&=VX#KC&-N>.M0_\ "321
M0Q7=U;-&DEKYR1))NSEE5<\<'YJ .DS1FL&/Q'+-Y<<=D&G><0@%RJ'*EMP)
M4''&#Q3X-?GO-L=I8!YT1GF1I@H7#E< XY)*GTH V\T9K 3Q5&]ZT?V9_(61
MHBXR6!4')(QC;D$=:DL-3O+S5[82PB"VFM&F10X;=\RX)XX.#^M &WFC-8LV
ML30ZI+:P0&>1YUB0/(%5?W>_/3I^=4SXGF25KF2!5M$M2[1ALMYGF;, XZ9_
M2@#ILT9K!C\22RA(X[(-.TZP@;R$.5+9#%0>,'/%/MM?FEFC\ZR"0R2RPJXE
M!.Y,D\8Z':><T ;>:,US$GB:6Y4Q1+'%(&A</%)Y@VM(%*DXQGGMFNG/4T &
M:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T48S0 9HS
M44UU!;C,\\4?^^X%49?$FDP_>OHR?1,M_*G9B<DMV:>:JW'_ !_V'^^__H!K
M,?QEI*]))F^D9JNWB_39KNV95N<QN<?(.<C'K[T^5D.I#N;2_P#(<G_Z]T_]
M":K>:YB[\8:98ZU<B5;DR(!"P"#'RD\CGWJ1/'>BMU>=?]Z*J=.782J074Z/
M-&:QX?%FBS_=OXU/HX*_S%:,%]:77_'O=02_[D@-0XM;HM2B]F3YHS1@BBD4
M&:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T#DUS.E>-8M4\43:*MF\;Q
M%QYID!!V^V* .FS1FJ6L7XTW2YKC*AQA8]QP-[' S^)K)AUZZ>QLC&$N;G[6
M;6X$6,.0"<@] #@&@#H\T9KGKCQ"[X^SAXI!M#QR*#M;S0C#/KS2+XCGCG):
M!I;5(9)7?@,-LFWIZ 4 =%FC-5(;];C[7Y"%A;G:&SP[;<X'Y@5EVGB6233X
MII;*1Y%MQ/<>4RXC4YP1GJ< G% &_FC-9^I:S;Z=;P2M\YN"!$-P4'C.23P!
MBJG_  E%OY%O*MO,RW)*1!<'=*#CR_KW!Z8% &WFC-9":^#*1)9S1Q"9K<3%
M@09!GC'7!QUJLWBV&.""22TD1IX_.1'E0'R_7KU/84 =!FC-8\?B.WFOX[:&
M&1A(JL&+!3AAD$*>2/7%2Z3K<>KM((H60*,Y+J3UQ@@'*GV- &GFC-9CZVJS
M3D6L[6L#,DMPN-JLHR>.N!TSZU2C\76TL3,EO(SX0HBNK%@S!1R#@')'!H Z
M#-&:PTUVY2:^%S9;5@D2- )5&-R@G<Q. />F'Q1"84NECE,?E2,T2[3EE<)P
MWU/T- &_FC-4[#4/MCW$4D#P30, Z,0>HR""/:KE %2V_P"0S>?]<HO_ &:M
M"L^V_P"0S>?]<HO_ &:M"FQ1"BBBD,*I7_\ K['_ *[_ /LK5=JEJ'^OL?\
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M7--N[FXO7MYF.;0,DQQ]]B?E/_?//XTG!H:FF6(M'M8F1_WTDB2B4/)*S-N
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MSHTH;2.&ZN+A2V^X*EP3Q\HP,5/45K(\MI#)* KL@9@#D9Q4M2]!IW14MO\
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M/M_^/F'_ *Z+_.F4^W_X^8?^NB_SH!#/$'_(PZA_UW;^=9]:'B#_ )&'4/\
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MXD2UEN7>:8-(K[1#M/&>WOS7-TT[DRBXA1113)"GV_\ Q\P_]=%_G3*?;_\
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MIGIW%:M% %6ST^*Q>9HBY,NW=N;/W5VC^56J** "BBB@ HHHH J6W_(9O/\
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M.64L>S,Z JZ-LE*EE=BS*?49-3+HUHL;1@/M:5)C\W\2 !?_ $$4 4F\3I%
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M_7=OYUGUH>(/^1AU#_KNW\ZSZZ([()?$PHHHIDA1110 4444 %%%% !1110
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M[";P$J80WS9')XJ:^O4L+832*S+O1,+URS!1_.L6'P;:0>*FUU;F8SL[/Y9
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M(VE."(9%(' )5P,X]:VZBBM8("###&A (^5<=>34M)M/8<4UN%%%%(H****
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MJ%YF6RAN8G$Z1PLX C#ME6&>/8]ZZ#3('MM+M()0!)%"B, <\@ &D,LT444
M%%% ZB@#PCQ<_F>+M5;_ *>&'Y<5CUJ^*/\ D:M4_P"OE_YUE4 =7X5L8-0T
M>XM[A,I+J%M&Q'#;3NS@]JT=-TK2C)%/#IS.9(KR(0O(7W-&."/<@UPJNR_=
M9ASG@XJ[;Z9JLML+NVM;QH%RPEC5L#U.10P.MB\-Z=:0Z;<1QR>9YELXE)++
M(78;D.1MX]N>.:EDTBSU&2V2>,$1_;95B3*F5EEX7CG\O2N!\^0H%\U]JG(&
MXX!]:03.K*PE8%>00QR/I0!VC^&;"*2Z-M87-^PG2+[.LA1K=63<2?QX!/'K
M2S:):7VF68@L&64:5)+&8VR9)5?&./O'J?QKBQ/(K,5E<,_WB&.6^OK3HI)S
M@1/*?+!8!&/RCN?:@#N[#P;8-J30W%L[0[;=&_>-N1W3+<#W[G@5SWB2!+;3
M]%C10-L$JDXY.)6'-88GE&=LT@W=<.>::69L;F)QTR<T,!*]1^%<&([J7'2-
M%_,D_P!*\NKUKX78_L^[_P"V?\C4RW1RU]:M->;_ "9U^J_\@B\_ZX/_ .@F
MN8\/0^))/#6GK;7.G10FW38S1LSJ,<=\$UU=[&DMC<1R/L1HV5F_N@CDU0T&
MXT^+3(+&RO8[@6L*KD'DJ!UQ5'48U_I*:-:Z%;+(TKG5$DDE?J[MN):DU&YU
M/7=5NO#LHM[&$KN:3<6>>+/.SM['TK>O;&'65L)TG^2"=;E&7D/@''X<U%KN
MF6]Z+:X>X-I<6TH:&X7J"3C;[@],4 9]NL>F>.FBD^2.ZL4CMB>AV$Y7ZX(-
M=-6?J&G6.MPM:76'>$ALH</$W8@]C6>?#=ZZ>3+X@U!K?H5 4,1Z;P,T ,TQ
MUO/&^J75O@P0V\=L[CHT@))'X#BCPW/';0Z[-*VV.._F9B>P !-;6GZ?;:79
MI:V<0CB3H!W/<D]S69+X9273K^S^U2+'?7)GE( S@D97Z'% &)H<VJR0WM\V
MB&Y&J.9-[7"KF+&%7!Z<?SK0\&7$\-A<Z/>QF*YL&P$+9/E-RG/?CC\*Z:-%
MBC5$ 55   ["L^71T;74U2.5DD$)@D0#B1<Y&?H: *7@?_D4;+_@?_H;4EI_
MR/NH_P#7E#_Z$U1V7AG4-.M%MK37IXX4SM7R$.,G/4_6M&UT@V^IRW[7+23R
MVZ0-E0!E<_-^.: *OB1HIHHK2-#)?.V8 APR'^]GL*S;Z&YO[D)IS;KV&+9=
M7$9VJ_'W?<UI?V?%!%>DZAB[8;I[A@-R(>@'H,"M.PLX+&T2&V $8&<]V]S0
M8N#D]2KH,]I)IRQVB>5Y7RO$WWD;OG_&M2L^;2E.I)>V\IAEZ2!1D2CT(_K6
MA0:1NE9GF.HIY/B;4X\8!EW?GS_6F5/K?_(W:AC_ &?Y"H*Z</\ P_O/)I:7
M7F_S')&\A(1&8CLHS3:V+$SOI'EZ?(([D39D <*Q7''/I4]\;-_/D"02RO,D
M1<G@';\S#'OWK3FUL=')I<P "QP 2?:G*CO]Q&;']T9KIC;VMK=0-&L4;CS4
M8J0 1LX[FLW2#.=,O5M)-DY:/;\X4XYSUHY[JX>SL[&3TX/6EV-C.UL8SG':
MNF\FRNKJ9Y!%-,OEK)R,=/F(Y'?O5<M"M@,,&5+5]JENO[SH?PI<X_9^9@45
MT"VFFBYC51&_G!ID!/ X^5#SZYJ.Y2RM8KJ1;>)Y%:,!&/"D@[L &GSB]GYF
M'4UFVR]@;TD4_K5[5K>UMH(C HS<'S5_V$QP/SS6?!_Q\1?[Z_SJD[HEKE9Z
M2>II*4]325P'I'/ZY%)))=+)'=.&B46XB!*YS\V<?U[4Q([XZDQD:8/YK9 1
MBICP<#.=N.G;.:WI;N"W95FGBC9N0'< F@74!G\@3Q&;&?+WC=^56I:6(<-;
MF!;I>6UJ)UCG+6T<+"+!^<;2&4#UY_2HY[?4(Y%5Y9]QC5HV16;YR26Z$ <G
MOVK;N-8L;:$S/=1%!(L9*N#AB< &IC?6H#DW4($?WSY@^7ZT<_47L]+&/+'-
M:P7>H,9C+!<E]I8X:,=0!TQR:EOK.6;PE<PR*\L\L+.R@G)8\X'\JO7$MG<%
M8[CRVB"B8.SC9UP._P#]:B35K*-[9?M$;?:7,<15@06 SUI-W5BHQL[G/A;C
MSOW*7PN?.C^RG#"-8,+D'/'3=G/.:ZP]:B6\MV\S;<1'RO\ 68<?)]?2J\NK
MV4<D$?GH[7 8Q;&!#;1D\U)1=HJO'?VS^6IFC620 B-G&[D9QC--N-2M;>.X
M8S([6Z%WC1@6 '7B@"U156ZU*VLK:*>XD\N.5D12?5NE.-_:*KLUU  APQ,@
M^4^] %BBHFN[=!&7N(E$GW"7 W?3UJ.SO[>_$QMI XAD,3X[,.M #D_Y"O\
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ML:EG954=V.!5634H(]2AL?F:>5#)A>0J^IJKK-I)/<64PM?M<$+/YEOD<DC
M;!X..?SJKHND3V=]!-<0H-MJR Y#%"9"0F>O"G% &A+K5I#=F!_-^5Q&T@C/
MEJYZ*6]>1^=-DUZQ2V:99&<*,A0AR>,YZ=/?I5.[2\O-8$=Q83&PA<&/RV3$
MC?WWYS@=A[9J[)H=G(NW$J_((\K(02H&,?3%'0.IH4444 >$>+4\OQ=JJ_\
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MO_;#_P!FJY5-/^0K_P!L/_9JN4V)!1112&%9FK?\?>E?]??_ +3>M.LS5O\
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M(/[L_P#WY;_"@"OYFL?\^=G_ .!#?_$T>9K'_/G9_P#@0W_Q-6/[4@_NS_\
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MUF>(%"W-JHC$>+9,H#G:>>* ,JBBB@!"H/4 _A2Q01-/&&C4@N >/>BGP?\
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M&K:ZG,N<JC XX(X! P#50G))/4T )1110 4444 %%%3VEJ]Y<+%'WY)]!ZT
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M=#T]5/J#0!Y=16QK/AVYTIC(@,UMVD Y7ZBL>@ HHHH **** "BBB@ HHHH
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MR-7* "BBB@"-/^/_ /[9?UJS59/^/_\ [9?UJS0 4444 %4K_P#U]E_UW_\
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M^[M"1<6TL?U4X_.O4:.HP>10!Y-17I\^F6-S_KK2%SZ[ #5&7PKI,O2W9/\
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M ,_TW_?*_P"%'V&?_G^F_P"^5_PH L457^PS_P#/]-_WRO\ A1]AG_Y_IO\
MOE?\* +%%5_L,_\ S_3?]\K_ (4?89_^?Z;_ +Y7_"@"Q15?[#/_ ,_TW_?*
M_P"%'V&?_G^F_P"^5_PH L457^PS_P#/]-_WRO\ A1]AG_Y_IO\ OE?\* +%
M%5_L,_\ S_3?]\K_ (4?89_^?Z;_ +Y7_"@"Q15?[#/_ ,_TW_?*_P"%'V&?
M_G^F_P"^5_PH L457^PS_P#/]-_WRO\ A1]AG_Y_IO\ OE?\* +%%5_L,_\
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MH_LTG_/S)^0_PH^S2?\ /S)^0_PH DHJ/[-)_P _,GY#_"C[-)_S\R?D/\*
M)**C^S2?\_,GY#_"C[-)_P _,GY#_"@"2BH_LTG_ #\R?D/\*/LTG_/S)^0_
MPH DHJ/[-)_S\R?D/\*/LTG_ #\R?D/\* )**C^S2?\ /S)^0_PH^S2?\_,G
MY#_"@"2BH_LTG_/S)^0_PH^S2?\ /S)^0_PH DHJ/[-)_P _,GY#_"C[-)_S
M\R?D/\* !/\ C_\ ^V7]:LU!%;F.4R-(SL5V\XX%3T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6755721312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">a.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>General</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Protalix BioTherapeutics,&nbsp;Inc. (collectively with its subsidiaries, the &#x201C;Company&#x201D;) and its wholly-owned subsidiaries, Protalix&nbsp;Ltd. and Protalix B.V. (the &#x201C;Subsidiaries&#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> protein expression system (&#x201C;ProCellEx&#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s product pipeline currently includes, among other candidates:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">pegunigalsidase alfa, or PRX&#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">alidornase alfa, or PRX&#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">OPRX&#8209;106, the Company&#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#x2019;s development and commercialization partner (&#x201C;Chiesi&#x201D;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA&#x2019;s Accelerated Approval pathway.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 18, 2020, the Company completed a private placement of common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing six months following their issuance for a period of five years from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The net proceeds committed from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April and May, 2020, the Company collected total proceeds of approximately $9.0 million from accounts receivable outstanding at March 31, 2020. Total proceeds of approximately $4.7 million in connection with its collaboration with Chiesi, total proceeds of approximately $3.0 million from sales of alfataliglicerase to Funda&#xE7;&#xE3;o Oswaldo Cruz (&#x201C;Fiocruz&#x201D;), an arm of the Brazilian Ministry of Health (the &#x201C;Brazilian MoH&#x201D;), and total proceeds of approximately $1.3 million from sales of drug substance to Pfizer Inc. (&#x201C;Pfizer&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;19, 2017, Protalix&nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201C;Chiesi Ex-US Agreement&#x201D;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&nbsp;23, 2018, Protalix&nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201C;Chiesi US Agreement&#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&nbsp;the &#x201C;Chiesi Agreements&#x201D;), Chiesi made an upfront payment to Protalix&nbsp;Ltd. of $25.0&nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&nbsp;Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per&nbsp;year, and to receive additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per&nbsp;year, and to receive&nbsp;&nbsp;additional payments of up to a maximum of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of both of the Chiesi Agreements, Protalix&nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into&nbsp;between Protalix&nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201C;Brazil Agreement&#x201D;) with Fiocruz for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">b.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Basis of presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S Securities and Exchange Commission (the &#x201C;Commission&#x201D;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">c.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Earnings (loss) per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic and diluted earnings per share (&#x201C;EPS&#x201D;) are computed by dividing net income (loss) by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The calculation of diluted EPS does not include 7,826,946 and 10, 694,517 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March 31, 2019 and 2020, respectively, because their effect would be anti-dilutive.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The computation of basic and diluted net income (loss) per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December 19, 2019.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">d.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201C;ASC 606&#x201D;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201C;performance obligations&#x201D;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenues from selling products</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue from Chiesi Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has identified two performance obligation in Chiesi agreements as follows: (1) the license and research and development services and (2) contingent performance obligation regarding future manufacturing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue from R&amp;D services</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsPolicyPolicyTextBlock', window );">Other assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;">Other assets include $1.0 million in connection with the March 2020 private placement of Common Stock and warrants, which was received after the quarter-end.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recently issued accounting pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774803520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,694,517<span></span>
</td>
<td class="nump">7,826,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables', window );">Total proceeds from accounts receivable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TotalProceedsFromAccountsReceivableOutstandingChiesi', window );">Total proceeds from accounts receivable outstanding - Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Alfataliglicerase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz', window );">Total proceeds from accounts receivable outstanding - Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Drug Substance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TotalProceedsFromAccountsReceivableOutstandingPfizer', window );">Total proceeds from accounts receivable outstanding - Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants', window );">Exercise of warrants, commencement period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivableFromIssuanceOfCommonStockAndWarrants', window );">Receivable from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReceivableFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from issuance of common stock and warrants in connection with a stock offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReceivableFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price at which the new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TotalProceedsFromAccountsReceivableOutstandingChiesi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total proceeds from accounts receivable outstanding - Chiesi.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TotalProceedsFromAccountsReceivableOutstandingChiesi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total proceeds from accounts receivable outstanding - Fiocruz</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TotalProceedsFromAccountsReceivableOutstandingPfizer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total proceeds from accounts receivable outstanding - Pfizer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TotalProceedsFromAccountsReceivableOutstandingPfizer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the proceeds from sale and collection of receivables during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_DrugSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_DrugSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772485776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,646<span></span>
</td>
<td class="nump">$ 10,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NonRefundablePayment', window );">Non refundable payments not yet recognized to revenues</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred', window );">Revenue recognized due to change in estimate of total costs expected to be incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">3,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,615<span></span>
</td>
<td class="nump">$ 6,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the revenue recognized due to a change in estimate of total costs expected to be incured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInEstimateOfTotalCostsExpectedToBeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable payment not yet recognized to revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759670624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6632599024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;2&nbsp;- INVENTORIES</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories at March 31, 2020 and December&nbsp;31, 2019 consisted of the following:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">March 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Raw materials</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,424</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,607</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Work in progress</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 759</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 552</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,305</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,996</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total inventory</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 9,488</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,155</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762111312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;3&nbsp;&#x2013; FAIR VALUE MEASUREMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of March 31, 2020, the carrying amounts of short-term and long-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of the $57.9&nbsp;million aggregate principal amount of the Company&#x2019;s outstanding 7.50% convertible promissory notes due November 2021 (the &#x201C;2021 Notes&#x201D;) as of March 31, 2020 is approximately $56.2&nbsp;million based on a Level 3 measurement.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&nbsp;(a Level 3 valuation) as of March 31, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2021&nbsp;Notes</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock price (USD)</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2.35</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Expected term</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1.63</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Risk free rate</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 0.23</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 100.57</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Yield</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 15.41</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764289776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,442,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772377968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">$ (70,322)<span></span>
</td>
<td class="num">$ (52,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">41,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="num">(7,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(30,881)<span></span>
</td>
<td class="num">(59,855)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="nump">$ 269,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">308,248<span></span>
</td>
<td class="nump">269,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(340,829)<span></span>
</td>
<td class="num">(322,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="num">(7,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (339,162)<span></span>
</td>
<td class="num">$ (329,817)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReceivablesFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761150912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Seven Point Five Percentage Convertible Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 56.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762202544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;4&nbsp;&#x2013; REVENUES</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes the Company&#x2019;s disaggregation of revenues:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three months ended March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pfizer</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,016</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,356</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Brazil</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,015</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total revenues from selling goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,031</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,530</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenues from license and R&amp;D services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,615</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,909</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the three months ended March 31, 2020, the Company recorded revenue in the amount of $6.7 million following a change in the estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#x201C;Kirin&#x201D;) to evaluate the production of a novel complex protein utilizing ProCellEx</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;">, the Company&#x2019;s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0 million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759553168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes the Company&#x2019;s disaggregation of revenues:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three months ended March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pfizer</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,016</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,356</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Brazil</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,015</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total revenues from selling goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,031</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,530</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenues from license and R&amp;D services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,615</font></p>
				</td>
				<td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,909</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772611072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 21,646<span></span>
</td>
<td class="nump">$ 10,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(3,426)<span></span>
</td>
<td class="num">(2,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET (1)</a></td>
<td class="num">(10,340)<span></span>
</td>
<td class="num">(11,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</a></td>
<td class="num">(3,187)<span></span>
</td>
<td class="num">(2,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">4,693<span></span>
</td>
<td class="num">(5,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(3,229)<span></span>
</td>
<td class="num">(1,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="num">(3,026)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="num">$ (7,264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK-BASIC AND DILUTED</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC AND DILUTED</a></td>
<td class="nump">17,381,074<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 5,031<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 16,615<span></span>
</td>
<td class="nump">$ 6,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762236128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;1&nbsp;- SIGNIFICANT ACCOUNTING POLICIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">a.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>General</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Protalix BioTherapeutics,&nbsp;Inc. (collectively with its subsidiaries, the &#x201C;Company&#x201D;) and its wholly-owned subsidiaries, Protalix&nbsp;Ltd. and Protalix B.V. (the &#x201C;Subsidiaries&#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> protein expression system (&#x201C;ProCellEx&#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s product pipeline currently includes, among other candidates:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">pegunigalsidase alfa, or PRX&#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">alidornase alfa, or PRX&#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">OPRX&#8209;106, the Company&#x2019;s oral anti-TNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 28, 2020, the Company, together with Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., the Company&#x2019;s development and commercialization partner (&#x201C;Chiesi&#x201D;), announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA&#x2019;s Accelerated Approval pathway.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 18, 2020, the Company completed a private placement of common stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;), at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants are exercisable commencing six months following their issuance for a period of five years from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The net proceeds committed from the private placement were approximately $41.3 million, after deducting advisory fees and other estimated offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April and May, 2020, the Company collected total proceeds of approximately $9.0 million from accounts receivable outstanding at March 31, 2020. Total proceeds of approximately $4.7 million in connection with its collaboration with Chiesi, total proceeds of approximately $3.0 million from sales of alfataliglicerase to Funda&#xE7;&#xE3;o Oswaldo Cruz (&#x201C;Fiocruz&#x201D;), an arm of the Brazilian Ministry of Health (the &#x201C;Brazilian MoH&#x201D;), and total proceeds of approximately $1.3 million from sales of drug substance to Pfizer Inc. (&#x201C;Pfizer&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;19, 2017, Protalix&nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201C;Chiesi Ex-US Agreement&#x201D;) pursuant to which Protalix Ltd.granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&nbsp;23, 2018, Protalix&nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201C;Chiesi US Agreement&#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&nbsp;the &#x201C;Chiesi Agreements&#x201D;), Chiesi made an upfront payment to Protalix&nbsp;Ltd. of $25.0&nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&nbsp;Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per&nbsp;year, and to receive additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per&nbsp;year, and to receive&nbsp;&nbsp;additional payments of up to a maximum of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of both of the Chiesi Agreements, Protalix&nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into&nbsp;between Protalix&nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201C;Brazil Agreement&#x201D;) with Fiocruz for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">b.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Basis of presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2019, filed by the Company with the U.S Securities and Exchange Commission (the &#x201C;Commission&#x201D;). The comparative balance sheet at December 31, 2019 has been derived from the audited financial statements at that date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">c.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Earnings (loss) per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic and diluted earnings per share (&#x201C;EPS&#x201D;) are computed by dividing net income (loss) by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The calculation of diluted EPS does not include 7,826,946 and 10, 694,517 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes and outstanding warrants for the three months ended March 31, 2019 and 2020, respectively, because their effect would be anti-dilutive.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The computation of basic and diluted net income (loss) per common stock was adjusted retrospectively for all periods presented to reflect the Company&#x2019;s reverse stock split at a ratio of one-for-ten, effective as of December 19, 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">d.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Effective January 1, 2018, the Company adopted Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201C;ASC 606&#x201D;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201C;performance obligations&#x201D;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenues from selling products</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue from Chiesi Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has identified two performance obligation in Chiesi agreements as follows: (1) the license and research and development services and (2) contingent performance obligation regarding future manufacturing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenue from additional research and development services ordered by Chiesi, is recognized over time using the cost-to-cost method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Revenue from R&amp;D services</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;">Other assets include $1.0 million in connection with the March 2020 private placement of Common Stock and warrants, which was received after the quarter-end.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recently issued accounting pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, the Financial Accounting Standards Board issued an Accounting Standards Update that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761269344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories at March 31, 2020 and December&nbsp;31, 2019 consisted of the following:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">March 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Raw materials</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,424</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,607</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Work in progress</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 759</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 552</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,305</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,996</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total inventory</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 9,488</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,155</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6755766448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="nump">$ 3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,305<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 9,488<span></span>
</td>
<td class="nump">$ 8,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>33
<FILENAME>0001104659-20-067982-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-067982-xbrl.zip
M4$L#!!0    (  8YP5!\]@ $;50  ,F[ P 0    <&QX+3(P,C P,S,Q+GAM
M;.U]:W/;2)+@Y[N(^P]83_>&'4'2!-^4NWN#UJ-'L[:EE>29V4\.$"B2F 8!
M-@J0Q/GUEYE5>!)\@T_A]GHLDD!55KZS*BOSE_]Z'5O*,W.YZ=B_OE,KU7<*
MLW7',.WAK^]\7M:X;IKO_NNW__=_?_F/<OF?GQ^^*(:C^V-F>XKN,LUCAO)B
M>B/ER9E,-%OYRES7M"SELVL:0Z8HW4JK4JVH:DLIE^4@GS4.+SFV0J/5*FKX
MRZ4<T+$OE.;'NOJQ5JU5E?9%O7I15Y7[K^+!U[YK*0"VS7]]-_*\R<7'CR\O
M+Q7\NN*X0WBI6O]HVMS3;)V]$T]>6*;]QX+'\><^P!4\_CKS_$N=GE:[W>Y'
M^C5\% 8RS/#9^+BMC^+'X%&#I9[C3*\,G>>/\ ,\KW;+5;5<5^,CFVNL<6*]
M)IZ>N(ZG6>9K17?&A,IJ/1H<:#O4M$GXPD#C?1I:_I !C\F=1DUM+X)(/!&\
MP%UO=GSX,F-LW?%MSYUFHT?^B*^U4RCB9A:5 !CUXS^_?GG41VRLE4-$ ?LH
MRB](O0M./SVP@4+4O/"F$_;K.VZ.)Q8BE+X;N6SPZSM :SG 7N65&^^4CV(<
MY%C']MBKISPRW0,)(@:%7W3YM6G\^N[*=S7\[8=:^Z%V?^#2?SPY\4\2XS\>
M_3XW#5-SIX^:Q>X&CYZC_]%[-7GXQ+UK/H.$W%N:SE $O[)QG[EB63 M?&-Z
M4_D)/IL&?C,PF:O0<ED"5P%V+V__^]UO5< 8,&RMH_[R,7HM&HJS(4X8?@%?
M"=Z^8*\3R]1-"8MBF/"<T"82ZHNYZWKW6_!(]L)^^9@Y1P35QR18OWQ,8."7
M"7--QX@MPM-<[PKF^8T84*V5U2Z,$7X;/LAL8^:QX+M@JMC@OWR4!)^E?H__
MN!O\J/^HJS^0AR):>S 6@G[]IP\07SKCB6/#1YZ@]P/S---FQK7FVJ"1^8G0
M>]':(IIG+RYOF@O9]WY#[)>K== =OWP,OMLG*7N&8:(:T*Q[S31N[4MM8H)V
M/BN*+ESCL1,6%#)1-JZ0"R'=MY *?7LP6A92>N24K1=">A1"FI\E+63TJ&0T
M3TO:*83T@$+:R=62KDO+0DJ/G+*;!C+P]=BQ*88_*V+.K.ML Y:"@B?NS!8$
M/'5/IZ#@T5K!*];W;F%$EPZYB&H3Z_7'(WMF]KUCVMZ-^<SNF:O#K]J073KV
M,W,]LV^Q;X['I%L7CG:CF>[?-<MGGZ?AGW\%JFBN/II^@3&M!%^$S]S:$]_C
M]$#]-#AD%F_O?@/$7:R'N&7\L@Y$J^$^8MX%R#]>7R Z7OHA&?G)B7$U=[T?
M]ZYC^+IWYSXR]]G46>I(B7X\;AZ#55QDK2)^@!1;QB[/C9!>*OS_)>=&$5DW
M.S?:EJQ?X N;LYYMR%]/G<!S%O0V2!U:W]^9,W2UR<C4-2LT3?<#\]_,/7X"
MSUV%,!3Q9;QULLJ,AQ^?'TZ4H'(!%Y\?SH^4(H$C"MX*&YM_;L8J9(UBN,.0
MM;"QYT3JPL:^,;(6-O8H25G_H79B_I+\L',2K>MVU,MJ9R6W Q_;B0=9G*WN
M^6SU^#S/@@4.R *'L7'SM,"<;6O:6H4'U=,@]KQ-Y-0RSD"R=W/\<-I47FN1
MQ[LEOTO2%@=+N^&6=0!Z$^=* 1,'SGAQ26E/EY32),3X(9<DDX.'4+O+OCBF
MI6V9EK"BNW=KZ\Z8A;[Q%T>GMQ*"^,@L"USAWYD-NLGJV4;/&)NV"9H4GGUF
MUZ\3W.T[D3!@P8(C"5UKQ6?@1.;(+ ^,,S1@@+0K-%#.A&(N@;$S8I$5UGE^
MC#%OWZ#0(D>M18YC%[W0(D>G18Z+,8H+(0>Y$')(AFC$_(WF\JPTW.:X<OTA
M!EE4B2.UF8'?LS]]Q"_$]-[3=)(\:4_]?MP\,_^<'7<M,M"0Y][$'$S&C%L6
M*G?M\316\WB:!V+-GC70L%+.$-8.)I^_8?:<@XJ"17?/HF?);071%^<U%/NJ
MARC^M*<$CM1!T!'M4N9] _6(EI;KU<Q"0 ]W\)'#'GK[A[R="2JW_:-6%Q_0
M%WS0[*$PJ_CIJVF;8W^<<OO02-T->JZ+SR:.;"]')N/F]\?>T&4G0&IT^<(%
MO_L-/R96G*=WEXDTX5O.P=I.X^).N=I>(2ZFQVKUK8W\R@RGO;XUAHNON&"X
MO!A.K0J.:U--T:JL*=K.3<==OYXTTQU,RV7@;:=LURZKU178CA[;O)KI)FRW
MD:8[<;8[F*X[<[:#L+D5CZ%;QQ%79826K=5"R]91W THCF;.[L1_.X8HRM.<
M'>&+LC9%69N=IQ\?E/VE2]J4+FE=?C*8^>,+&VK6-8$>W>B5W3$^F\[3"+ W
M8;YGZAS3/]R)(P:57+_J/=(5W-L>?#*8(>[AGHB'"QB\2&%0WB9>&85Y\']N
MMV%S\K@7D7*G3G=S-:>;'MM5\L]1^=S'=1/O;';QCG.';:_W\Z(]W(*Z>SCX
MB;9%MSJ6C/:CSG"_Z9CV@F*4"[=XMJ%<\T>M<1Q;.LG#R&:YUMC-A9Z#+W1/
MJO4_RN7OMCG3*,W'[Q!+^*/:"+%AF,^PDFAR?.X;1&" 2B?AR(V9QGV7_28[
MSUU\?[SZY6/P9<36V>_3L%?,=L:F/6]@:L)WP4>:R_B\D6>'^.5C; 7BH:P%
MU\,%)Z>;P)_)R>:/49L98RXNY@\R!XZL9<<' :H^^1.+I<D*WU];I'?2OV L
M08XS_GAC:4-%LLD#MMI;)BL#S>* F)E!HK$O?=?%+TT.@<'_,LV]%BRZUC3E
M((-DT8C1G%>R(:9XY)YDX :^XVM-^C]ROKFCS9L085I_.OS?K G#T6:G$[!L
M@M"XSI@[XNR$:.+6F@=,T/\D9\ AHH%% 'L)W[N:=0O1V^M_L^E:,\1U[=P1
M9R:,MAT?2:+N? ]-"7993<R>MH(*BAK](J14,9ANCD$(?GT'L-1KC4:M56\E
M(%DPU0Q8@K,?&,3J'OR.P?6:7/2_J!V6C9B>]QKT\! O6+G.BS?"O5K-7H\*
M,3VP8,CTO#>FQ=Q+X+2AXZXW7T_7F87&@QD*C1*?.S%L>LY;F,35=+PW!CRN
M201M@^/L$=/S/K A75BSO6_:>#TA"G9UE-2V3DFYM?5*')3D)&D0'D?,LG*A
M;GRDF5E '*S//C=MQM?C7<_UD[/$1XJF>7(U%)['Z;CO6.LA\LL_Q?B)(<3(
MM($4'DGUQKAY=:]-M;[%;ARWIX,'_TP&]&X 6/8M]"VF/=M ^6:N;FK65V [
M[CD ;(8*R2D$2NF?6EP!E9NH@:KB_X'KE^."]H*B/$+[9?AIM_:,'RZ'?'(N
MG6?FQNXF7CK<.R"GU)J+$+$$[#S7NP^R+Y:*E1=[.4*(;NUK[L'@'@#YA)J9
MGL*KICJ8HR?G,SRAHQ$PUE!..UQ\JQU;^[I+F%W\W03M+FC/+Q"#L =S. ()
M^<Y9CW/F+53XZ1WKA8!#)%9OS8"]>/(\@4T;CV7 EM59)*\,K6-96M\1M]EC
MI'_ (TV?\>"".SJ0,%ITMCEG :=_\);"=CV.;8BOU4J(ZDU1%V$_/(X%LOCC
M":XV%(4KVC2PC0=8\CKL<ORG_(LPW("PJJ(V&ZK \<H(6@VG?W? EIH6NJMO
M#:O(M\WV<JRF4+08KP\F_^,&Q(?B$'!(WAQ6JX!5/*)8"T&+<?K$W/%9H?"W
M>_5_VU_5]M5\-.&:(ZS\KIGV%X?S.ULZ23<^JNM;^X%Q9-*[P?5X8CE3)NP:
M_SYQX"?/=,4N8YZ6M=D-+>MV4$6K ]OFHDV^8N+?6_NS9O]QQ28.-_/U"^H)
M/WOQO+/PW=I?3*V/F@!\/PA+P%2#3^%-[RV(\2$8P>RZR3*$K^MWJ;7.#, K
M [*C-:R+=K71SF4-(!Y8%^)N$-O'@T?_H:&KX?%O#%@N> B=Z%M;[/)MHCPV
M305=O"FI0LS;: 3Z<>,%;8$34C1Y$K>AUAOUB+P;P;/']>2:_+T";BBT/T_<
M+&7^6470R0T9\A8)14^6W!I*;Q;(/00P\7AN<[CM'36QX[$^Y#FO>B][>\V<
M5OQ-\WP7@)/A.[A&]XYEZM,G6--G"WAFK4WG_[2\3X;Y_)]#[Y,2^_O__=__
M\W_PXT3AWM1BO[X;:WA@<E&=> K^I];@?YJ-B?<)9RJ;-N817"AEM0-?#6#^
M\D ;F];TXLD<@[GYQEZ4!V>LV27Z7.+,-0?BN1>&KM!%W[$,\06'B/M"46&6
M3^\"4 @6_#4 QS#YQ-*F%Z9MF383#VJ5)4_-C+\JH/$UXGL"&66+#<3GB6;@
MAOU%B!F))@$70O41I\(/LDI@XKL V1\G*Z.^WEH7SQNC=>[YSG]JX\DGN\\G
MG_"@1WFO.Y;%Z*#)FBHOIC=2T%GE0;T $)N2XHV80N_]Y17D[?*3/*6)OKKZ
M]$'1;(->?1G!B-.R\V(S(S5. %0$PQ?/J-";$;R5OP-4Z1D?8^,DIBTIX$@H
M?=.9@$<QUG1:I89'. @B/*T,\)P;0'%L6H<1"2Q-K(=;[^:_2>849Z"X#+[N
MFS9H<'PIP)XR 2B9:7.EK\6&G$%']Q/'1R< K:>Y4US<);.LZ]<$ RTA8T3_
M)@JL,[DHH^225P]@7KC,H@VJ3_AT>20$$E3TSX)]!3"]ZT_KS$FO!JM4V.L$
MG#1,2%/XE(,E5=[':1*M*DZ0BO+D* ;8W5(<-\I(0Z;2=1AOX -_!'0 +(I*
M5+ZH1*5HUD!3WH/T_,'P(!9#,9=&LO&($[CY*RAWW[1'#J=G$W6L%(#ZLZO]
MV[0$;<$3A^!.<9"&RA?<-E5Z0&W@$%L1&XO((?CHM07\SYW3() I^ [W'9!;
M\6^/N:[I.;B>#\#R F4>A"@><3H\];OFZR/*,N08N, #FD=DZ3-F*]H$J/X,
M",=W!?8Q;T'.A,81?B-_"N18H+BDW')78P+5 L7B10X\D"*]IM@^Y3@"(!-1
METS1,6'!H(TEF.89! 5GY+B'P8-EZ;!JDN>XV,( R$>)69+"1U5<V7"JF%SQ
MG.#EA$S&13P4:\()*I28T&O(K=RGK#<71V/@5!!R,H?0Q5$]O!/R<$ .CAP,
M!LD4Q49YY83LR5Q4!]2<F!.&C\<08-JZY1O(,!IXQD/)(Q'9+U98/W@V 5@O
MIN&-8@($OWIXQ#;[^Z=W(/J6)0T\1JSTF4\T77X.!W##OXSD.(3;\+E)QH\1
M0I-.PR3\RS-BHS^CHK)_?0>*XITB_T9?Y%UR:$7M5*JS] D!V)3<&?P3FV*&
M![(>7W]JFEDJK??JAQEZ9Q \B;0$:JH+*(*_17^M29H$->)TVB<)5K$V*TQ*
M T[8$ *;(80Q(&G2J)844$/W#_\4XMNI5;N?U&H-9#/+PXFD--N8W&A]T*'2
ME. 8+FC-DC($/QE'05/* 30+'W%<,.&S5BZ3&!\C@?Q(PAU^2H4XA5XX&[U0
M*_3"OO0"+,%P7'N12E"K*,YQ3VF"6]DD* F/9^3#%,H5<UZGKMEW;%^WR*]4
M:=2K;_#W)W0-"\$O!#];\.N%X.]+\._2AK]5FK]UX;@:!G6>67[Z=C,;KBDO
M(U,?86C59Q@&19$\!GHVO6Y-RP:$ \\,,]9H*-,>6-IX3!F/,5\",W&',17#
M%1$MXG8I;N-H$^Y;D1,BMR1@4.FH5')6+\<2;]WU<><"<1,%XR)&!ZS0-ITK
M3J<Q(L4H>Y9,X,6)I&Q*H$)Z&6S":#]TX<Z5.,Z<XL#F>")O^- .#,.P6P3/
M0?(JK(%-.'SQIV\BK>$EAT#'W9Y1"')J2P" M!U/P1-4QP9R(/@,XF(QC^-[
MV)U#[@&@K<+]23IA/:60^<Y6OFI3I=8I*;AKGQ X^. ,&<7#1$QQ/J'\;CE]
MH.\#;D%<"><:HV<ZI4!TR,=NHJU.4WFL3"J]R@)Q7K[C.=%<SP90$MM[8J[T
M9BO0S;=U)#1N:/C]L2DV"!VYV+98+ *KX6Z=Y0Q-G2M?3!U3YI3>!*^DBEG?
M?_[2^X ,0SM,E<>*<N,X!H&(_1.4>$,>?#R])WQSU4ON0*.2R(I\LD,8S? M
M#Y8.;&7CMC62(1'6*,\FQ49*8B+$:/RF2"\02AAI]*)-3XY#71!3-8M':0_=
MHATL= BI.C!J:E$>&%&HTY$GS(#G5TBW%WGJ65%N<8/5ML6]0(%<$NW!@&'.
M9'(BX"$?9E';I5:U46K4ZL#P+ET[(?LA+B@&6X*9/!Z'I(3\C%;;9\I/F,>E
M E>X8I19+A+'M@J=VZ:9W<.%^X @Y ; @,YB(P$X/]4JC4XSL7+DY_ 5,(9:
M>/ >7UZTHOCT-"%NNZ-TAC.*>>JM:&JA2\,9$1CY#GF_)-^V3INIYJL"PWLC
M/ :Q+.<%OP0,F"[A',^D23@T15SJQ<D&8+65*=-<>,=UQN+0!$D/OP4OH:C"
M6SK9%C+@OCMQ>'!6E !-MS10$0-3^ >,3N*1-T! B142;\2IBGO:XY/2^$]D
M).4&-3,$6YH>[0$'J)P5I!=@<F$H7RE]'JSA3PVU4E< 6@M8!QAQX.'&/4,#
M3XZ \8S;*E-EP.3QA=A:93(!WPCE#!TFRE4^)32"[N@!FL3! EB5;-U$QY;D
M<7BH?0.4HV9/XK);J0:H%&20?(M>B\Z &B@T3NRR)HBA4(MU54R-9UI+)FE4
MVN$DYJSN$PF 85IY\+6PL:7E:ZBGU\ U2RB0V3,PT$"8P:A)6;IN!V=-U_5/
MCG+'7S3+<)1+U_]WTN#?F(X.7\Y8?)#B<:!\Q<F/"5]^%;9YBK_\E6D6K&9&
MM\:>=OXZ,^X*I(M)06K9!GH(/&BQA&L62?^*.-5.G%/2#\E#RBVDH;-W&WVG
M>TY?KH!.S=4N\B78DT4GZM)79+8PHJ9-@8)R_:I;$'2!C@]\,GSXT0?';*J$
MZ3$9=E(,=_U:_OX8/9=TP, *H'V@F$0$B>&Q/H(U1!4O8@0Y&EF[ !Y+PD,&
MR;*"PT023; 5 0LFSB)QK+@_RS(=P(H"6/R;;TTC--7JA,+.7!1NB+>X-S\/
MA_,1F [LZ @T*T$AT\W-.JP](4[_3D?]3 .V"5R]3)X3JB/Z.?%;(I\EENPR
MAQ3AB^FL$OG[6#/(C?,GH'[PF%>;BG#8F<<WY*XU*]7HZP5F06QI,-T/Z$JK
MUP*@R(T./,A2+!<B&S%S>1E"?R:2UDCX8CZI7 ^I5'^"/\X'/I/GXL&EC@EP
M)=RSH<T@#_1W-6NL25R7H:<96 -ID-D2".NUK&%+ ?]K0T#(D#)0X)O85D4R
M^$7#(J[:AG-4E.]I%&^"WUF0-6 DRAT4[)&)%=)DS^3GI5 Z-[ MH07\5[ )
ME)BC76EN@/CHU^BOA;1(3=K:%6%.38O)E)PQH:H/WGE*I45Z9RY3O9AD VU_
MH.F8.THV48Z2*8HV.%&)C"DM-DF,48*L*+"\3-S2*<4=!IHWBGHS]U/0%0O
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M<SR@IR:.%4HTH18%I<I[V;459J:>FZ!#$%NVACTT/Q!=3(,A #;3&>?8[I1
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M\L!\H!*+>O. TQ'VU0LR./NF[8RI]GF46F0%>Z*D2$$781JXQL44!JI3NM=
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MY6L"['"BB<.]<@;,1$3D*A,;&,:HZ8IO7&91;EW(Z6MID5,C_6QH\R("%/C
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MAIZ>OPM;1$%7:!,2(]?.0)#;LC\/^?F_4$L#!!0    (  8YP5 [?J<'8PD
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MBDC\XO@D8,N:$V36&6S\0HD/9WX\$C ,A]>+;DX;CX[(VXN[>:&O-"1N1+S
M?Z;A]Q<Q%96';SI&'/:*&=V> #1)P>W:=@>NX?MEWQ4QI-]L@B-S)$NZH<RI
M/'ET3F-U\:X9"E* ;R!&(<ZO@+<?[M<R4X[Z$Q22XXP(PQKIRGDM!?\=) DS
M'')%X.1#ZUWA[E:Q8'XR+*QD- *K '$L0,^RK/=E*.O:KF.AI!D<D)RM;W'T
MNB'/#H?$4]^9_\I8#,(3LSZ-1$40')55L2DKJ_S<NIJ67U[ZV!D(=[TXFMF
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MYB=1UE?@RDS'H;DWNT@HMJ0;ZK["$?OHEEG]RO&THBI&IQ&V?>_50KC47S5
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M6>A-^-Q*R>UR<4_R7LKCR7KV:;:>35<_#R0FAFG.W[@>+71'6P?]F/AE7C6
MV+?G8=/&NSV]!S?&[56(NK@V>QDI-WUDC[\VIX0TD"'$Q"$;&#9D83:B?JD[
M(GL,/VY@5(]B($G>*=;)7HWH[M0'YJH*913 B 5=6M9+55TE2)S2+@T;QL>&
MD;H--&:=#&G5=P.;0!NW2K>+(#@:K6)3UF/YN77M+;^\].%E$*Q*G(YLVM/)
MVR"D[K,_.88A]3>G=>@P,]GPLC'']6'J>O1#ZGC0;D C:S,2.#K=1DQ9YYO@
M6[>)YLR5.Z\+$B2E020B!*@DX=F(Y*2P+@SI0US7=UBXY'B$IHUEWHF@Z3NQ
M]?H.SNIY)_9X\P+M,<C6W>THO ^UR/:!\0K=0/PMOTWB(6#!(HU9$ @1X37U
MZ<ZMN=^P$06DV\6;"UFX>]P<W?[-Y$UY*]];+BCPK3MQP4F1"$FH1*)#RSNX
MK3.,F*+SO<XH1KK4JKO@$VZ'$2Q>G,TFA,I4SW6>7 ^.V4(#>)KTT2$A]-&-
MR/' ABE_26\%$ZF36?AB SVZ/?I;6,TM:72@FWBQ2SOZ+#DCCP?8ODC94.SZ
M=B5HOZRBGR%(*RVZ44,IONB#Y9*&BVE6K-G!P@5ELN.D0>]#01Q,N4;9[99G
M7&XT@"I9^"2A2P1A* =+2$.M6$J<".H$R).EUO!M%')<9$3X8'14#,2,]CX(
M8_=?20^S) #SGWGS,EU>K1(%*<-L($8A4UP!;S_C6\N,JD@L0P']NJ%/<;$Z
MTW)-9H^R;$&60H5EQ.,J_OO6C39@9ZC-R-DR)J(W5/Q?RA<GM1(U.SM-"*"U
M*6\HXEG/<D-LC ;FC5A3=0#GB.1=2N([\/3Y_D?6;P!Y\Z.SI%)@+^U*1!%-
MK#&-\G%W*,IB3@*?B_6K&[],CE$<[&EXEZY(C >KALI0S-)(V&K;K"0Q  ,U
MX,_42E-2Y(W1(BFQ$<G(8:6E^Y$ZQ091-PE^)*W&(97F'?D9>S_PKS8\41>3
M \R^@8^8/BN+/][P23[**Z^-1TZ%.A1SU8M5;:-EO $8IHXI4VM,\4E. "MU
MW8=P(@$F))(J_6&J#'A"4,R=O>6[Q/PL3>MWP 9?MRYVCQ$=\]<I%L&FB/;S
M5\U$2O-49E@H^:@FK%6< ^(5@6*_HQ!K<FHBO0()ER/[AZ!H-\_42<I&<F'D
MC'J0C@?1//$#7Q/$:>\++C7CSOQ7ILA!Z&J;P=3@#&6.50A2/;E*" .854O<
MF$ZG$N)PIM%Z:;*@%:+37!I7+\T0XM('YP2S.URL(C:][O+5<.,8HYK84.RJ
MB>AFT6P5I0%8HCF;C2/>A*2X42?9-96H#F<9VL<8R('Q01*<;Q<[WJ#LF^^"
MSYEYB+5Q&ZNN(C$46ZX7LR:?J\4?@-W6,6><T^6KMIS0Q2VT34ZWJ:QRCD@L
M2[V 1=SLU7LYH_LU')'3#%(3 D,_$J>R1G/L 1^!Z^_HVV4L,8@=K\H2>Y&T
M]N3'X*P0POFHCX.JE80&994&(AM89P65H5AI+8M-K34C.*0S8;T)?WY0=3;_
M-%WU<5!5W>>N-/-?._X?-_001*XRR5N'@-"QSDB$K"U=)31.[SD#EBJ2N&X6
M96[E*'.;X),7ZFW%QN03(VN[JUP;V31Q,V"2%!4C8]M-&"8!?(#\PTC;IA K
M7_%8.7V*>>A 7 ,*+5LV_,0I<VHLB(A/#TRPF"W5X:ZC@Z*XN0T!I",'C44L
MG#@PQK9_X* A:^7S!@D!WHY(D" IC1'A5$8\RY(1PDH*=Q>5,?4"ELF<Z"'!
MY:)1G6B8&:0EBR-"=\,&!>(,XX7\.=I0,D5J<:JS0T6< 62$5 R9SF8Y+H]U
MA[.U8B249G<ES(5*)C+\:>PV")EGV%"ZY4T6>69+$9;7>!EC*K@36D-A5;.:
M(0FTJ:T1?_KY#8Z0O4L)\;Z9WR696=7Z$GN2ZR;TN,,)$GX^]FM(&'5>F \_
M0=0M,33@A%!_B:!!I6V;25I(V[J9; -.VV:G<+JF;2L)#<HJ#40VL,X**D.Q
MTEH6:S.7M[/Y>#ZY5.92G@X;]^Q7)'<ZTK.?]^QE -*T:"=B*%G3'C@N!X=R
M.&C61EU]<X/=).M%AX)WS^]PF8?]&SP&K1E?PQS>>:(8_IS=;:X>\!S=+I+.
M" TUDFXF*8^D#Y*DNTR^(433T]U.](1(FDTMG9@N?!";>2;X'V2N7QV/EN_@
M:4<"QQK;B"G;8Q-\ZQ;9G+GRM<2<!,P0*1$"5*#E!S=5F$SX'Q(IG.*&/H2]
MO9U.UM O?_J/R2_C^<<I68[74R+^7I'%7#32'\]OQ!_3_WJ<?1K?09=]/$L%
MV<[D*Z;'F?S%'R1(<6=%.<&>;/K*@RD&6#/ZMIG \18X0RW[&[L<6/=8&.*5
M<P2,[*CDU4;GNV'<]YW_5D!(KKA1;*[![8%I7471L0K.<.*:08S^?+HF-]/)
M<CI>3<ELL!X7KF:!VG/V9YY!];>*&/#&C39>$!U#6I-W[$X6SROV,1SG?JX+
M313/U9UAI2\B0'=$$LK2C@(X(-6JB.3DT6M.+S0NJ\>'ASM^O]%X^1MS$[>+
MY?UX/6,1&OM/*D=E?D.5XB7SQ1K %G>?X$&>%>Z_:G7F2P=3Q!:I4:%:2QIX
MM:V-!3TO=S4F@%H!VY#+REI+Z= 1W^L_9$5L!Z!6+/3"*8KM3=R9+Y\A(XQ4
M5K,G2O9XGO9"%7M&ERKW)/&02_;..C<LGF+']2%WE89G3-YBKX>Z[F&=*.+$
M*ST,@ARJ="!G/4KIS&OY$F.@>!7LKA[31B4DI0H>+EO<@'L[;W)RV=9CM:')
MA0:CV.:$!-)H4'DT?/HF'7SS^(AT/(6J#$3@^N6\DU-?6]&]4+4?K/0X&&GX
MT@-)E("F-[Y[O/!["#O5%QZ7Y=FXS*1Q*6Q;.Z5MZP!]V_KKT1G$IN*BWP=S
MZ@^!YVX,+KNL0$!J*%XK0J&=N!;:?C/Q&E;*>839Q_GL=C89S]=D/)DL'N<\
M;_"PN)M-9E/$'..U$[G18O? 1BCUX<RJ5NZS[^[<#:Q$2J*NZ9?XFK'TAV9P
MNI'$T<0^AD'6U2[TK&MS=V9+^LY)@K.4B7)W*I$E.5V2$B:?@33AM"^32C3H
MT72! 1FL TB[QYV,]P\J,;#.U-4*43Q.IP5'.$E7PTLYU37_-)VO%\NAJ4W=
MO%"-,AC%J?3K5?!#4)TZ-Y2A%/9N!N!RV\@R!#NX==SPD^,=:<YW71Q>C8)T
M1ZB!&(4[02O@[=\!6LM,^1+,\6Q)/HWO'J?D?CI>/2[Y'M^PU*C.G];@#$>1
M*CUJ)<(@5*G.#P$.X4B24QU&(-M*G(&9!MSBZ1\A'12P^#N)Q6_HCH8AW28/
M:SQN,Q)(NT4MQ"QL#S7 M[\?U)BY\I['E,WVC^VF>N5^1?+:^OBU#MC^[D(]
MZ^FF@1X292^@CIW25U^_4,+H0>>=;1ZPPEZWX_J0-X@#$@JB=K/WC25)$*S&
MW94Y]N82]&V!<R=FKUWLDLW/P(]X-N5498@&. B[?::"9'MY=0@X.W5F7)7W
M5#@>G';,,45"[S([[MH=M3[Y_RQP"6(4UT6FC]1G"![ZQL)9IO14;>%-D5$W
M"PQ%4VP+U&!B;0 8L:5/]>?HH\3ZAV!$_<IXD+8$$ ]-.B$$/W 68O7BA-3,
MJ&JQD(Y&F@E3. U9C6+_ *0)/^5C@ D6G-\A',^ZW=2?=NPFV3L664;?0;Q.
M(D ?4A;!S&@,\(:2+S PG%JD 60&S%0L74Y)B$.<=;J*%^:(O2V[>,,\<:.>
M24QFAF)_T64J1KKFJH-'67*9,:5,BTCY$!:8.'DIQ4%H/]3^RI>BVLV/M!1,
M=)T4>$.RY\XB85]&.:=O4N@;!C[[<\.;6AHY@?9DL+K?M!.WV .G&0V$3CAM
M&%1TB7DK5&(5" TO).U):B@O]F/OQ,MYZ;;@0 M$\6QVM7FAVZ-'%[NL.F(B
M[B!;0^URG:V:H^/8:%/Q9-LTQ;5ND\T8*Y<))NB\!C\E,"()"?*9$QE"8'L)
M.?$L[88^Q3,_BD,>K(V_N+I>4RI '.O1LRS;21G*ND7H6%#TT7^*20Y)/@-L
M2<&QE&+N[.E-L'?<\S"^'GP("E)F7Z\F.2RRLIPS4JLR@$ ^"Q2D\*2;!*-J
M$3H=SHS8KQ_NZ?Z)AF>\*R%P#DTJF)0/0$J/K>FF]MW*PV4<BGP6< C;^@TX
M)96L(A0_BL7UV)=OOKZG#N0XM@N?1>PLPA ]7>:!'Z;_Y)LS@,^3+&NZ>?'=
M?QYI9!0D6WHW<C&FC8%5%G5>\L5XQ:&7EZJJR#1Y$Y_P9O[A&$?\8%5&F>2D
M![1@P!P\>;61MCXXP4G?0^##*#XYT/PW@)LFV(^4.(=#&#B;TD54K:??U?%P
M\/@7<\+3C+]D%3LQ_V7F[X)P+\2J\E@=Z-B?RCL)G$[XK8B@I/$[<*K,[<?.
MT]%S0CG'#^G\*'^-E^IJE+['<H*_3Y$+M(@@1C)J1"(W (?6N_"2<YHPE^3X
MIV\C^/+.\W,(MV*!V.Q94N;:7\.6ZO.LP+I*<@,D!'=C+$KF6VHQ<!R)(5ME
M+:H]5@W(_VW91UQ8&KPERYJ]8+$;0V>09UJ3,]3 XBP)*AF70W@EH/60NX*+
M\L3)8'D=8@[- V,61EXYTF]K]F<$=Q_P,E_D)*/$;"1"7HE5F5-EXJ8U%:1^
M+^V$+32!:4;"?F>8-OR5+ZF4J/!^E44Z9RJ,DFNZH,#U1MMW>G3,WK&EVX>=
M^R\:CEG8Q5^JS956@]L/?TS83P.?*EB4D*>>(<4=KAR%"!R2(5W6%'11SE<C
M0&7>V(84K>US\L*B/O=Q56^:6DC[5EG#=&J0&C"KVQN5/)2;Q7-H\DA6@]#<
M=LR;\-Y17Z=?S#56"8NELQ6,%[56 8B@MUHN=!]_^F5@RMM*@KXT&+B/TI5,
M1#??/P>O[[?4%8L8]L?YVH7]]/L=?7:\*5N6QR?%TE<)85>;*Y@$'58\MJ:Y
MVG>7OC:'(@*LXU*U\1<6;U66O)0?V_^V*O;2#RL_L_I5RR\NGXU*/B9*D4H_
M/':YISIV//?+M1NL7VCH'.@Q=C<1)-##0R#.-VOGR2;(*#=0-Q1-NF[:$!/K
M;NE&[*FN"^8$"*- 9!*D0".;PJS?%VU7/)0[H'%%;)U-C<)8RJ2R?YW/4^RG
MW[.-MX\T>&:LO;@;QU/$)#6P=EV&$>/@(2H!K<UM!EPH.E#D8'VGV<T4@SZ?
MLZN,9FI@$12CCO%,,72 =A6CFHORYIZ )T4%08F'VK!OQ';KJ)SO=88GT.Z_
MIO\ Y?ZKI-S)S[]?+\_$D1_85=LR2Z"C^:_6%/+\E>56'N3STK*6U?,4.O]R
M/:3Y<PE[+)KY4GIFWPV6&$O=7O; JIL[>VOY0"&_<0ECHN-O5JZ;2D^1OF)Y
MY7/VR/Z7K(QXDV^)$K(WXK#C]--.W^Y=W]T?]UJ-.WMN7^>4#*9:5WAH5>\4
M;RY]UP0&4??ZX/+"^N=\J=:_XG,$_5,QF.F?_-"N_I7?7/ZR @93_WK@\C(U
ML7>N3V=L#7P>*35!'%AM;$DDH_K8#,OJ9E\3EII7E (!PBD@5@-*=]L]..$B
MY#F7+3\VDW9@.QN81I@X57\-A)(K_0S0K%?W&?-4WK>5KEP<$89,@E <<=@F
MQ[JR+H X=7SM10-A7KD([UR?; //<\(H[_GW'6)Q+3/RK>L=8_>5KN D&3]L
M-OVR\8Y;NH5K)>' Q5'L?2QVY\T.QWMP$YKQZHDV4B%NGP-3*,_M@[#]HMW^
MN"X7R4FT24Z<I-3%#:02?2AA5[4&%6_IKT0)[/2);]V\4JG\-ND\R*0_4#^B
M$;P=YED:0K\DYUEU**@#+802IZZ"9R50;0FA[.-VY%8QH4GTB%RJG1Y4XW7<
M5)#E4P'OK971M;O/>UGQY2,G2UG\E"Q)Z)*<\% :VTS8MSO!@>NJV:X:90@-
M;M1BZ)O<%.&1&]VHF"D7@P7^\Q6+X_8$D$?D8QA$B-WIBA+,?,89C>(EBQI%
MZ*B=,=H0&(*&F8BHU[<J;&3MJV>MOFU12H, D5&ZLM%[NUY$-&@[T5G23##F
MZMD*QV%^/9W$6JULE,'8XX$IGA_SAA>[H[^%TZWL'Y.0;MT8_O'@G,1LE5Y<
MKYCBVA"Q'WZU%S6-NYI30 FXVK*I; CA\(D!E@9'079$?+94R"GS: -^VF3T
MR4&\ )J()V\@#)JM*&*@F-6.0V<)SV4*'4& $KK/+[9[2?0V5 DA4J#$SQ+F
MM$A"C.34^CM'N-WR7NV.)V;RB+V+]X ()@%S5C<L-/2" Y_Q@RA6Y9$;4T X
M;=A.R.P 8C-TG#.);7A4&NX^V:E(#/@@Z,"U=7%RM5U\@G]M@"[9YH39+XQR
M8K"9L=JURWZ&(:>2Y# BDM AZX!P2D0B13BMWDPRV2KB)>VB9<MB=\YX(@^+
M!7ZCCJKVO T1^X;97M34-IM30#'/MFPVM-!ZZW1]-N^>R(F] ==2>QN1=&=5
MH@07XY7L,S==2%$"P8M-HHFSN W"\>;%98P(\9;T^>@!R=/8W\+N!0O*7<>[
M=ST6K0<^-9E=VY/&GW:[#HMN/FY+=Q 3=3?FU;W8X/"#WCM ],SCZ?Q]HEM7
M^D8>F6^R=Y)]]E+<R;SGH2K-\MDDS]Y I%> .\E?PKN;Y*\A^7OZ.W4FXOV%
M/Z?QRF'D*_<R*J$1SI75,Y\=)-.#XIP<J^-'<2='<K]BQ$TJ7;_*.1>&#.:U
M._(K6WT:DPA(6SXTUEBR=,VY\ G#(1RIXUZ NGX)]N]G_$:3FV.RD>$&6_[+
M0\@6^>F>Y9R^\1^5M4PMB"#4-;46-:MQ:DP!IR=@2S;+2IB69) #H!$G)F\O
M[N:%&YM/WT@$;THOQ-GR=PE#Y"^TW#NP+ZDY(2(H$4&*"%HC\2OAY.2M=K@1
M2=!$:2[:V_=FC+TX4?JYAU:=,_&<*%KL?N5[Q_$B7$+F<7Z$@L[%+J^4F#B>
M1[?7IP0N2@!UW18[4T4JDNMG, H%=-U(VB^NZX/?\D8]4(60(8&'NCN.P,R<
MTX9G4EV.($^>3BE"E&%8]P:7'9E<_+=4TL3U@Z?@WB$:FGN8?H%U0B3\8/8P
MD_1#DP&LIS4@5V J>*T#J",T#+,WX[*)L:<4D]D^AQFJ?;<<@DS.0RIG9MW]
M!0#*M4?*(5O1"Q;YLCZY1E'$,+=!F/*72Z0(@=J3LK\.Z2IVNAII2P=E3=*-
M6=7*A&&0'5/.X"U==<!DY#"29,M+2N"G3)6?*+\C@(H70)II!,GX;Q_\W_Q[
M_V;M_\+^M_J6B%;\(YZEHU^<_0$ OWWX\-N?[S_\>/,M"?., _LS"*%H9>=L
M> HO\"G/[#-LJ/';!W[\$HUX.B]^<1DH9>;DG"SG'GH>^<P)0AY.$!P1F62R
M5N)9O,RW+'+OB;%"ZGD,,K$D9SD2*=MT$,0*&"\8*DF\.,91S%21&<N:AGO-
MQ%*/AA/BF(HC1S-U.-8#%S.&]!;G9!9'),P1 5RL2*2E3/!(MAX\0WD(@PVE
MVP@.;<R2"62Q8S'4*YM$'CQ'V+-&>E-D'*-I)IIL.F:8U@VH"5NJIF0<69R?
M2=%!"1,")*. 94R=Y(-M@D-!QD,BUT$G%XZ5P5X&WRKT/+H1!Z3RRCI=EJX)
M 7QK,Q-19W'5V*A69\):C>4!"3Z5Y43 ""4R0S"_5H*N^<Y_T0@=<78\DHMJ
M@WR.[&TQS=\M2Y <6H]RMJ6I672%5D3*[<C87T1W$3==0+>A@;)X;L]H'RI*
MKH@@:7?=VKO013>44I,<CQQ59T+;;[\ZD*^-Y)ENW6 3'O_5>5PR.D/W36<"
MMW-."9&OP#L5..U)81.: W9/)E(W]4^7E+I'!V7Q@UMR4>+ZHLX#DY(9NH,J
MBMO./PD:7X%[DAGM25D%R2$'3P9"-W5.@N30?=/%OC9>IH47@[T$WI:-TO2?
M1S<^07\)-F+\P>K@N;IDIA$F3FZE@5!R4L4 S7HVQ9@G=5UB@ODM$;@CDF"+
M1F&$X^/T VLO6"J"J":- )+P&R)ZF]]SXR^F5J4>9F-_6U%?T)2 _3F]G8CI
M;-X,&V4>;\.BX@;*]%B\Y,"Y9W>E#8&-Z+TG]!%2E7F]F\\>^GZ2MGQSXQ?B
M)'#!;D>A^-;N1-_+J$BS^&UA<V2Q(W(?0K[GC[F/W[>TYE\>;T*?^:_,*H+P
MM'3>[AWFAEW'B^:4G[R*:/BJW3(Q0<29SLU%DF?S>BSKD[DI2XHF,0DBF\"=
M-Y+ACOAI'[X=(O!QYO+6<H$P^Q1A #;S:Q#^,?/Y>B!J9C15F,A64R^4TFST
M:'AV4\=3E>$ +DS("?;03*>Q:*D\;,7YS%@;@OG<NKX;O=#MQR#8-C.?*DQD
M\ZD72FD^>C0\\ZGCJ<I\4ES"D8=F/8TER\1Y!HS^SL="<\Z'P/7C6_>5Y@=P
M)P'C-(Q=WG@JII'V%M*F!!#.Q;82,3L3VPC;;O__%JPI+I]C1 BG0H",= B;
M2(0(IX1X:6<OPC+U_U CB;U9Z-9Q0]Y._OJ4_?F+2T.FUB^G.^@OH[B$K"DR
MSES43#1Y.C+#M#XC-6&K[+H91G*G08;#%]_S\:>^[T=KKX7WU(F.(:^CC,HR
M*B\*;4D#62>;"*I431,">!IJSEV5HLI4B%*!<2XHO9"X"KOL^R:Y]I8Y\P_'
M..)>YD=E'&:$@6QU>B&4-E8&Q[,H'2]5"B5PB$!""IOZ$&242#(2HA"]+!:W
M@.&8+C\%K-NJDP"0-G1++!;V;;.G]K=GSUY=7@_P?C@< JM.O9Y'OGV1-'%Y
M7-WT=V0[,Y5Q%!WW!]@%BQ3'":M![2]QZ]A.%[,Z.)0-SVIF=$>B^4%HJ<^^
M$T64MS7P7.?)]: #H1OQ6U8V<'8Y#LA3H82E\[%H8. K.1K=<(2EZ4M"0#E^
MV8+[:?;)%?SVZA"6;O3';4BI?'F"JJBB >XP7$:E8%4^1(DX&*=2P5UY@X_!
M7NT8,',3\CT73D:.'".F9,R)P!5_4!/G^))#PC?P)M)J+!Y($*!1O,4$I22B
MCP]*^ >%[WA1OY!ZH$^!Q]03IJ(FGD&+/0S?4"-<E7?0H [&/U3R5VX(+A(.
M,.MOW>C %E^,!H\JI(ZL, =%Y!V$$^ ;H/Q&-&SA88@3;J%WNIM<;PBWA88N
MP'PG(A"'/+N0E8_R.!??KS0;)8UGR2;IG,JP7$LS*7,H*X[EQGUUM]3?MG$K
M9[C#<BI*P4Q<2@%Q< Y%P9T^;-TFP%&R9CDX+E^^)"7'X&_ @?!;%3RX&R_I
M2 C^8^?ZS'U N_ \$F'NAZV"H-""$5=TC.;>B"_V$R<ET+Z-A,/Y;C@>QV08
MZ_Q-2F.8WL9$PM]<ZK5JN-1EW[_KMO_@=_T[;?H/=\^_MRW_X>_X6ZANL-CC
M-><)+FK,?,:-&VV\ .).;9MG$TRD_JWF0A6ZM=:CV>_-:LJ3XG[D7-O$=;72
ME"6A]W?+!S^HIW7@Q<<(]W@HV,LN[I">6?6NY1>7T] <!-$M=N>QM4I-7N!2
M[YD_C6(7JN 7.WZ&E-]_E88RZ^":06R.84BW"NZ;D["OFFW%3-6W*3[*NJ4=
MDU5WL9;V2/BU[W 0+7CVF4+"#1K\HBB';/C+(6="D]?S%0D_D"PNDCO;P'&!
M"VKYQHV>ADB0(3.?I(3@W)DX?2VNCLM6*>N 7 .DH&??M_0D\5+[Z=M]>,58
MM/9A\\!?9C?A)K<0*49"#6;?%U6QF_H;%0R*3]$S4G%0]>S:YO2.*S^(R8G&
ML@XQC4B<BN5]U 9R,5"2PZ97*]NWY(8LES] 5/,%$,M_CD^1NW6=\ 1-#!<[
M<2Q67RI= 8]4'%0G0*%62 =LOW2HFI/RVAL:8<)=,GP7 [O.6>)Y[NQA9@L=
M/W+X0??*XF831"0],A:IH%"U6/8URY EM8HM4A4#7!Y:Y=C(5<K=!,MM![T6
M^;Q'<V49L@X8JV]Q%>O%'L4J2(1^Q'HV%+V'SWI[(]<:7XAYN]$%_>>1,3.%
MHYIK]KZ:V$()C1=95#!_'E<H0%&B"BT?9;^801,.3@ >/[8HRU =4NCA!Z,W
M%0&$#G@(NE,]JZJU!S=$N*@,:#90&2!H8 >A^_KP0 F(K?/5NY_GNH(;&UR$
M]=:)P+&W<V+'<Y\]=T-#)]+7.F@A[:<#:YA.,X(:,)2D8"4OBOT$-R)[#B%J
M)2->$<DOW0Z#[7$#1S[.*=K-!C83J 2-N'5X*<Y;V^!->'P&2^<%LEK[4T+9
MM[T*9E.[4X"@V)R6CU;VMF742)22LVMLYI( ),E $:VL5Y:3O^_8.]B_V;_8
M'T_,%O_]_P-02P,$%     @ !CG!4#"BWWFG(0  BR$" !0   !P;'@M,C R
M,# S,S%?<')E+GAM;.U=77.C.+J^/U7G/W!Z+\[L13JQDTXZ73.[Y3A.CVL3
MVV4[W;M7*0*RK3,8/(#3\?SZ(_%A@T%" A&$TC75-0Y(0L_[//IZ]?7K/U_7
MEO8"7 \Z]F\?.A_//FC -AP3VLO?/FR]$]TS(/SPSW_\]W_]^C\G)_^^F=YK
MIF-LU\#V-<,%N@],[0?T5]K<V6QT6WL K@LM2[MQH;D$FG;]\?+CV<=.YU([
M.8D2N=$]%,FQM2"U[L?._DT_2M"QOVB?3L\[I]VS[IEV]>7\[,O%)VWRL _X
M@#*X@(4A+6C_\8R^IB&0MO?;AY7O;[Z<GO[X\>/CZ[-K?73<)8IX=GX:!_P0
MAOSRZL%4Z!_G<=C.Z;\?[F?&"JSU$VA[OFX;AU@XF;QXG>OKZ]/@+0KJP2]>
M$/_>,70_,'MAOC1B"/S721SL!#\ZZ71/SCL?7SWS [*!IOWJ.A:8@H469."+
MO]N WSYX<+VQ<,:#9RL7+'[[L+%>3[ 9S\[#Z'^[C8B._]^SS8'M0W\WM!>.
MNPXR_T'#R3].ARD4&]?Q=0N^?C2<]2D.<,J6UFG%',]\I!^<?-^Q36 CG:$?
MGF-!$^OJ1K<P7;,5 +['FG&N).O-__ZM-UZ,-\ -C"8(""GM)A!-=!<]6@$?
M&KI5)[RC#[T=UOY*MY? &]I]?0,1D%NP@ 9$%>]./%S:M]X0L>ZM[BSG1PUR
M321=%<\M] S+\;8NF,&EC9H80T=5E6$X6U17V<L)^CPR'3,&YN3$Y7MHOR"K
M.&ZI7*8BB\O3G0[=;[JU!0] QW]CWO@SEY^*N%Q. 0*_+6.V0\PWTE]-.JQ9
MCW/]V:JHRCB)>K59-J.TM,3KM&PNC^._D69O@:]#2[1D]ZG6HMC2><Y+HU[-
MWD/]&5JH/]UWUAO'1D^^ZUX0R S&6V-[B(9U:]#;H'SKQJHT-*$?K]<F/=.$
MN)^G6XE!AE#@]"^(+_/8OKJ]FZ$W^G+I@F7PP?$B?E\:'/<'(FP;%WC(#D&H
M>P0E H13%S(@3-H,O/H =07-_5/HXZ^<G9U=GVDG6IQ0\J=NFUJ8JI9,-L@[
MRKWE&*DO6'A$[KAI6C *#\$(QMT>,#XNG9=3$T T_NY<XQ\G^,?)62<:=?\-
M/7KJ.R_ [3U[OJL;?IR>I3\#Z[</F?=/E^=7G4_7YYVS\\ON]>?+RVXG-G"M
MF8S--$?IYN0Q^1IGL7OYZ=-9]^*B>]VY..]>)+*85$'/36=7=XTX;?0S(XRT
M-R,*<;H)!F8GQ@I:>[H7KK-F-5Z4 8<1B..:P/WM XJX]5#VG$U8IC]H"-@"
MN"XP[T.S$#,>Y#JPW9LR-P$N=%"Y,6_1<(A"82J<$EP6(XI([;:&U+"BFH(E
MQ-:P_9&^SN,T+UBK*64&%#%ZWAI&YZZ.'>FSW?K9L7*H3+UO-8?%2"+R+EI#
M7BC+_M;%=IJ"C>/B@0=V/&T]8K',#]YJ:KF!14Q_RF$:HB&1OPLJY3=C<&C[
M $.%+P"U%7H$A,A@?G %&.0 %C%X*0F#=] ";A^U\TO'W1&)2X52@*]B/!%-
M5RVK4F=KW;)NMAZT@4>N25.A%*"S&$]$Y^>6T3E8 W>)6H2OKO/#7T4.!"*M
MN:'3YN@B<WQJ&[WLN"*:KUM&\VP%+*N(W60@!4@MA!,[#LXD:2E17M>./?,=
MXX_9"AG$&V]]O$8%]\W)?59*) 5(Y(87D]H>=U $%)G.Q9YH$[S^"Y +Z5$X
M%2AF0!2SVAY_4-1#OX.>H5O_ ;I+]O.1@K::6RY0,;WM<0[%GLP#OCOT)*]#
M3 C9:G)Y,,7<ML=WE$87^JK9V$V$58C?(E0QPWD^(SD9[B%P9@#0TO.Z5JGW
MK6:R&$G,7IZ_J#1[OYX>SRU7G7'F6LG+-/'<.<,3S_MTT>_^>'0[&,T&M_C7
M;'P_O.W-T1\WO?O>J#_09K\/!O,9__QSK,Z%[CT'1MMZ)TM=WX02!9;OQ4^.
MM1H]?MIG<KRX@S9""E&I=+Q@]0)AGIHG*M;%V47GHMN]OKPZ[YY=79^5*8;5
M<?8\#_%7@"@=2)K26=G@AX++@530Y+</7 _<EZU_11$?]1F9^#\**YT,&+@C
M$<X"31'>\>KOGFWB_PW^W,(7W<*KPGM^7W?='1KB!TNV"#I@BILTWOG99V2\
M<QETP4)Q5A[E$3<NE\SR./3@:;9R7'\.W/6-;O]Q"S:XECSN9!/#I7%>7YR?
M-S2K4(59/G2"%L4D63QX.L\;JOG#5<'>%!@ *?K9 B/@YT_SLD110A6E@0I:
M8]-TJS#V5VB0DS0<00G9@$KQSPA/T.*<IEF/E]WOD,@)?">#*,5T(3#*LIPV
M<<Q2J-4MS\Q%N:HOQL?>D\9I'CFVP3&BRP:7E/Q2K#.BJZ&+UU1=[OG!%E\T
M8 G:L80! H-0JOB"F)+*@I'A_,J_#.0:!G6-#P?P_G8;F#? 1C_\B:7;H0'N
M'!?_$3U/V)H@(^YT5!.5& ,H4AU-7&<#7'^'D0=[U?[<P@TN<.2N)BV*:EKA
MQJK*.#,\2\1>W@/= U.X7/GCQ:,' G.2AIRT.*H)@Q^LH+'H"W"?G9Q6J=36
M2O']6<9^K&IR8,(G:J2:&,(<^+]HDG\JZY)R76JL4FN=W_#0-#[M  +<V0X6
MEJX<"T'S<*OG[PJ&JJS1I9.#P&GI2C80U*-,-Q -"XEMWIH<03JQ5&*8*A@6
MY(+&M:0^1*DE_>(FNB;Z#L_D(+NB)^X6@>$54HF49%882U;)<V-5C=#XS'@M
MZL([N@';+&I.#.G4(HKL0AD56D%-N00^1RZY)&.\7[D46D$1_UG:#W X,(P^
M.4^-E#)7YPS]NU)5-"4,(6BP1>H"->3<[SMV8+?OT%_UMY[OK('+*":6J-))
MJK)R2J-6I-X9.3Z("R1='SDAU9,#*\@:W/.-N^"RQF,>9JLG!$:,HA:&R>.R
M8UY20HTCLR $^UL8P2O27J#V$G5Y?(CJQUOP[!=.V!##RZP01DIS>Q,<:!49
MZ5*[4"P"88FMJEQ*8U>D/ID &U^M%*_*FCC(@,"'T?'1MHD?@/7&<G;X06*M
MC9=+ &FIB=BO*"G&M["1DJM:V.NZPGA*"JL<ZAJV7!Q&6)\:T@TN6#SU%CF"
MFDKA@ZO(C@T>0;1."[4-MFIM7^09CA?KX!VQK[(+!A_#!_=;%/#( +68P#;(
M&J#$4%T3O- 5:2FR=B-((QLP;9:.<HI@1%S#[C^9_/:YEBRYSE)UQ93"+^A(
M\7S][.>,W_IL+]+EMDE2B8=\=5D/^9K-T?\>!J/Y3!O?:>/)8-J;#U& )H[[
M"N];VV>:,-6!,O!4$..I>]70CHE]5H*+"HD-03*0-$6:V;!Y%7TAHJ:OJ\IP
MZ[E^@E?TUS&GZ!'>(F9N#7_LSH#[ @W0>X7'/3]2,&EXY2#IP"P7*B*W;TQ3
MT&:$>?5NG;4.;3)7V;#2$,9E^US*&,$I,M<5@7X ZV?@$NK<5!@9F6:D+&>*
MH!"9(C3?(].@3M+!3E3"":&5HIX'HR)3D_M&#'6UP1#])#EBL@&EH;Y4@\R)
MJ^F+)*LS?;B@/I??^+6\K-()RC)+1:1('=YW/']_,3/1A9H(HPZ]Q;"JEMGK
MD&,;7X =A6VJZ'H 610?VGJ+\%I.<*K&X'6#6RMB>:;$44<%_#"K3I])HXH9
ML"Q\V1BP@:M;>*.)N89V<'\NOM^1+@^VR.KHI +>JG-OT@AFOT8E]$;=.YF;
M%RDAU9$"*SA%YM/B@^"<&#:]8B %5XA_'H15Y]+D*?S'J$/ULZH@#)TV45<E
M$5  BIH/:WP7W#%:>DU #*^."O@@"KJ;M^E%."/@%W8 4F$4XKL0EJ"+>9OF
M>*"[-M*T-P%N<-_IC>Y! X^1H+7U#_/;1ZP7Q%)'!V6 TJ[Y;?%Y0M\!/HX1
MF#V4+WT)1EOL\1XO K,D+LEE$U"YQ-31E4#\HBX@SO8ZY%AX,PE86 $?&A@4
MXRJ<3]56X6B_I#[[]W:ORKGH=*XN&ZHV*B_,:;"8\]B6;VW.4=EM[V31D5GN
M\9<P,=GE.@PQI"&>@\(L[[P ZUS$(XK/W$4]3'&DXY27'F:"*7@5F42DSJ%0
M%X4PQ&R+4"@T<\XZ47 K(ABVR12/*AVN-)04474+*+(&:1!LN <@6G05C\CQ
M*&*-;1 2:UF1D?&DO^$L;?@7,,,[Y?%2 .^^8 &3X*]()\E2G9JW,$K[ETY%
M!D!#V5S[T-WH;)&ED]-;*".KQPK&JJUM;=)?TE_I]A)X0[NO;R!*!5_'9$!@
M&_L-;P4ND_-R&Y?ZO_=&7P<S;3C2^KW)<-Z[UVX'=\/^<##J_Z<)KTGBW@'F
MRQ:2XWRF^$^75Y<_W2E5W"D<9GZGGI4]R- FN'9S[&"/-]FW0HTCC0XJ=43X
M(4KE7SG*-=6ODAM67A:9"<GI73(C561@C(]L<.R@YJ,.?C/AI*.?G;HL[6SH
M%*&\9YHPS/E$A^:^HT:EGQHG;:SS=DN!'ZDB/HTI\'5\<6J\TJ# C9H76"DA
M<$!4Y/Q$83OK)&"^6I>.CJO][B%A)Q;)Q#2=M#RVF; ):O4W@8L)9=;UFRSB
MV$GE)1;VD'@_#J<0[4S0!)5Q25C'2A]ZWA:8MUL700[]G:$E1N!'\(I<V;-$
M5D@?Y?$*Z@>8^ ;[H!/Z=0M-W39 I9N@-]8K$@9./I(%>O"$4>"4QXO$V*=G
MF]]UU]71F'D$_/$B#H0=X]]T*[-?MWQ"[9>+8.RUGJO,?>N5&,D,[;#0B%!-
MG-8[%0X5?@W;_D1K9PH, %]P5]R[0^:;Z181>XY:.&*KH8^J@&O9 ]CX+7H]
M\_^V7GB\[-PA^&F"8O)\/ L[!:A_[T$_GAL.F_1H_A<'R&O=WNJS[9=LHY92
M9:]CM3UN;99-,2Q!^QA)&YD:FT(7Z87IM)1]5G""]CF&(_*!W>@Y* *],*VE
MG0V;J#V,^;0WNE!*]U9WEO.#]4#GBY+KHGJSW[6[^_'W1@YT3JRNV>/E6_N4
MB?9T==%0?8W:*9R;B>N\0,30S>X1T3NT]Z>S] P?OH0GE]/OZ.1/2)K&GH^E
MW+9>!'1%IN+;W^D3Q&>%3F';-9 :-.$1CVU "Z3@SQTQ]4X=GWH_BGPSZRFR
MH"1_03RMJYL)G#;/1?/B>C,-$#K,;!92I&:\!2B_!J3))AGDIU@X["*HCDE[
M5)H0R9WC KBT^\'U@\9N[NJH9!C!Y*D.;6SC1]L%:)#V%_$,&)XD?HI,H-V4
M.=B6>DES="<S?<\=1PH_)2C.;#5,NPN8+8V+S]CNK9TM,NO=%KN$AO84>!M@
MH/%VO-=QBD]O\AXW> 8EAITS@5HMP9^"J\V*5:?N"R9J&[KZ$)G']>%?T3;;
M.VCKB"![&>RO)0U-*5%^ZJ^"G41=K=GP6 !9UL7WU-^"\/\)6T83RP6^#_8$
M?LI-F-44F9O/6@'?;8Q1?X?^JH_(032X\<VEI%E<SE2DDV%%+;"(B]\@@EP=
MS8]CL\;H&4;0RS@L!F,65C;J>U03HQ4DN'0G=Q00GJ21L,L]AA5T+<<+5,'W
M/ _D+I=DBZBN(BK:0!FO1-:@0_L%D8 &!\3='M0XZDJF/'QE[MHAUY\3?8<K
M3WS>FV&X6Y3+PQWMW$T2+;'WJ*_2=A&TZE_&GD]\U8D1>);],G(C)_$>1<9I
M#45\!NPK 2JOTY).5'6NRZEB$U%')31_(TV>%7!GP1.Q%)"2D#12JVDI("_T
MQE?+Y&^6S-3!-[K]QRW8.![,';31(TA#NF#RTH.V$C:HZO^1<Z<;Z@S&NZB,
M/[?0!<C.J(+U=Q-+MWW41\0;)38YDWW\":BO+$$VD<!-5%=_>XHLZT(#90M;
MGKF/G8[V?H14RA*U>)4:G^F-R]2=XR([&P"8P8;E8+R18^B"VHHQE;1]/RFL
M-!&&4<9!Q6[ERGWM]Z.PBC81=?2$G,.Y_?**JL,Y2D+22*VFX1PO=&([*6!0
MEJQ#N8]@R1FS54I/&N(%$Y@>THDW40V;&QH?[[&;OG*]H[[L!-E$E%\IT;0U
MWET?+!;A.M57(Y@?GZ)J?FQC*Z%BB/^'A\ ON@6RYS"524(:K55MVRJ#;GR=
MN:#3XA'4([CIH2\R1_I!(F1XID]V\&Q86WS^0]*VH;T)"GS;3"BC80G,ILAH
M(;_<]U!KX[H[9 W:86),<9727#FT@J:@Y3A_MPG!-'0N4%.*Z0A;;"[# 5&Q
MN?"2#?3SX(VQS9SNZRWT#,OQMBXH\$Y435:I>DFX(00=4E?31/303JSZ"?W)
M3#.*I=*01BBU$IX_>5W-2(H<W7"TT'K\'-ZE,K3CGB(R3'II=M'NF0HIOC<U
MUF6R&E;:'#PB72&UW<CQP6&[AR@_KX!4WYL&ZS1;#=<MY7B Q9\->3#B#"YM
MN( &;A'"]=_XG@G'PC?ELIT'V3E#_VDGVB%-?#CD\.MH>#?L]T9SK=?OCQ]'
M\^'HJS89W^-[<!LY #(+C^'X1W*DI\]GW!6%&" WN@>]\6*2+*FV225RCKB[
M05GZ@]"D54DR73 NY>B*%_&6;:*$FZ#&_:!U5@@Y&[,*BG\W6_R'HV^#T7P\
M;:BHQQAVA>/1I&8HL9X^-[5 +I.EHJ),BR)E42TP>]ZB-TZ$+2V)=SIT R?3
M ^H0;],GZA04R?-LD;SK#:?:M][]XT![&/1FC]/@8.8F2N<>UR%_+$TQ+=I3
MMZ'I\KQ,%950:APIBVBAZ;.%E!]D2TOI%*#::,O<6%YD2^9T@!K+QV9:RBCW
MB>M-4*?G-K)W]++ E<N7A) ;G((TBYM$>F!I2EH5+@[7-''!K'7E4J?Q<2O7
M^!65C+,NY_A5^R7^Q-^E'LJR1!#AZ])]9+;Q(G+A.7;(P(Y6, OC2%<^BZV^
M=S>5PJ;, 4+14/K(7CNZ)O@BMU0< D J<UQR?)O]!+C!@>)L\BB(U7)=E$%7
MJP^:^XK?NKJE;.HHC)>VX!7Z][E-^BB'3]"23]*===="^A#!3K+P+"R6YH(E
M2DO)+@VMEG-X)-B1\"-A-]>QT4\CO+J,IU_!FTQ+Q2,4;FVG[[S1!,8\N+>8
M:11XCNJC<\HTAO9+F%@CXSWQ\QF=LX9:]IFQ N867R*]SUYX:X,?V+>H%+-&
MEZ;T<A&2+<:5\+;4HYHW[\%5DL^S)3E_]J/10EW'-$BGR]T9$U2LXZ6O<\KI
MP.E 4A;18NOFE-%B6()*HM7<:/T6//M#&QEBBY'V7B%I5UXVH#1$<Q"699D1
M%Y'IYDD;Z6MPZZQU2+["+#^X= 0R<E%$8@'"QA= $]>5>NAIYP&LGX%[1&5.
M",G9*R#AR+'. *UQV@2WJ/?Q=>9%K>I]_KWG$C!>JL)EQ"7(']Y@T[KO<X3^
MGIZ=/' YZ@.;8WL*\)FYX;KHD6.[\9_!7 *.'S Z!\;*AG]NH\$O\UJ4.K\M
MKQ[ITJ*L:GES<[5T+!>OCN$:OUUDQV_Q&IE&1VQOO%@&ZZ!S>?7YHGM^_?GJ
M[/KS)S$[4V;;S<8*Y*^[N_#BIGV!&-H+QUV'\J35'Z73D:XNJ,Q(NH<BSBBU
ME'B95NG< E^'%ENE<%%BDXGV2_0%N=?H,&Y;Z%Q=B2G]U!T-.=X;MDC2E&L>
M<QX5W7(@V^_;F:,/C!<]O/%M"0K<.[EAI2&_ HW9SAX[5*F</HD,>V'_4S\\
M2=R,[>4Z$$JFDC;+9[Q#LMEFG9V\+/$BL#?NA<BM_'OKH'&=+.!?P.TM71!
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M"B^Z43U'!'G!U"":&5D-Q\#FD)F[;.#74YQE?&3F/_X?4$L! A0#%     @
M!CG!4'SV  1M5   R;L# !               ( !     '!L>"TR,#(P,#,S
M,2YX;6Q02P$"% ,4    "  &.<%0CM G-4D+  !G60  $
M@ &;5   <&QX+3(P,C P,S,Q+GAS9%!+ 0(4 Q0    (  8YP5 [?J<'8PD
M )QW   4              "  1)@  !P;'@M,C R,# S,S%?8V%L+GAM;%!+
M 0(4 Q0    (  8YP5#FBLBM=!(  #__   4              "  :=I  !P
M;'@M,C R,# S,S%?9&5F+GAM;%!+ 0(4 Q0    (  8YP5 75!#C7S0  "R7
M @ 4              "  4U\  !P;'@M,C R,# S,S%?;&%B+GAM;%!+ 0(4
M Q0    (  8YP5 PHM]YIR$  (LA @ 4              "  =ZP  !P;'@M
F,C R,# S,S%?<')E+GAM;%!+!08     !@ & (0!  "WT@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>58</ContextCount>
  <ElementCount>215</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20200331.xml</File>
    <File>plx-20200331.xsd</File>
    <File>plx-20200331_cal.xml</File>
    <File>plx-20200331_def.xml</File>
    <File>plx-20200331_lab.xml</File>
    <File>plx-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608472880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&nbsp;(a Level 3 valuation) as of March 31, 2020. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2021&nbsp;Notes</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock price (USD)</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2.35</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Expected term</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1.63</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Risk free rate</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 0.23</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 100.57</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Yield</font></p>
				</td>
				<td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 15.41</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6612115824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsTerm', window );">Expected term</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsRiskFreeInterestRates', window );">Risk free rate</a></td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">100.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedDividendRates', window );">Yield</a></td>
<td class="nump">15.41%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]-V'IM#N8?&U\%^PY^_8O^"U!+ P04    "  &.<%0F5R<(Q &  "<)P
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M1&)C#P(4$]A20*?_"NP@@N$"#,V >3H;T3.<GJ'TS-.S$7TV>0$0,<<%9JC
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MPOMS^"RE$78KZ9,MD:MMS89))<[&#1=VK+K^I)L8V?:]5S(T@,4?4$L#!!0
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M+[0"AEA!A3[E1L8D<$X:RLE9\YAVH*D;0>6\3[B100F<E(:2$@146F"H%&2
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M5:DKB@(""#&Q,H%V+B"<RST& #Y;$><  G7E( "T?0%A7VC:!3Y1<IXRB<[
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MT?F7C?VO$1UX*9LK/T*M_V"S(:%VX;CW9S..V6@X[*8?Q.9O7'P 4$L#!!0
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M_,/&]M=:._"I)%=^@EK_OV9#0.W"\9L_FW'*1L/I;OI 9/[%Q5]02P,$%
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MO69,@@H,GE19C7K_E@&%6NKN3O7Y] I, \F&^8%#RRM;_ %02P,$%     @
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MYKVX6UT+H<%8B7;F5%LSMI: 0JWM-C5[.3W>*="BG^<26H9C\1M02P,$%
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M*,T+<@V@27,8-?2=9C-KB.?/)C1I0B-@_0ZP?3!):79IDU729)4 ?$H#UDG
M^B-@E3U4.6IV4:.B)M\L:-HE3[KD"9?E@TO^T66[>.R%W!UQN$$_F3ES9=%)
M._^UQ#-MM7;@@=G"$SM_:>= 0.O"=.OG9OQTQ\#I?KJ59/XU5/\!4$L#!!0
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MX.@FR60C ; D0^,"!W=7L7U,OU-YJAKE[80VM[J[>X]":&84T8NI3FG>[V'
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M#:RUU"J />,0'EZSHGW"-Q^D%P'LMIA;'R8?[-FVV!Z+?VJH!:CD,2K,29X
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M:RDRHE+\@U%.ZNBUQ;3 YK(4W-"$3RA,]9DNQ,G32QZ]@:#&W2)<C[:)W"]
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !CG!4('%\YON    *P(  !$
M             ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M!CG!4)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  &.<%0C2O$Q)0"   ,"@  &
M    @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M!CG!4-3D<?L1!   C1,  !@              ( !P0L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    (  8YP5#?*1PL 0,  $P+   8
M          "  0@0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  &.<%0A=?*<@8"  "F!0  &               @ $_$P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ !CG!4#8Q^\5V P  H@X
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M965T.2YX;6Q02P$"% ,4    "  &.<%0/HQP1;0!  #. P  &0
M    @ %&(P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M  8YP5"C=,7J^0$  ,H%   9              "  3$E  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ !CG!4+"YC9RU 0  T@,  !D
M             ( !82<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  &.<%0*^#">K0!  #2 P  &0              @ %-*0  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  8YP5 0ET )MP$
M -$#   9              "  3@K  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ !CG!4/M8XMU#!   ]18  !D              ( !
M)BT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  &.<%0
M31!90?H!  !Q!0  &0              @ &@,0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    (  8YP5!\*)B8Z $  "@%   9
M      "  =$S  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ !CG!4##.]U^Y 0  )@0  !D              ( !\#4  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  &.<%0XS_J3UH"   Q"
M&0              @ '@-P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    (  8YP5#=R)CSQB(  (&J   4              "  7$Z  !X
M;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    (  8YP5"[4KBN3P(  +@+
M   -              "  6E=  !X;"]S='EL97,N>&UL4$L! A0#%     @
M!CG!4*)KOSE_ @  DPT   \              ( !XU\  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  8YP5!1!:Z8+P$  ,X,   :              "
M 8]B  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  8Y
MP5!$AK]A90$  /$-   3              "  ?9C  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     < !P =@<  (QE      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772084112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,166<span></span>
</td>
<td class="nump">$ 17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">22,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">8,876<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,488<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">57,767<span></span>
</td>
<td class="nump">32,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Long-term bank deposits</a></td>
<td class="nump">12,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,879<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,012<span></span>
</td>
<td class="nump">5,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,713<span></span>
</td>
<td class="nump">5,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">25,109<span></span>
</td>
<td class="nump">12,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">82,876<span></span>
</td>
<td class="nump">45,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">9,430<span></span>
</td>
<td class="nump">6,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">13,757<span></span>
</td>
<td class="nump">11,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">19,014<span></span>
</td>
<td class="nump">16,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory Note</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,628<span></span>
</td>
<td class="nump">40,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">51,777<span></span>
</td>
<td class="nump">50,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">7,130<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,531<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,481<span></span>
</td>
<td class="nump">4,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">66,129<span></span>
</td>
<td class="nump">75,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">113,757<span></span>
</td>
<td class="nump">115,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(30,881)<span></span>
</td>
<td class="num">(70,322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 82,876<span></span>
</td>
<td class="nump">$ 45,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772859152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="num">$ (7,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
<td class="num">(241)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(7,171)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(4,091)<span></span>
</td>
<td class="num">(3,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(1,333)<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,117)<span></span>
</td>
<td class="num">(7,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Increase in bank deposits (including long-term deposits)</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Decrease (increase) in restricted deposit</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(35,079)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">38,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">38,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(3,626)<span></span>
</td>
<td class="num">(7,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,792<span></span>
</td>
<td class="nump">37,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="nump">30,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Note receivable from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">$ 2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note receivable from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
